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1 Introduction 
“Diabetes and cardiovascular disease (CVD) are, together with cancer and chronic respiratory 
disease, the world’s biggest killers, causing an estimated 35 million deaths each year, 80% of 
which are in low- and middle-income countries.” [1]. 
In 2008, the WHO estimated that more than 10% of the world’s adults – 1.4 billion adults in 
total – were overweight. The incidence of overweight is age-dependent and increases between 
the ages of 20-50 and decreases between the ages of 60 and 70 [2]. The WHO published an 
estimate for 2010, according to which 77.2% of men in Germany over the age of 30 had a 
BMI higher than 25. Of the 1.4 billion adults, over 200 million men were obese [2]. Obesity is 
a spreading disease, which is not only a serious problem in high-income countries, but also a 
rapidly growing problem in developing countries. The prevalence of obesity is progressing 
worldwide [2]. 
The graphic of the international association for the study of obesity in Figure 1 shows the 
prevalence of obesity on the different continents.  
 
Figure 1: Prevalence of obese men in the world, published by the international association for the study of obesity in 2012 
(1). 
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Worldwide, at least 2.8 million adults die each year as a result of being overweight or obese 
[2]. In addition, 44% of the diabetes burden, 23% of the ischemic heart disease burden and 
between 7% and 41% of certain cancer burdens are attributable to overweight and obesity [2]. 
The following graphic by the DAG (Deutsche Adipositas Gesellschaft) (Figure 2) represents 
the weight distribution (%) of the German population in the years 2005/06. It shows that in 
total, more than half of the German population (58.2%) suffered from overweight and obesity. 
20.8% were obese and 37.4% were overweight, but there are only 40.4% of the population 
with normal weight. In summary, it can be said that overweight is also a significant problem 
in Germany. 
 
Figure 2: Deutsche Adipositas Gesellschaft (DAG) representation of the percentage of obese, overweight, healthy weight 
and underweight people in Germany (2). 
 
 
The metabolic syndrome, classified by ATP (Adult Treatment Panel) III criteria, in Germany 
in 2007 showed a prevalence of 18% in women and 25% in men [3]. The risk of a 
cardiovascular event in subjects with metabolic syndrome is about three times higher than in 
the normal population [3]. 60% of all subjects with hypertension have the metabolic 
syndrome [4]. 
The metabolic syndrome represents a complex medical condition which is associated with an 
increased risk for the development of diabetes, chronic low-grade inflammation of the vessel 
wall, stroke and cardiovascular disease. Interest in the metabolic syndrome has been 
increasing since diseases connected to it are major health problems in industrialized countries. 
Early detection and individualized risk stratification are key factors in lowering disease-
Obesity
Underweight
Healthy weight
Overweight
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related morbidity and mortality connected to obesity, type 2 diabetes and the metabolic 
syndrome. 
1.1 Definition of the metabolic syndrome and obesity 
1.1.1 Obesity  
The DAG (Deutsche Adipositas Gesellschaft) and WHO (World health organization) define 
obesity as more than normal or excessive accumulation of fat tissue in the body, which results 
in too much weight and presents risks to health [2], [5]. One way to measure obesity is the 
body mass index (BMI), i.e. a person’s weight (in kilograms) divided by the square of his or 
her height in meters. A person with a BMI equal to or more than 25 is considered overweight 
[2]. A person with a BMI of 30 or more is generally considered obese[2] . 
The WHO classifies obesity into three groups [6]:  
I: BMI: 30-34.9 
II: BMI: 35-39.9 
III: BMI: > or = 40 
Since obesity-associated diseases correlate with abdominal fat, the waist circumference or the 
waist-to-hip (W/H) ratio is more accurate than the BMI, because the BMI does not distinguish 
between central and peripheral obesity [6]. In Europe, a waist circumference of over 88 for 
women and over 102 cm for men is a sign of abdominal obesity [7] . 
1.1.2 Metabolic syndrome 
“Metabolic syndrome (MS) is considered a medical condition caused by over-nourishment 
and reduced physical activity as a consequence of industrial revolution and affluence, being 
the most frequently referred disorder in the recent literature. However, there is no general 
agreement regarding its denomination, and various synonyms exist in the literature such as 
Wohlstands syndrome, plurimetabolic syndrome, hormonal metabolic syndrome, syndrome 
X, insulin resistance syndrome, and hyperinsulinemia/insulin resistance syndrome” [8] Alberti 
et al. described the metabolic syndrome as a complex of interrelated risk factors for morbidity 
and mortality of cardiovascular disease (CVD) and diabetes [9]. Even though there is no 
common definition for metabolic syndrome, there is a consensus in the medical field that the 
term metabolic syndrome is acceptable for the condition of the presence of multiple metabolic 
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risk factors for CVD and diabesity [7]. All major health organizations deal with dyslipidemia 
with an increased plasma TAG (Triacylglyceride) concentration, decreased HDL (High 
density lipoprotein) concentration, hypertension, impaired glucose tolerance, and overweight 
(Table 1). 
Metabolic risk 
factor 
World Health 
Organization 
NCEP  
ATP III (2001) 
AHA/ATP III(2004) International 
Diabetes Federation 
2005 
Insulin  
Resistance 
Required (Impaired 
fasting glucose, 
impaired glucose 
tolerance, T2D)+two 
other risk factors 
Not required; 
any three of the five 
risk factors 
Not required; 
any three of the five 
risk factors 
Not required 
Obesity Waist-to-hip ratio 
≥0.9 
WC ≥ 102 cm WC ≥102 cm Required + two other 
risk factors, waist 
circumference 94 cm 
TAG ≥150 mg/dl ≥150 mg/dl ≥150 mg/dl ≥150 mg/dl 
HDL <35 mg/dl <40 mg/dl <40 mg/dl <40 mg/dl 
RR >140/90 mm Hg >130/90 mmHg or on 
medication 
>130/90 mmHg or on 
medication 
≥130/85 mmHg 
Glucose IGF, IGT, or T2D ≥110 mg/dl ≥100 mg/dl ≥100 mg/dl 
Other Albumin-to-
creatinine ratio >30 
mg/g 
Includes T2D Includes T2D Ethnic cutoffs for 
WC 
 
Table 1: Different definitions of metabolic syndrome by the different organizations (3). 
 
The metabolic syndrome is not an absolute risk indicator or a score like PROCAM 
(Prospective cardiovascular Münster) that could be applied in order to calculate the risk, 
because it does not contain many of the factors that determine absolute risk, for example age, 
sex or cigarette smoking [7]. “In the absence of CVD or diabetes, the metabolic syndrome is a 
predictor of these conditions. Once CVD or diabetes develops, the metabolic syndrome is 
often present, and the number of components of the metabolic syndrome contributes to 
disease progression and risk” [7]. Recently the WHO proposed the waist-to-hip (W/H) ratio 
[10] and the NCEP (National Cholesterol Education Program) proposed waist circumference 
as overweight criteria [10], but the International Diabetes Federation (IDF) suggests that 
obesity can be assumed at a BMI over 30 without measuring waist circumference. The 
different organizations have now agreed on waist circumference as a common standard [7], 
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[11]. In 2005, the IDF and the American Heart Association/National Heart, Lung, and Blood 
Institute (AHA/NHLBI) attempted to reach an agreement for the different clinical definitions 
of the metabolic syndrome. However, despite all efforts, a common agreement is far beyond 
reach. The IDF dropped the WHO requirement for insulin resistance but instead declared 
abdominal obesity to be one of the five factors required in the diagnosis [12]. Abdominal 
obesity can be determined by focusing on waist measurement as a simple screening tool. The 
remainder of the criteria was identical to those provided by ATP III. The AHA/NHLBI did 
not list abdominal obesity as a required risk factor, but slightly modified the ATP III criteria. 
Recently, IDF and AHA/NHLBI representatives held discussions to resolve the remaining 
differences between their definitions of the metabolic syndrome [7]. Both sides agreed that 
abdominal obesity should not be a prerequisite for diagnosis, but included as one of five 
criteria, so that the presence of any three out of five risk factors constitutes a diagnosis of 
metabolic syndrome, as ATP III criteria have suggested before [7]. The WHO defines two 
levels of abdominal obesity in Europe depending on the risk for metabolic complications. 
There is an increased risk for waist circumferences of ≥94 cm in men, but the risk is 
substantially higher at ≥102 cm [7]. In this work, the IDF criteria for group stratification were 
applied. Our patients were exclusively from Europe. The IDF proposes reference values for 
the waist circumference adjusted to ethnicity. If waist circumference is used as mandatory 
criterion, makes no difference for our distribution into the groups. 
1.2 Lipid metabolism 
1.2.1 Normal lipid metabolism 
Lipophilic lipids need transport vehicles. Those transporting lipoproteins are particles 
classified by their density. They contain neutral lipids (Cholesterylesters, Triacylglycerides) 
in their core and polar lipids (phospholipids, fatty acids, sterols) at the surface. 
Triacylglyceride (TAG)-rich lipoproteins originate either from the intestine (chylomicrons) or 
from the liver (VLDL) [13]. Their specific apolipoproteins permit their characterization. 
ApoB-48 is a specific apolipoprotein for chylomicrons and their remnants [14]. Chylomicrons 
(CM) transport exogenous TAGs. The lipoproteins undergo lipolysis in the circulation, 
thereby delivering fatty acids to tissues [13]. After reaching the plasma compartment, the 
chylomicrons release their apo A-I content during lipolysis and swap it for apo-CII [15] 
(Figure 3). 
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Figure 3 [13] Lipid transport: The TAG-rich lipoproteins are chylomicrons and VLDL. Chylomicrons are secreted by the 
intestine and carry the chylomicron-specific apolipoprotein apoB-48. They are split by LPL into small remnants which can be 
absorbed by the liver. VLDL are secreted by the liver which secrets the apolipoprotein apoB-100. LDL, a cholesterol-rich 
protein, is formed out of VLDL and by the liver. Since its half-life is longer than that of VLDL, the apoB-100 in plasma is 
mainly in LDL. HDL’s main apolipoprotein is apo A-I. Apo A-I is secreted by the liver and intestine. HDL is secreted by the 
liver and can carry more than one apoA-1, unlike LDL which only carries one apoB-100. HDL picks up cholesterol from the 
cell and transports it in the form of ester. It is able to make an exchange with VLDL by taking up TAGs from VLDL. Since 
TAG-richer HDL has a shorter half-life than the other HDLs, the HDL concentration in plasma negatively correlates with the 
TAGs concentration. 
 
This enables them to bind to endothelia-associated LPL (lipoprotein lipase) and to degrade 
their TAGs [16]. Chylomicrons have a half-life of approximately 5 minutes [16], whereas CM 
remnants have a much longer half-life time [16]. Chylomicron remnants and about half of the 
VLDL remnants are alternatively taken up by the liver [13]. Excess fatty acids and 
diglycerides in the liver induce very low density protein (VLDL) synthesis and secretion [16]. 
VLDL and CM are both degraded and generate the HDL precursor [16]. HDL is formed in the 
circulation from lipid-poor and protein-rich lipoprotein particles secreted by the liver and 
intestine and formed from surface components shed during the lipolysis of TAG-rich 
lipoproteins [13]. VLDL remnants are also metabolized to IDL and cholesterol-rich LDL, 
which constitutes the main cholesterol-carrying lipoprotein in humans [13]. For this cycle, 
LPL activity is essential and VLDL and chylomicrons compete for LPL-dependent acyl 
glycerol degradation [16]. Over 65% of the LDL is degraded after binding to LDL receptors in 
peripheral cells and hepatocytes. 15% are degraded by scavenger pathways in blood vessels. 
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Macrophages, which are also called scavenger cells because they carry scavenger receptors, 
take up chemically modified LDL such as oxidized LDL [15]. Increased levels of oxidized 
LDL are highly atherogenic [17]. Remnants formed during the cleavage of TAG-rich 
lipoproteins are also atherogenic [18]. However, remnants are rapidly and efficiently cleared 
from the circulation by hepatocytes which catabolize them [19]. 
1.2.2 Disorders of lipid metabolism in diabesity 
Elevated LDL can be due to a primary hereditary dyslipoproteinemia such as LDL receptor 
defect or impaired LPL activity, but also to a high alimentary input of saturated fatty acids 
(FA) [20] and cholesterol. The most common dyslipidemias are familial hypertriglyceridemia 
and familial combined hyperlipidemia (FCH). FCH includes intra-individual and intrafamilial 
variability of the lipid phenotype [21]. What characterizes FCH are elevated LDL (low-
density lipoprotein) cholesterol, especially the small dense LDL particles [21], and elevated 
triglyceride levels [22], often combined with a high prevalence of small very-low-density 
lipoproteins (VLDLs). The latter are mainly associated with an increased plasma level of 
apolipoprotein B-100 [21]. Patients with FCH show a relatively greater increase in apoB-100 
compared to the TAG increase [23]. Some patients may show a decrease in high-density 
lipoprotein (HDL) cholesterol plasma level [21]; [24]. Non-HDL cholesterol is elevated [25].  
Stratification according to Fredrickson: 
Type Elevated lipid fraction 
I Chylomicrons 
IIA LDL 
IIB LDL and VLDL 
III ß-VLDL (E2/E2) 
IV LDL 
V VLDL and Chylomicrons 
 
Hypertriglyceridemia can also be caused by high caloric input and increased fat and glucose 
intake [20]. Disturbances of the lipid metabolism can also be due to secondary diseases such 
as hypothyroidism, nephrotic syndrome, and cholestasis [20], which can be responsible for 
high cholesterol levels. Diabetes mellitus, obesity, alcoholism and terminal kidney 
insufficiency, on the other hand, can result in hypertriglyceridemia and low HDL levels. What 
is important is the distribution of LPL among tissues [26]. As Wang et al. described in 2009, a 
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loss of LPL in muscle cells can lead to obesity and insulin resistance in cells other than the 
skeletal muscle [26].  
1.2.3 Adipose tissue metabolism 
Adipose tissue can be divided structurally, functionally and topologically into white and 
brown as well as into visceral and subcutaneous fat. It is not only a storage organ, but has 
many different modulatory functions in the endocrine and immune system. Brown adipose 
tissue, which is nearly absent in adults, is essential for children in order to maintain their body 
temperature. It uncouples oxygen via uncoupling protein (UCP) from ATP (adenosine 
triphosphate) production to produce heat and ROS (Reactive Oxygen Species) [27]; [28]. In 
healthy subjects with normal caloric intake, the caloric output can be induced via adrenergic 
receptors. The increased cAMP (cyclic adenosine monophosphate) can then trigger the caloric 
output via activation of thyroid hormone and UCP [27]; [28]. In obese subjects, the UCP 
pathway is less frequently provoked due to an increase in SHP (small heterodimer partner), 
which itself triggers diet-induced obesity and an impaired glucose tolerance [27], [28].The 
white adipose tissue, which is subject of this work, contains adipocytes, preadipocytes, 
fibroblasts, leukocytes, macrophages and endothelial cells; it provides energy and fatty acids 
from its stored lipids.  
 
Figure 4: Communication between large and small adipocytes, involving cell-to-cell contact and signal peptides like 
adipokines (4). The resulting parallel upregulation of esterification (↑) and downregulation of lipolysis (↓) leads to an 
enlargement of the lipid droplets and the size of the adipocytes [29]. 
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Moreover, white adipose tissue produces hormones and adipokines as well as influences 
different bodily functions. Large adipocytes secrete adipokines and microvesicles, which are 
taken up by small adipocytes, switch off lipid release and switch on storage. This process 
leads to a conversion into large adipocytes [29] (Figure 4). 
1.3 Etiology and pathogenesis of obesity and the metabolic syndrome 
The development of obesity is associated with multiple factors. The reasons for obesity can be 
summarized as a drift of energy homeostasis to the positive side (orexia). A positive energy 
balance is caused by excessive food intake, especially saturated FAs, and a lack of physical 
activity, which are the main reasons for obesity [30]. This shift from a balanced energy to a 
positive energy balance can also be the consequence of a lack of the hormone leptin due to a 
genetic mutation or a defect of the receptor. There can be also a defect in the α-MSH 
(melanocyte stimulating hormone) liberation, for example due to an enzyme defect or a lack 
of the receptor of α–MSH [31]. It should be mentioned that studies have found a more 
significant relation between MSH and type 2 diabetes than between MSH and obesity [31]. 
Genetic influence is responsible for 40% of the cases of obesity [32]. The energy output is 
influenced by basic metabolism, thermogenesis and activity. During the development of 
obesity, the energy regime is kept positive by the input of rich and too much food. Later on, 
energy input and consumption are balanced, but due to the increased mass of fat, the basal 
metabolic rate is elevated. Urbanization and the modern lifestyle, in which less physical 
activity is combined with an elevated fat content in the diet, are almost certain to lead to 
progressing obesity [2]. Psychosocial factors can also influence the development of obesity: 
anxious and depressive individuals are more likely to become obese [33]. The suggestion that 
a lack of sleep in youth leads to obesity has not been confirmed yet [34]. Of course, 
environmental factors such as the workplace may influence a person’s nutrition. People who 
work with food, for example butchers or bakers, are more frequently affected by obesity. 
Notable relevance should be given to the impact of cultural and social values. Whereas in 
some cultures, obesity is a status symbol which makes overweight desirable, in other cultures 
it is not socially accepted [2], [35]. Endocrine reasons for overweight include Cushing’s 
syndrome, Hypothyroidism or Insulinoma [36]. Changes in the mass of adipose tissue, the 
hypertrophy and hyperplasia of adipocytes, connected with angiogenesis and proliferation and 
expansion of the extracellular matrix, lead to changes of metabolic pathways [37] and 
epigenetic modulation [38].  
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1.4 Consequences and clinic of obesity and the metabolic syndrome 
The first symptoms of obesity are dyspnea, pain of angles and back, fatigue, cardiac 
problems, edematous legs in the evening, obstipation and mental stress. The associated risks 
of further diseases depend on the distribution of the fatty tissue (Figure 5). Even though 
women have more body fat than men, their pear-shaped body fat distribution is associated 
with lower cardiometabolic risk in contrast to the metabolic consequences of central obesity 
typical in men [39]. The pear-shaped phenotype reflects the subcutaneous white adipose tissue 
depots just under the skin, which are mainly in the gluteal and femoral areas, but also in the 
waist [39]. The intra-abdominal depots including visceral adipose tissue often consist of more, 
but less differentiated, adipocytes [39]. “Obese patients with the metabolic syndrome 
generally have a visceral (apple-shaped) fat distribution and are at an increased risk of 
macrovascular disease, while those with peripheral (pear-shaped) obesity do not tend to have 
metabolic abnormalities and are at lower risk” [40]. “This difference appears to be related to 
the differing metabolic functions (and secretory products) of visceral adipose tissue and 
subcutaneous adipose tissue, as well as the fact that visceral fatty tissue drains directly into 
the liver” [40]. 
 
 
Figure 5: Different types of fat distribution with different risk for associated diseases (5). 
 
Both phenotypes (pear and apple) differ in their predominant type of growth [39]. With age, 
the capability of increasing the number of fat cells does not vanish, as has been suggested, but 
the fat cells mostly gain in size [41]. The consequence of excess lipid accumulation, even 
though it is limited to 0.8 µg per cell, is devastating. The change in number, unlike the change 
in size, is not reversible [42]. The change of the adipocytes’ size causes changes in the 
 18  
composition of the cells, increases lipolysis and thus an elevation of the fatty acid 
concentration in the plasma, which then alters insulin sensitivity. The changes in number and 
size of adipocytes lead to changes in hormone and transmitter secretion and finally to a 
chronic state of inflammation in the entire body. Thus, the alteration of the tightly controlled 
compositions of the cell content causes the loss of specific functions. As a consequence, the 
risk of developing type 2 diabetes, hypertension, coronary heart disease, hypercoagulopathy, 
stroke, gallbladder disease, sleep apnea, osteoarthritis, osteoporosis and cancer is increased 
[41].  
1.4.1 Diabetes in metabolic syndrome 
Insulin synthesis 
Proinsulin, the precursor of insulin, is synthesized in the rough ER of ß-cells in the pancreatic 
islands and plays a key role in insulin biosynthesis [43]. Proinsulin consists of the three 
polypeptide chains A, B and C, and their folding is ensured by three disulfide bridges [43,44]. 
The precursor of proinsulin is the mRNA pre-proinsulin [45] The pre-proinsulin is translated 
into a single polypeptide chain of polyribosomes associated with the rough ER [45]. During 
the transition through the rough ER, proinsulin is cotranslationally processed by the 
elimination of its signal sequence. Proinsulin forms its tertiary structure by intra-molecular 
disulfide bonding. The precursor was discovered as early as in 1967, and it changed the 
perception of hormone bio-synthesis [43]. Proinsulin is separated from its C-peptide, which is 
secreted in equimolar concentration as insulin, by the endocrine part of the pancreas [45]. The 
plasma concentration of C-peptide is used as a biomarker for endogenous insulin secretion. 
Insulin secretion and impaired glucose tolerance 
An increased plasma concentration of glucose, certain amino acids and acetoacetate, which is 
a product of ß-oxidation and fatty acids, up-regulates insulin secretion [46]. In the liver and 
pancreas, glucose is taken up via GLUT2 (glucose transporter) depending on the glucose 
concentration. But GLUT4, which is responsible for glucose uptake in adipose and muscular 
tissue, has also been identified in pancreatic cells [47]. GLUT2 only has a low glucose affinity 
(Km 17mM) and the velocity at which glucose is transported in the cell by GLUT2 cannot be 
increased by the blood glucose concentration, but the velocity by which the glucokinase 
works depends on glucose concentration and can be increased between blood glucose levels 
of 3 and 15 mmol/l [48]. The exocytosis of insulin containing granules of ß-cells from the 
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pancreas is regulated via mitochondrial ATP/ADP ratio, which increases in the presence of 
glucose [48]. Elevated ATP levels provoke the closing of potassium channels [48].  
A closure of potassium channels results in a depolarization of the cellular membrane, which 
causes the calcium channel to open and finally an exocytosis of insulin granules [48]. The 
secreted insulin induces GLUT4 incorporation in the membranes of fat and muscle cells, 
where glucose is rapidly taken up via passive diffusion. This type of transport is called 
insulin-dependent glucose uptake [48]. This first phase of the insulin response lasts 2-5 
minutes [49]. Insulin increases the V(max) of glucose elimination in the blood [48]. The 
danger of an insulin overdose lies in the increased insulin-dependent glucose absorption by 
muscle and fat tissue, whereas insulin-independent cells in the CNS may develop 
hypoglycemia. In the muscle tissue, glucose uptake results in increased glycolysis and 
glycogen synthesis; in the fat tissue, the elevated availability of acetyl-coA, which is 
dependent on the activity of the pyruvate dehydrogenase complex, results in a de novo 
synthesis of free fatty acids and their incorporation in TAG and thus increased lipid storage 
[48]. Insulin is an anabolic hormone which reduces lipolysis and activates liponeogenesis in 
the liver and in fatty tissue. The reduction of lipolysis implies lower free fatty acid (FFA) 
concentration levels in the plasma. In diabetics, the elevation of FFA in the plasma has 
lipotoxic effects [49]. Glucose tolerance can be maintained for a long time in obese 
individuals despite a decreased sensitivity to insulin. This is due to an increase of insulin 
secretion. The normal insulin secretion works by calcium-dependent exocytosis after an ATP-
triggered cell depolarization. Insulin secretion can be either directly influenced by glucose or 
in a second step, which means by the metabolic intermediary products when pyruvate is 
converted to triglycerides. This mechanism is defined as “glucose-stimulated insulin 
secretion” (GSIS). Glucose-stimulated insulin secretion also has a long-term impact on 
glucose transport and utilization and is itself positively controlled by fatty acids and lipids in 
the plasma. For this second step of insulin secretion, the amplification phase is mediated by 
citrate, which is exported from mitochondria [50]. Citrate is a substrate and the resulting 
products are short-chain FAs which induce insulin secretion [50]. Thus, glucose increases its 
own insulin-dependent uptake with an autocrine amplifying mechanism, glucose-stimulated 
insulin secretion. Especially under fasting conditions, endogenous fatty acids are important 
for the secretion of insulin. The maintained insulin secretion is important in order to oppose 
lipolysis and its consequences, lipotoxicity and ketoacidosis. Exogenous, especially long and 
saturated, FAs can also amplify insulin secretion by GSIS [50]. This is necessary in order to 
develop an acute hyperinsulinemia to oppose the reduced glucose uptake. In the insulin-
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resistant state, GSIS is not enhanced but even reduced by the chronically elevated fatty acid 
level. The exaggerated lipolysis leads to lipotoxicity and a false distribution of triglycerides as 
well as an insulin resistance of the affected organs. PPARs decrease the concentration of 
lipids in the blood via RXR, thereby opposing lipid-dependent insulin resistance. Thus they 
lower the need of increased insulin secretion. A chronic elevation of FA is a problem. In this 
state, GSIS is reduced, but the insulin secretion by other mechanisms is not affected or even 
enhanced. 
From impaired glucose tolerance to type 2 diabetes  
In impaired glucose tolerance, the first phase of insulin secretion is reduced, which results in 
high postprandial glucose levels, whereas fasting glucose levels are normal. Later, glucose 
levels are also elevated under fasting conditions, but basal insulin secretion can be kept 
normal by compensation. In manifest diabetes, basal insulin secretion can also be reduced. 
Elevated plasma fatty acids as well as high insulin levels in the blood increase insulin 
resistance. High insulin levels in the blood are responsible for less insulin production, thus 
blood glucose remains high. The insufficient supply of the tissues with glucose leads to an 
increased glucose production by the liver. Since the hunger cannot be satisfied, the glucose 
intake is elevated as well. Insulin resistance is one of the main reasons for a higher glucose 
intake and thus obesity. It is triggered by inflammation, stress and free fatty acids.  
1.4.2 Inflammation in the metabolic syndrome 
Inflammation can be modulated via adipokines (signaling proteins that derive from the 
adipose tissue); therefore an increased volume of fatty tissue is associated with a chronic state 
of inflammation. The first link between obesity, insulin action and chronic inflammation 
involving TNFα was established in 1993 by Hotamisligil et al [51]. The workgroup named the 
chronic low-grade inflammation associated with overnutrition  ”meta- inflammation” [52]. 
This meta-inflammation lowers adiponectin and insulin sensitivity, and it prevents the 
differentiation of preadipocytes into adipocytes. On the other hand, meta-inflammation is 
accompanied by a chronically increased macrophage concentration [52] and ER stress. The 
complex mechanisms have not been fully understood so far, but e.g. IKKβ are involved in the 
inflammation pathways, which results in the activation of NF-κB [53] as a mediator of TNF-
induced insulin resistance as well as in the activation of serine/threonine protein kinases.  
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1.5 Adipokines 
Since adipokines are cell-to-cell signaling proteins that derive from the adipose tissue, altered 
blood concentrations and dynamics reflect an altered physiology in subjects with changes in 
adipose cell number, volume and composition. Their modulating role in obesity, insulin 
resistance and inflammation have already been reported previously [54]. Their origin and site 
of action are graphically displayed below (Figure 6, Figure 7 Figure 9). 
1.5.1 Leptin 
Leptin is mainly expressed by adipocytes. It is also produced in the placenta, bone marrow, 
stomach, muscle and brain. Its main function is controlling the appetite. Leptin opposes 
adiponectin and acts as a proangiogenic and proinflammatory agent [55]. It stimulates the 
proliferation of circulating monocytes in vitro and up-regulates the expression of activation 
markers on monocytes and neutrophils. Leptin stimulates ROS production [55]. Moreover, 
Leptin regulates lipid metabolism (Figure 6). Leptin levels are increased in obese subjects. 
Subjects with metabolic syndrome often prove insufficient regulation due to leptin resistance. 
 
 
Figure 6: The peripheral action of leptin. Leptin is mainly secreted by adipose tissue and the gastric mucosa. It regulates 
appetite, inflammation and lipid absorption (Image taken from [56]). 
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1.5.2 Adiponectin 
 
Figure 7: Effects of a decreased adiponectin level in the blood and the association with plaque formation (6). 
 
Because of its exclusive secretion by adipocytes and its pleiotropic positive functions in 
reducing the diseases associated with obesity, it is a suitable biomarker for the risk of 
metabolic syndrome. Scherer et al. showed that, in mice, adiponectin is capable of boosting 
the sensitization of the liver to circulating insulin. The decrease of adiponectin levels in obese 
subjects leads to inflammation and insulin resistance and thus to hyperlipidemia. 
Inflammation directly leads to the formation of foam cells and, due to hyperlipidemia, 
increased levels of oxidized LDL support foam cell formation [57]. Increased oxidative stress 
leads to endothelial dysfunction. The result is plaque formation and an increased risk for CAD 
(cardiac artery disease) (Figure 7).  
 
Figure 8: Adiponectin increases fatty acid oxidation [58]. 
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Figure 8 depicts the role of adiponectin in hyperlipidemia. It describes the effects of 
adiponectin on signaling pathways by mediating ß-oxidation and decreasing triglyceride 
concentration. 
 
1.5.3 Omentin 
Omentin is especially expressed by visceral adipose tissue [59]. The plasma concentration of 
omentin negatively correlates with glucose tolerance [59] and positively correlates with  
endothelium-dependent vasodilation (Figure 9). Plasma omentin levels negatively correlate 
with carotid intima-media thickness, which is a marker of early atherosclerosis [59]. “Low 
levels of circulating omentin are also associated with the prevalence of coronary artery 
disease These data suggest that omentin may represent a biomarker for not only metabolic 
disorders, but also cardiovascular diseases” [59]. 
 
Figure 9: Omentin, leptin and adiponectin have modulating effects on the vessel wall (VSMC = vascular smooth muscle 
cells). Omentin/intelectin is shown as being secreted by the endothelial cells of the blood vessels of omental but not 
subcutaneous fat (7). 
1.6 Lipids 
Lipids are classified into classes such as triglycerides (triacylglycerols), fatty acids, 
phospholipids, plasmalogens, sphingolipids, and sterols. Each lipid class contains numerous 
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lipid species that differ in various aspects e.g. defined by fatty acid chain length and 
desaturation. In any eukaryotic cell, more than 1000 different lipid species exist [60]. When 
challenges in the environment destroy homeostasis, the maintenance of the physiological 
functions is usually restored. But a change of 10% of lipid content can already have 
significant consequences [61]. Due to the concentration of stressors, the response to the 
environment can be inefficient. This phenomenon is called “allostatic load” [61]. An example 
for an allostatic load would be an ablation of SREBP1 (sterol regulating binding protein), 
which preferentially regulates the FA metabolism. In this case, SREBP2 would be 
automatically up-regulated, which might lead to an inappropriate cholesterol accumulation 
[61]. Another example is elevated insulin secretion in persons with insulin resistance. The 
allostatic regulations might compensate certain failures, but the symptoms of damage and 
allostatic overload can progressively lead to symptoms. Oresic noted that these allostatic 
responses could be used as early biomarkers to quantify the risk for certain diseases [61]. 
1.6.1 Plasmalogens 
Plasmalogens constitute 18% of the total phospholipid mass in humans [62]. They are 
synthesized in the liver and transported in the blood stream bound to proteins. The majority of 
PE-plasmalogens (ethanolamine plasmalogens) in the plasma are transported in HDL particles 
[62]. The ethanolamine plasmalogens are important in this study because of their antioxidant 
effects [63]. The quantity of plasmalogens in a cell reflects the quantity of peroxisomes in that 
cell, because peroxisomes are the location of plasmalogen synthesis. Ethanolamine 
plasmalogens have a half-life of 3 hours [62]. And contrary to other lipids, they revealed a 
high level of variation between different tested individuals, which could make them an 
interesting marker for peroxisome function [62]. It is known that with age, plasmalogen 
synthesis in humans decreases [62]. A lack of plasmalogens is associated with ER stress, the 
“unfolded protein response”, which, as a last consequence, leads to apoptosis. Plasmalogens 
also serve as a reservoir for PUFAs and a reduced quantity of plasmalogens could be 
associated with a reduced quantity of ω-3 fatty acids species, which serve as anti-
inflammatory messengers, and of adipogenesis-regulating fatty acids [62]. Since a decreased 
number of plasmalogens is associated with diseases such as diabetes and obesity, our 
laboratory proposed to use plasmalogen species as early stratifying biomarkers and indication 
for disease and therapy [62]. 
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1.6.2 Fatty acids 
The fatty acid composition in serum is an important determinant of the metabolic syndrome.  
Kotronen et al. showed that there is a close connection between the quantity of saturated fatty 
acid in triglycerides and diabetes. His work group has already proposed some species as 
biomarkers [63]. They found out that serum TAG molecules containing saturated and 
monounsaturated fatty acids, such as TAG (16:0/16:0/18:1) and (16:0/18:1/18:0), correlated 
positively, whereas those containing mono- and di-unsaturated FAs such as (18:1, 18:2) 
correlated negatively with impaired glucose tolerance, hepatic lipogenesis and waist 
circumference. However, saturated TAGs only correlate positively with features of insulin 
resistance in VLDL, IDL and LDL, not in HDL. Free FAs only have a half-life of 12 minutes.  
Saturated long-chain fatty acids can up-regulate ceramide production, whereas short-chain 
unsaturated fatty acids protect ß-cells from the toxicity of ceramides. Polyunsaturated fatty 
acids (PUFAs) can be classified in ω−3 fatty acids and ω−6 fatty acids, and in the westernized 
diet the predominant dietary PUFAs are ω−6 fatty acids [64]. 
1.6.3 Phosphatidylcholine and Lysophosphatidylcholine 
Phosphatidylcholine also counts among the glycerophospholipids. Lysophosphatidylcholine 
(LPC) is a signaling molecule with functions in cellular proliferation and inflammation [65]. 
A negative correlation between BMI and LPC has been published [65]. The exposure of 
adipocytes to LPC in vitro has caused their improved glucose tolerance, thus LPC might be 
involved in glucose regulation. Reduced LPC levels in obese subjects might contribute to 
insulin resistance [65]. Enhanced LPC levels may be an early marker for development of type 
1 diabetes [66]. 
1.6.4 LPA 
Lysophosphatidic acid (LPA) is a phospholipid, which consists of a single fatty acyl chain, a 
glycerol backbone and a free phosphate group [67]. By binding to specific G-protein-coupled 
receptors, LPA activates multiple signal transduction pathways, including diverse processes 
such as wound healing, brain development, vascular remodeling and tumor progression [67]. 
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1.6.5 Sphingomyelin and ceramides 
Sphingolipids derive from the sphingosine backbone. They are components of cellular 
membranes, enriched in membrane microdomains (rafts) [68]. They can be found in nerves 
and are important for signal transduction. Those which are interesting for our study are the 
sphingolipids belonging to the main group, such as ceramide and sphingomyelin. Ceramide is 
the simplest sphingolipid, consisting of one free fatty acid (palmitate) and serine to form the 
sphingosine base. The intracellular elevation of ceramides is stimulated by stressors and 
inflammation. Ceramides inhibit cell growth, proliferation, differentiation and induce 
apoptosis. An equilibrium of ceramide and sphingosine-1-phosphate is crucial for the balance 
of death and survival [69]. It is known that sphingosine is elevated in the serum of type 2 
diabetes subjects compared to healthy controls. Ceramide can contribute to insulin resistance 
by inhibiting GLUT4 translocation, glycogen synthesis, altering pancreatic cells and insulin-
stimulated glucose uptake [69]. Risk of atherosclerosis is associated with high levels of 
sphingomyelin, which is overexpressed in obese subjects due to the higher levels of serine 
palmitoyl-transferase in the sera of obese subjects compared to lean ones. 
1.7 Current biomarkers 
The clinical utility of a biomarker depends on its ability to account for a significant proportion 
of the disease’s evaluation, its accuracy and reliability and on its ability to provide good 
sensitivity and specificity and a high predictive value [70]. The well-established biomarkers 
for the metabolic syndrome are already incorporated into the diagnostic criteria. Additional 
potential biomarkers for the metabolic syndrome have been identified. The predictive values 
for the risk of metabolic syndrome of inflammation parameters, e.g. CRP [71], or adipokines 
such as ghrelin [72], adiponectin [73] and leptin [74,75] have been published recently. 
Elevated fasting CRP concentrations and decreased adiponectin levels as well as elevated 
postprandial triglycerides are not only a hallmark for the metabolic syndrome, but are also 
independent predictors of CVD risk [76]. In previous studies, only the basal values have been 
taken into account, but the dynamic has not yet been compared between a metabolic 
syndrome group and a control group. 
1.8 Aim of the study 
The aim of this study was to identify novel biomarkers for diabetes, hyperlipidemia, 
atherosclerosis and CVD risk which might have prognostic value. Since those diseases are 
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connected with the metabolic syndrome, the risk for those diseases was measured based on 
the risk of having metabolic syndrome. To this aim, we analyzed the differences between 
three groups: control (none of the criteria defining metabolic syndrome), risk (two of the risk 
factors) and metabolic syndrome as defined in Table 2. The aim was to test the hypothesis that 
metabolic syndrome subjects have an acutely and chronically altered lipid metabolism 
compared to the control group, suggesting an altered postprandial lipidomic response in 
diabesity. The examination was carried out by observing the effects of an oral fat tolerance 
test on those body compartments which are associated with obesity. 
For the oral fat tolerance test, the subjects were given a drink consisting of 66% fat and their 
plasma samples were compared to the fasting plasma sample 2, 4, 6 and 8 hours after the 
drink. Adipokines, inflammation markers and signaling proteins as well as lipids and 
lipidomics of the adipose tissue, blood compartments, kidney and bone were measured on the 
assumption that persons with metabolic syndrome react differently to high fat load than 
healthy subjects, because their metabolism is acutely and chronically altered. For this 
investigation, the dynamic of blood components was compared between different groups 
(named control, risk and metabolic syndrome) according to their diet and risk factors 
associated with obesity. With this work, we hope to contribute to the definition of a new 
multimarker panel – with greater sensitivity and specificity than the current ones – in order to 
screen and monitor diabesity patients with the metabolic syndrome, assess their courses of 
disease and predict the outcome of the disease. 
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2 Materials and Methods 
2.1 Materials  
Consumables Manufacturer 
Inlet liners Carbo Frit Retek 
Silica HPTLC plate, phospholipid standards Avanti Polar Lipids 
Test tubes for diluting samples Eppendorf 
 
 
Reagents  Manufacturer 
Acetylchloride Merck 
Ammonium acetate and acetyl chloride Fluka 
Cholesterol (95% purity) Sigma 
Cholesteryl ester standards (98% purity)  Cambridge Isotope Laboratories Andover 
2-13C acetate Cambridge-Isotope Lab 
EDTA EDTA 
Ethanol Merck 
FA standard D3C-16:0 Sigma 
FAME standard Lordan 
HCl 1N Sigma 
n-Hexane Merck 
Medical Isotopes (99%purity) Pelha 
Methanol Merck 
NaOH 10N Sigma 
PHMB Sigma 
Potassium phosphate buffer 0,1M pH 7,4 Sigma 
 
 
Instrumentation  Manufacturer 
Agilent 110 binary pump Agilent 
CAMAG TLC scanner Camag 
HTS PAL auto sampler CTC 
GCMS-QP 2010 detector+autosampler+PTV (programmed T vaporizer) Shimadzu  
Graduated cylinder for dilution buffer Braun 
Triple quadruple mass spectrometer with electrospray ionization source Waters 
Vortex Mixer  Sigma 
Orbital microplate Shaker Sigma 
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2.2 Selection of subjects and stratification 
A small presentation of our study was prepared with contact dates on business cards and we 
placed ourselves in the city once, another time at the University Hospital Regensburg and at 
Regensburg University. The project was explained to a random sample of people who passed 
and who were asked if they were interested in taking part as volunteers. Then we checked 
whether they met the inclusion criteria. As an incentive for participating, we offered the 
volunteers their laboratory parameters with interpretation and a treatment recommendation if 
necessary. We handed out our cards and asked them to call us for an appointment. 
Additionally, the medical doctor in cooperation with the department of cardiology agreed to 
put us in contact with patients meeting our inclusion criteria. We recruited 70 healthy male 
volunteers from town, University Hospital and University. 3 of them decided to abort the 
experiment prematurely without providing reasons. The 67 healthy volunteers were stratified 
in three groups according to IDF criteria (Table 2): the metabolic syndrome group contained 
subjects which fulfilled at least three of the criteria, the risk group consisted of subjects which 
fulfilled at least one but less than three criteria, and the control group contained subjects 
which did not show any of the risk factors from the IDF criteria. Inclusion criteria were ages 
between 35 and 70 and male gender. The IDF definition of the metabolic syndrome is that a 
subject is afflicted by the metabolic syndrome if abdominal obesity and two or more of these 
criteria are fulfilled (Table 2). 
Parameter Reference range 
Elevated triglycerides ≥150 mg/dl or drug treatment 
Reduced HDL cholesterol <40 mg/dl for males or drug treatment 
Elevated blood pressure Systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg or 
drug treatment 
Elevated fasting glucose ≥ 100 mg/dl or drug treatment 
Elevated waist circumference men ≥ 94 cm 
Table 2: IDF criteria for metabolic syndrome [77] To fit into our metabolic syndrome group, the subject had to fulfill three 
(obesity+2 of the criteria) or more of the five criteria.  
 
Immunoassays Material Manufacturer  
ApoB-48 Serum Shibayagi 
FGF-23 Li-Hep-Plasma Immutopics 
Leptin Serum Bio Vendor 
Ghrelin Li.-Hep. SPI bio 
Omentin Li-Hep-Plasma Bio Vendor 
Su-Par Li-Hep-Plasma ViroGates 
 30  
Subjects were excluded if they had a history of malignant disease or disorders in their 
gastrointestinal tract.  
2.3 Design  
The approval of the hospital ethics committee (no. 08/119) was obtained. Each patient who 
participated in our study especially had to be informed of the potential side effects of the 
drink (nausea immediately or diarrhea 1-2 hours after drinking), sign an informed consent 
(Annex 1) and complete a questionnaire (7.2) with questions on medical history, physical 
activity, eating habits, medication, allergies and family history. The oral fat tolerance test is 
similar to the oral glucose tolerance test (OGTT).  
 
 
 
 
 
 
 
 
Figure 10: Procedure. Blood samples were taken following strict 12-hour fasting at time points 0, 2, 4, 6 and 8 hours after 
drinking the high caloric shake. The samples were analyzed for their lipidomic profile, as well as for cellular parameters and 
serum cytokines. 
 
The oral fat tolerance test (OFTT) was carried out as suggested by Hanefeld group (Dresden) 
with a minor modification of the variant by Henkel E. et al. (2005) [78]. As described in 
Figure 10 blood samples were taken from the antebrachial vein, following a strict 12-hour 
fasting period at time points 0, 2, 4, 6 and 8 hours after drinking a high caloric shake. The 
shake consisted of 250 ml cream with 100 ml fruit juice in combination with 60g sugar. Sugar 
was added to adjust the combined fat-glucose content. The fruit juice was added to the high-
fat cream to neutralize the metallic taste of the pure drink and to make the drink appetizing. In 
total, the drink contained 3% protein, 66% fat and 32% carbohydrate, adding up to a total 
energy of 1016 kcal (Figure 11). 
0h 
 
Oral fat load 
2h 4h 6h 8h 
Blood 
Serum/Plasma EDTA-blood 
Basic clinical hematology 
Clinical chemistry 
TG/HDL/LDL 
Apolipoproteins 
Lipid extraction 
Quantitative lipid species profiling 
Cholesterol/cholesterylester 
TG 
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 Kcal Protein [g] Fat [g] Carbohydrate [g] PUFA [g] SUFA [g] 
Total 
FA [g] 
250ml/286g 
milk cream 
720 6.2 75 8 2.8 22.6 45.5 
100ml/100g 
fruit juice 
53 0.3 0 12 0.2 0 0.1 
60g white 
sugar 
243 0 0 60 0 0 0 
Total content 1016 
 
6.5 (4.02%) 
3% kcal 
75 (46%) 
66% kcal 
80 (49.5%) 
32% kcal 
3 22.6 45.6 
 
 
Figure 11: Composition of the oral fat drink according to manufacturers’ declaration. 
 
We first measured the patients’ blood pressure, waist and hip circumference. Waist and hip 
circumferences were measured in a standing position between the lower costal margin and the 
iliac crest in the narrowest section. Hip circumferences were measured at the level of the 
greater trochanter. Blood pressure was measured five minutes after relaxing in an either 
sitting or lying position. Immediately before the drink was handed out, we inserted an 
antebrachial cannula for blood sampling or, where this was not possible; we drew blood with 
a butterfly needle. After the first withdrawal of fasting blood, the blood was immediately 
transported to the laboratory, and the drink then had to be consumed within a maximum of ten 
minutes. During the experiment, the participants were advised to stay in the hospital building 
and were only allowed to drink water. We took a sample of every drink; ten samples were 
randomized to control the fatty acid composition of the drink. Six tubes were filled with every 
blood collection: 4x EDTA, 1x lithium heparin, 1x serum. The samples were analyzed for 
their lipidomic profile, as well as for cellular parameters and serum cytokines. Special 
emphasis was put onto adipokines which might be regulated differently in persons with 
metabolic syndrome compared to the control group. Samples from each drink were aliquoted 
and stored at -80°C for further analysis. 
2.4 Laboratory parameters  
2.4.1 Lipid mass spectrometry  
Mass spectrometry was developed by J.J. Thomson in 1910 [79]. It is an analytical laboratory 
technique to separate the components of a sample according to their mass [79]. Since the 
1950s, gas chromatography has been coupled with mass spectrometry [80]. In this case the 
samples are vaporized into gas and then ionized. The quantity of ions at different deflections 
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is plotted as a spectrum of different masses [79]. Figure 12 shows our modern instrument for 
quadruple mass spectrometry with the CTC PAL HTS autosampler. 
 
Figure 12: The laboratory instrument, an instrument for mass spectrometry with autosampler and Agilent pumps, API 4000 
QTRAP. Samples were vaporized and ionized and plotted as a spectrum of different masses. Source: Gerhard Liebisch, 
University of Regensburg. 
. 
 
Figure 13 shows a short overview of the workflow of analyzing the different lipid classes.  
 
Figure 13: Strategies for lipid analysis. On the left, the separation and identification of the phospholipids that were prepared 
by the method of Bligh and Dyer and then separated by electroflow separation is depicted, on the right the identification and 
quantification of the fatty acids is shown. Here, the first step is preparation, the second GC-MS. Source: Gerhard Liebisch, 
University of Regensburg. 
 
Parameter Preparation procedure Reference value 
Ceramides  Bligh and Dyer  
Fatty acids  FAME 0.3-1 mmol/l 
LPA  0.1 µM 
LPC  < 150 µM 
Phosphatidylcholine Electrospray ionization tandem mass 
spectrometry with isotope correction 
algorithm  
 
Plasmalogens  Bligh and Dyer  
SPM Electrospray ionization tandem mass 
spectrometry with isotope correction 
algorithm 
 
 
Table 3: Parameter list of mass spectrometrically tested substances and reference values. Values found in [81], [82], [83]. 
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Fatty acid analysis 
Fatty acids (total hydrolysis and non-esterified fatty acids [NEFA]) were measured as methyl 
esters by GC/MS after derivatization according to methods published by Ecker, Liebisch et al. 
[84]. Fatty acid methyl ester (FAMEs) were prepared by transesterification in one step 
reaction with acetyl chloride and methanol according to the protocol of Lepage and Roy [85]. 
Cyanopropyl polysilphenyl-siloxane columns are preferred to wax columns as they have a 
high temperature stability [85]. The inert gas helium was used as mobile phase and carrier. 
The FAMEs were transported by the helium, which interacted with the solid phase. Each 
compound had its own retention time. The comparison of retention times with the standard 
analytics made it possible to identify the peaks. And with mass spectrometry as a detector, the 
contents of the samples could be determined. Sensitivity is gained by using a programmed 
temperature vaporizer, which can even be used for samples with low concentrations [85]. 
Preparation: Fatty acid methyl ester (FAMEs): 10µl plasma were methylated in PTFE screw 
capped pyrex tubes [85]. 1µl of C13:0 for quality control and 1µl C21:0 iso as internal 
standard were added in 50 µl Methanol [85]. Derivatization was performed by shaking 2ml of 
methanolic acetylchloride (10%) and 50µl n-hexane in a 95°C water bath for 1h [85]. At room 
temperature, 5ml of a 6-percent potassium carbonate solution were added. 100µl of the  top-
layer were transferred into a 500µl autosampler vial [85]. Gas chromatography coupled to 
mass spectrometry: An aliquot of 1µl FAMEs was separated by BPX70 column coated with 
70% cyanopropyl polysilphenyl-siloxane using a GC 2010 coupled to a GSMS-QP2010 
detector. PTV run in split mode 1:20 for 3s switched for 1.3min to the splitless mode and a 
split ratio of 1:100 until the end of the run [85]. The liner was packed with CarboFrit
TM
 
 [85]. 
The temperature was 50°C for 0.75min, then the temperature was increased by 40°C/min to 
155°C and afterwards more slowly by 6 °C/min up to 210° and held there for 2min. Helium 
was used as carrier gas with a constant linear velocity of 50cm/s [85]. The detector 
temperature was kept at 250 °C and FAME identification was performed in scan mode. 
Quantification was  performed by selected ion monitoring (SIM) of the most intense 
fragments [85].  
Cholesteryl ester analysis by ESI-MS/MS  
This method is based on the creation of an aerosol from the analytic by the use of solvents. At 
a high voltage and under high pressure using argon gas, small charged droplets of the analytic 
were produced. After the solvent evaporates, the droplets decrease in size and disperse. The 
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ions were collected into the vacuum of the mass spectrometer and heated in order to leave 
room for the next analytic aerosol. Lipid extraction was performed in the presence of not 
naturally occurring lipid species as internal standards and the chloroform phase was dried in a 
vacuum centrifuge and dissolved in 10 mM ammonium acetate in methanol/chloroform (3:1 
vol/vol). Samples were analyzed by ESI-MS/MS in positive ion mode after direct flow 
injection using the analytical setup and data analysis algorithms described previously by 
Liebisch et al. The triple quadrupole MS or tandem mass spectrometry allows to first 
determine the mass of the ion, then bring ions together with a gas and determine the mass 
again. Preparation: For lipid extraction, the method of Bligh and Dyer was used [86]. 100μl 
of a chloroform solution containing 100ng/μl of each cholesteryl heptadecanoate (CE 17:0), 
cholesteryl behenate (CE 22:0) and [25,26,26,26,27,27,27-D7]-cholesterol were placed into a 
glass centrifuge tube and evaporated [87]. For absolute quantification, a defined quantity of 
free cholesterol as well as different naturally occurring cholesteryl ester species were added 
[87]. The separated chloroform phase was dried and derivatized by adding 200μl of acetyl 
chloride/chloroform = 1/5 (v/v) for 60min at room temperature and the derivatization reagents 
were removed by vacuum centrifugation [87] It has to be considered that acetyl chloride 
decomposes to hydrochloric acid, which may corrode the vacuum centrifuge [87]. The 
residues were dissolved in 10 mM ammonium acetate in methanol/chloroform = 3/1 (v/v), 
resulting in a 200-fold dilution corresponding to the initial plasma volume, and 20μl of this 
solution were injected and data were acquired for 1.3min [87]. Mass spectrometry: Samples 
were quantified by direct flow injection analysis in an HTS PAL autosampler. A flow gradient 
was performed with a flow of 55 μl/min for 0.1min followed by 30μl/min for 1.0min and an 
increase to 250μl/min for 0.2 min [87]. The triple quadrupole mass spectrometer with positive 
ion source was used in a mode with capillary voltage 3.5kV, cone voltage 50V, collision 
energy 13eV with a collision gas pressure of 1.0 × 10
−3
 Torr argon, and quantification was 
achieved by a combination of selected reaction monitoring (SRM) for FC and precursor ion 
scanning of m/z 369.3 in positive ion mode specific to CE. SRM analysis for FC 
quantification includes two transitions: m/z 446.4 > 369.3 (CE 2:0) and m/z 453.4 > 376.3 
(D7-CE 2:0) [87]. Labeled 
13
C3-FC and 
13
C3-CE species were monitored by a fragment ion of 
m/z 372.3 [87]. Lipid extracts were analyzed by thin layer chromatography as previously 
described by K. Simons et al. [87]. Samples were separated using silica gel HPTLC plates and 
a solvent mixture of n-hexane/n-heptane/diethyl ether/acetic acid (63/18.5/18.5/1, v/v). Plates 
were stained by immersion in a manganese/sulfuric acid reagent, followed by heating. 
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Quantification was performed with authentic FC and CE standards by an analysis of 
fluorescence excitation using a CAMAG TLC scanner.  
PA, LPA, LPC, PC, plasmalogens, sphingomyelins and ceramides 
Lipid extraction was performed according to the method of Bligh and Dyer [86] in the 
presence of not naturally occurring lipid species [88]. The standards were bought from Sigma 
and Avanti Polar Lipids. The following standards were added: PC 14:0/14:0, PC 22:0/22:0, 
LPC 13:0, LPC 19:0, Cer 17:0, PA 32:0,PA 36:2, PA 38:4. For the plasmalogens, internal 
standards were used which do not belong to the same lipid class: PE 14:0/14:0, PE 20:0/20:0. 
For SPM analysis, the internal standards of PC were used. LPA and PA were identified by 
liquid chromatographic separation (LC-MS/MS). The internal standard LPA 17:0 was added 
[89]. The chloroform phase was dried in a vacuum centrifuge and dissolved in 10 mM 
ammonium acetate in methanol chloroform (3:1vol/vol) [88]. Phosphorous assay was 
performed according to Bartlett and Lewis [90]. PE-based plasmalogens were quantified 
according to the principles described by Zemski Berry and Murphy [91]. For this purpose, 
fragment ions of m/z 364, 380 and 382 were used for PE (P-16:0), PE (P-18:1) and PE (P-
18:0) species, respectively [88]. After the identification of relevant lipid species, selected ion 
monitoring analysis was performed [88]. 
 
 
2.4.2 ELISA  
Parameter Reference  range UKR Source 
Adiponectin 2-13.9 µg/ml  Syn Lab 
Leptin 3.7-11.1 ng/ml  Labor-Stein¹ 
Omentin 2.6-27.4 ng/ml [92] 
Ghrelin (EIA) 200-600 ng/ml [93] 
FGF-23 26-110 U/l labor-limbach² 
Apo B-48 3.53-7.39 ng/ml UKR 
SuPar 1.04–4.01 ng/mL [94] 
 
Figure 14: Reference range of the parameters measured by ELISA. 
¹http://www.labor-stein.de/service/untersuchungsprogramm/?tx_laboratoryeditor_pi1[s_uid]=46161 
²www.labor-limbach.de 
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Background: ELISA kits are used for the quantitative determination of the substance 
examined from EDTA plasma, serum or lithium-heparin plasma. The ELISAs used were 
simplified double monoclonal antibody “sandwich assays” (Figure 15). 
 
Figure 15: ELISA sandwich model, high capture antibody, http://proteomics.case.edu/proteomics/elisa.html (8). 
 
The first layer of the sandwich consisted of a surplus of “capture” antibodies (in our case from 
mice), which captured the antigen and immobilized it. The capture antibody is fixed to a solid 
phase and so the antigen is trapped to a solid phase [95]. The second layer consisted of the 
captured antigen. The biotinylated detection antibody was added and a complex with the 
antigen was formed. Biotin was used as an amplificator. We used a secondary antibody, 
streptavidin, which was linked covalently with the enzyme (horseradish) and detected the 
detection antibody by its high affinity to biotin. After all loose antibodies were washed out, 
the fixed antibodies were brought together with the enzyme-specific substrate, in this case 
TMB. The substrate was converted after the enzyme-linked antibody (HRP-linked antibody) 
was brought together with the substrate (TMB). The subsequent reaction produced a color 
change. This detectable signal was measured on a Tecan sunrise photometer. The amount of 
fluorescence corresponds to the amount of antigens. 
ELISA: Procedure 
As a preparation, the washing solution was diluted ten-fold in distilled water. A serial solution 
was made with the standard solution and solution buffer. The first concentration produced 
was 64ng/ml, which was the source for the next solution, until the concentration was 2ng/ml.  
From these standards, a calibration curve was created. The quality controls were mixed with 
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the volume of dilution buffer provided. The biotin-labeled antibody concentrate was diluted 
according to the instructions by mixing it with its diluent. The patients’ samples were diluted 
as recommended in the kits instructions. The standards, quality controls, dilution buffer were 
transferred to the microplate wells pre-coated with antibodies. The plate was incubated at 
37°C for the prescribed time (1 hour for SuPar and leptin, 2 hours for apoB-48 and omentin). 
After incubation and washing (to remove the unbound material), biotin-labeled polyclonal 
detection antibodies were added and incubated at 37°C with the captured samples for 30 
minutes. After another washing, streptavidin-HRP conjugate was added. After 30 minutes and 
the last washing step, the remaining conjugate was allowed to react with the substrate solution 
(TMB). The plate was covered with aluminum foil and incubated for 10 (for SuPar 20) 
minutes. The reaction was stopped by adding acidic solution. Afterwards the absorbance of 
the resulting yellow product was measured spectrophotometrically at 450 nm with a Tecan 
sunrise photometer. The absorbance was proportional to the concentration of the substrate. A 
standard curve was constructed by plotting absorbance values against the concentration of 
standard solutions and unkown concentrations of substrates. 
2.4.3 EIA  
In contrast to the ELISAs applied, with EIA all components were in solution [95]. In our 
study, a double-antibody sandwich technique was used. The plate was coated with 
monoclonal mouse antibodies specific to the C-terminal part of human ghrelin. The sandwich 
was formed together with acetylcholinesterase (AChE) – a Fab' conjugate which recognizes 
the N-terminal part of des-acylated ghrelin. The concentration of human des-acylated ghrelin 
was then determined by measuring the enzymatic activity of the immobilized AChE using 
Ellman's reagent. The AChE tracer reacts to the Ellman's reagent by forming a yellow 
compound. Specific description of the EIA used: In preparation, the EIA buffer was mixed 
with 50ml distilled water. The standard solution was mixed with 1ml distilled water and after 
5 minutes was mixed by inversion. The standard was mixed 7 times with 500 µl buffer, so 
that a serial dilution was made from 250 pg/ml to 1.96 pg/ml. The quality control was mixed 
with 1ml distilled water. 10 ml EIA buffer was mixed with anti-des-acylated-ghrelin-AChE 
tracer. The 1 ml wash buffer was mixed with 400ml distilled water and 200 µL and mixed by 
magnetic stirrer. Ellman’s reagent was mixed with 49ml distilled water and 1ml wash buffer. 
The plate was prepared according to the instructions.  
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2.4.4 Clinical chemistry   
Parameter Assay manufacturer  Reference range 
Creatinine Siemens <1.1 mg /dl 
Glucose Siemens 100 mg/dl 
CRP Siemens < 5 mg /l 
Cholesterol Siemens <200 mg/dl 
TAG Siemens 20-200 mg/dl 
HDL Siemens 35-55 mg/dl 
LDL Siemens <150 mg /dl 
Apo A-1 Siemens 115-190 mg/dl 
ApoB-100 Siemens 70-160 mg/dl 
 
Table 4: Laboratory internal reference values 12.07.2011 
 
Creatinine, glucose, CRP cholesterol, triglyceride, HDL, LDL were automatically analyzed by 
ADVIA 1800 (Bayer Siemens). ADVIA is an automatic serum collector system which uses 
photometric tests. Cholesterol and LDL were measured by the enzymatic method and 
subsequent measurement was performed by Trinder reaction of the hydrogen peroxide formed 
in the first step. HDL and TAG were also measured by Trinder reaction. But CRP was 
measured turbidimetrically. Glucose was measured according to the method by Slein. 
Apolipoproteins AI and B were determined by nephelometric analysis on a Dade Behring BN 
II nephelometer. 
. 
2.4.5 Hematology 
For blood count by EDTA, we used a standard hematology analyzer: Sysmex XE-5000. The 
principle of flow cytometry is based on measuring energy emitted in the form of fluorescent 
light caused by electrons falling from an elevated to a lower energetic level. The exact degree 
of differentiation and characteristic of the stained cell was determined fully automatically by 
combining the information about fluorescence intensity with size and granularity state, which 
was measured with scattered light. 
2.5 Statistical analysis 
For data administration, we created a central database in Microsoft Access. This database was 
linked to Swisslab, making it possible to directly query the parameters in the Swisslab 
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archive. Excel and SPSS also allowed making a direct query of the substances in the Access 
database. Excel and SPSS 19.00 were used to produce the graphics. Most of the variables did 
not follow a normal distribution, so significances were tested by non-parametric tests. For 
dichotomous categories, Pearson’s chi-squared test was used. For paired scaled variables, the 
Friedman test was used, for non-paired variables the Kruskal-Wallis test was performed to 
compare the significances of all three groups.  Finally, the Mann-Whitney U test was 
employed to compare all groups with each other. In diagrams, standard errors and standard 
deviations were shown. I deliberately decided to exclude values beneath the detection limit. 
One exception was ghrelin, since there was a very small number of cases. Pictures were also 
created including cases beneath detection limit. The detection limit of the test was 0.2pg/ml. 
To elevate the number of cases, all values beneath detection limit were set to 0.2 pg/ml. The 
leukocyte concentration was corrected by the dilution factor. To calculate the dilution factor, 
the hemoglobin (Hb) concentration at every instant of time was divided by the hemoglobin 
concentration at time zero. This was necessary because the Hb concentration showed 
significant fluctuations over time in the metabolic syndrome group (Friedman, p=0.13 
control; p=0.18 risk; p=0.006 metabolic syndrome). 
The correlations were created in Microsoft Excel. Nominal statistical significance of a 
correlation was based on a correlation coefficient of > 0.6.    
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3 Results 
3.1 Subject characteristics  
Study subjects were characterized and classified into three groups. This was based upon the 
“International Diabetes Federation” criteria. The stratification of a total 67 participants 
revealed a control group of 14 subjects, a risk group of 20 subjects and almost half of the 
study participants were classified as metabolic syndrome. The subject characteristics in the 
various groups were as follows: The average age in the control group at the time of the study 
was 47 ± 8, in the risk group it was 51 ± 13 and in the metabolic syndrome group 56 ± 11. 
Measurements and the evaluation of the questionnaire showed 2 hypertensive subjects among 
the 20 risk subjects and 14 hypertensive subjects among the 33 metabolic syndrome subjects. 
Only the metabolic syndrome group contained patients with type 2 diabetes, which was a 
criterion for that group. Of the 33 metabolic syndrome subjects, 10 suffered from type 2 
diabetes. The waist circumference in the control group was 85 ± 6 cm, in the risk group 96 ± 8 
cm and in the metabolic syndrome group 117 ± 14 cm (Table 5). 
  Control  Risk 
Metabolic 
Syndrome 
p-Value 
Age 47(±8) 51(±13) 56(±11) 0.03 
Waist [cm] 85(±6) 96(±8) 116(±14) <0.001
 
BMI 23.4(±2) 26(±3) 33(±7) <0.001 
TAG [mg/dl] 82.5(±32) 121(±46) 202.2(±86) <0.001
 
LDL [mg/dl] 119(±42) 129(±34) 115(±33) 0.9
 
HDL[mg/dl] 66(±16) 56(±16) 42(±12) <0.001 
Non-HDL [mg/dl] 137(±38) 152(±31) 156(±33) 0.2  
Cholesterol [mg/dl] 203(±35) 209(±37) 189(±37) 0.6
  
Glucose [mg/dl] 91(±8) 100(±9) 120(±50) <0.001 
Diabetes frequency 0/14 0/20 10/32 0.002
a 
Hypertonia frequency 0/14 2/20 25/32 <0.001
a 
 
Table 5: Characteristics of the groups (laboratory values are given at time = 0 hours; data is represented as means or 
frequency, SD is given in brackets. The calculation of the p-value was performed by Kruskal-Wallis if not marked 
otherwise by a) where chi-quadrat was used. 
 
As shown in Table 5, the triglyceride concentration differed significantly between the three 
groups, with high levels correlating with an increased severity of disease. Subsequently the 
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cholesterol-transporting lipoproteins (HDL and non-HDL cholesterol, e.g. LDL) were 
analyzed individually and in relation to the corresponding apolipoproteins (apoB-100, apoB-
48, and apo A-I) to derive information about their absolute levels and their atherogenic 
properties. The results showed that there are significant differences in lipoprotein particle size 
and distribution between the groups (see Figure 16, Figure 17 and Figure 19). 
A 
 
 
B 
 
Figure 16: ApoB-100 containing lipoproteins. The data is represented as means ± 1 SD, distribution between the groups 
was compared using the Kruskal-Wallis and Mann-Whitney U tests. Changes over time were tested by Friedman, p<0.05 = *; 
<0.01=**; <0.001=***. A) Comparison of LDL distribution in the three groups at the start of the experiment and at 4 hours                    
B) Comparison of the LDL/apoB-100 ratio in the three groups. 
 
The LDL distribution in fasting and postprandial state in the groups is depicted in Figure 16. 
The LDL distribution did not differ significantly between the groups (Mann-Whitney U, 
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p=0.9). However, all of the values were equal and below 130 mg/dl and therefore meet the 
NCEP guidelines for subjects not having had a coronary heart disease (CHD) event yet [96] 
(we did not consider diabetes as a CHD-risk equivalent). Also, over time, our results did not 
show any significant changes in any of the groups (Friedman test, p=0.207, control, n=3; 
p=0.7, risk, n=7; p=0.59, metabolic syndrome, n=13). The results also showed that the 
metabolic syndrome group had smaller and therefore potentially more atherogenic LDL 
particles [97] as demonstrated by calculating the LDL-cholesterol/ApoB-100 ratio, which was 
significantly higher in the control group than among the metabolic syndrome subjects, 
yielding a significant p-value of 0.02 (Mann-Whitney U). The control and the risk group did 
not show significant differences (p=0.13). When comparing the risk and the metabolic 
syndrome group, p-value was <0.001. However, according to the Friedman test, there were no 
significant changes over time (Friedman test, p>0.9).  
 
    
Figure 17: The comparison of the HDL concentration between the groups at t(0) and t(4): n=13 (control), n=19 (risk) and 
n=32 (metabolic syndrome), p<0.05 = *; <0.01 = **; <0.001 = ***. Data is represented as means ± 1SD.  
 
Since the HDL level was part of the stratification criteria, the baseline values of HDL 
cholesterol declined from control to risk to metabolic syndrome group as expected. This was 
confirmed under fasting and postprandial conditions by the non-parametric Mann-Whitney U 
test (p<0.001). Over time (4 hours) in the postprandial phase, there was no change of the HDL 
concentration in any of the groups when comparing the HDL plasma concentration under 
fasting conditions and four hours after the OFTT (Friedman test, p=0.59, metabolic syndrome, 
n=17; p=0.359, risk, n=7; p=0.354, control, n=3). Next, we looked at HDL’s major 
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apolipoprotein apo A-I to examine particle content in the study groups. “Apo A-I is the major 
apolipoprotein in HDL particles and has a central role in ‘reverse’ cholesterol transport. Apo 
A-I can ‘pick up’ excess cholesterol from peripheral cells and transfer it back to the liver in 
the HDL particles”[98]. Apo A-I also possesses anti-inflammatory, antioxidant effects and 
anti-atherogenic properties [98]. 
A 
  
B 
  
Figure 18: A) Apo A-I at t(0), n=12 (control), n=19 (risk), n=32(metabolic syndrome). The differences between the groups 
were not significant. 
B) Comparison of the apo A-I/HDL ratios between the groups at time zero t (0) n=12 (control); n=18 (risk) n=31 (metabolic 
syndrome). Data is represented as means ± 1SD, p<0.05 = *; <0.01 = **; <0.001 = ***. The apo A-I/HDL ratio was 
significantly lower in the control group than in the risk group and the metabolic syndrome group at baseline. 
 
Figure 18A depicts the mean apo A-I concentrations at baseline. Even though the control 
group showed the highest level of apo A-I, the differences between the groups were not 
significant (Kruskal-Wallis, p=0.58). Nor was there any significant change in the apo A-I 
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concentration in any of the groups over time (Friedman, p=0.057, control; p=0.071, risk; 
p=0.4, metabolic syndrome; supplemental, S 1). Still, the apo A-I/HDL ratio, which is 
depicted in Figure 18 B, was significantly lower in the control group than in the risk group 
and the metabolic syndrome group at baseline (Kruskal-Wallis test, p=0.01). Moreover, the 
results showed that there was an inverse relation between the control, risk and metabolic 
syndrome groups in terms of HDL and apo A-I levels, indicating an increase in apo A-I 
containing HDL fractions and an impaired generation of mature, cholesterol-rich HDL in the 
metabolic syndrome group. This can be deduced from the fact that the premature discoid HDL 
primarily contains apo A-I [99]. When taking a closer look at the influence of the OFTT on 
the apo A-I/HDL ratio, the time course showed that during the oral fat tolerance test, there 
was no significant change in any of the groups (Friedman test, p=0.1, control; p=0.59, risk; 
p=0.52, metabolic syndrome). Tian et al. found that the apoB-100/apo A-I ratio could reliably 
and sensitively reflect the HDL subclass profile [100]. The results for the apoB-100/apo A-I 
ratio are shown in Figure 19. 
 
 
Figure 19: Comparison of the apo-B100/apo A-I ratio in the three groups. The data is represented as means ± 1SD, p<0.05 = 
*; <0.01 = **; <0.001 = ***. 
 
 
The mean apoB-100/apo A-I ratio was significantly lower in the control group than in the 
metabolic syndrome group (p=0.002, Kruskal-Wallis). For the purpose of the test, we 
combined all points in time to obtain a higher number of samples; n=118. The metabolic 
syndrome group showed a higher apoB-100/apo A-I ratio compared to the other groups. But 
there was no acute reaction to the OFTT, shown by the fact that there were no significant 
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
control risk metabolic syndrome
 ApoB-100/apo A-I ratio 
                     ** 
 45  
changes in any of the groups (Friedman test, p=0.084 control; p=0.32 risk; p=0.9 metabolic 
syndrome). While apoB-100 is selectively synthesized in hepatocytes and secreted as a 
constituent of VLDL, apoB-48 originates from intestinal mucosa cells and is secreted as the 
core apolipoprotein of chylomicrons. Figure 20 represents the apoB-48/apo A-I ratio. Our 
results demonstrate that the comparison of the means of the apoB-48/apo A-I ratio did not 
show a significant basal difference between the groups (Kruskal-Wallis test, n=63, p=0.487). 
To evaluate the effects of the oral fat tolerance test over time, we used the Friedman test 
(p=0.082, control, n=3; p=0.006, risk, n=6; p=0.001, metabolic syndrome n=12). 
   
Figure 20: ApoB-48/apo A-I ratio over time. The differences between the groups were not significant. Over time, the apoB-
48/apo A-I ratios showed significant changes in the metabolic syndrome and the risk groups. The data is represented as 
means ± 1SD.  
 
In both the risk and the metabolic syndrome groups, an acutely altered metabolism was 
reflected by an acute response to the drink. Additional data for “ApoB-48” in connection with 
chylomicrons will be presented in chapter 3.3.2 on plasma lipids. 
 
3.2 Composition of the fat drink  
The oral fat tolerance test (OFTT) was carried out as suggested by the Hanefeld group 
(Dresden) with a minor modification [78]. Table 6 depicts the composition of the oral fat 
tolerance test according to the formula of Henkel et al.  
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 Kcal Protein[g] Fat[g] CarboH[g] PUFA[g] SUFA[g] Total FA[g] 
250ml/286g 
milk cream 
720 6.2 75 8 2.8 22.6 45.5 
100ml/100g 
fruit juice 
53 0.3 0 12 0.2 0 0.1 
60g white 
sugar 
243 0 0 60 0 0 0 
Total  
content 
1016 
 
6.5 
(4.02%) 
75 
(46.4%) 
80 
(49.5%) 
3 22.6 45.6 
Table 6: Contents of the test drink of the oral fat tolerance test. 
 
The total calorie content of the fat drink, based on 250 ml cream plus 100 ml orange juice and 
60 g white sugar, was about 1016 kcal, with 66% fat, 32% carbohydrates and 3% protein. To 
analyze the fatty acid composition of the drink, 10 samples were randomized and measured. 
The fatty acid composition of the samples was presented and classified according to their 
degree of saturation (Figure 21A) and according to their chain length (Figure 21B). 
A 
 
B 
 
 
Figure 21: Fatty acid composition of the fat shake. A) Concentration of the FA in the drink, separated according to their 
degree of saturation  B) Concentration of the FA, separated according to number of C atoms. The data is represented as 
means ± 1SD. 
 
Saturated fatty acids (SUFA) were the predominant type of fatty acids in the drink 
PUFA/SUFA = 0.13. Among the saturated fatty acids, the most common species is palmitic 
acid (C16:0), followed by stearic acid (C18:0) and the minor species C13 and C14. (Figure 
22) provides a more detailed view of the fatty acid species in the drink.  
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Figure 22: Fatty acid species in the drink. Data is represented as means ± 1SD. 
 
3.3 Plasma lipids 
3.3.1 Lipoprotein transport from the intestine: Chylomicron and apoB-48 
 
Figure 23: The mean apo B-48 n=14 (control); n=19 (risk); n=33 (metabolic syndrome). The changes over time were 
significantly different in all groups. Data is represented as means ± 1SD. 
 
The chylomicron-specific apolipoprotein apoB-48 enables the transfer of lipids from the 
intestinal mucosa to the liver. Figure 23 depicts the apoB-48 concentration in the three groups 
over time. When only looking at the fasting levels, the difference between the groups was not 
significant at time zero (Kruskal-Wallis test p=0.607). But a time-independent comparison of 
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the groups showed significant differences (Kruskal-Wallis test, p=0.02). The calculation was 
performed considering all points in time between t (0 hours) and t (8 hours). Furthermore, the 
changes over time were significantly different in all groups (Friedman test; p=0.002, control, 
n=14; p<0.001 for risk, n=19; and metabolic syndrome, n=33). Moreover, there was a similar 
peak at t (2 hours) in all groups. But the administration of an OFTT resulted in a lower 
increase in serum apoB-48 concentration in the metabolic syndrome group compared to an 
increase in the control group. At t (6 hours), the highest difference between the groups could 
be observed. The Mann-Whitney U test showed that there was a significant difference 
between the groups (p=0.026; metabolic syndrome-control). The apoB-48 concentration in 
healthy controls returned to its basal value after eight hours, whereas the metabolic syndrome 
group showed no decrease compared to t (4 hours) and did not even reach their basal value 
after eight hours. The apoB-48/apoB-100 ratio also positively correlates with CAD [101] and 
is depicted in Figure 24. 
 
 
Figure 24: ApoB-48/apoB-100 ratio at time (0 hours), n=45. The differences between the groups were not significant. Data is 
represented as means ± 1SD. 
 
Our results indicated that even though there was a difference between the groups, this 
difference was not significant (t0, p=0.246).   
3.3.2 Lipoprotein transport from the liver: VLDL and apo-B 100 
VLDL carries TAGs from the liver to the periphery. In contrast to the data on apoB-48 
(Figure 23), the basal differences in VLDL concentrations between the groups were 
significant (Figure 25), but there were no changes over time (Friedman test, p=0.717, control, 
n=4; p=0.96, risk, n=7; p=0.204, metabolic syndrome, n=11).  
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Figure 25: VLDL A) Comparison of the VLDL concentrations between the groups at time zero. Data is represented as means 
± 1SE, distribution between the groups was compared using Kruskal-Wallis, p<0.05 = *; <0.01 = **; <0.001 = ***. 
 
 
The fact that the basal VLDL concentration varied significantly (p<0.001) between the groups 
was not astonishing, as this is a marker for prolonged postprandial state in steatotic liver 
disease [102] related to diabesity and metabolic syndrome [103]. However, the control group 
had a significantly lower basal VLDL level than the metabolic syndrome group. This 
supported the hypothesis of a prolonged postprandial state of the metabolic syndrome 
subjects. The OFTT provided additional information related to apoB-100/VLDL metabolism.  
3.3.3 Free fatty acids  
Major fatty acids in plasma  
In order to analyze the free fatty acid composition in metabolic syndrome patients and to find 
a characteristic reaction in metabolic syndrome subjects following an OFTT, the types of fatty 
acids in the plasma were measured. The results showed that the major free fatty acids in 
plasma in all three groups were oleic acid, linoleic acid, arachidonic acid and stearic acid. The 
major medium-chain fatty acid was tridecanoic acid. When there was a basal difference 
between the groups, the metabolic syndrome showed the highest values, which will be 
referred to in more detail below.  
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Figure 26: Medium-chain fatty acids at time zero. The differences between the groups were not significant. Data is 
represented as means ± 1SE.  
 
FA 10:0 12:0 13:0 14:0 
p 0.897 0.811 0.853 0.076 
 
The medium-chain fatty acids showed no basal differences between the groups.  
 
Figure 27: Long-chain fatty acids at time zero, data is represented as means ± 1SE.  
 
 
FA 15:0 17:0 18:0 20:0  23:0 24:0 
p 0.126 0.018 0.048 0.019 0.49 0.13 
 
Comparing the levels of saturated long-chain fatty acids between the groups (Figure 27), 
margaric acid (17:0), stearic acid (18:0) and arachidic acid (20:0) showed basal differences 
between the groups. The latter fatty acids are products of the transformation out of palmitic 
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acid. Due to the pathway of further transformation, the pathway could end up in death or 
survival. Below, we will refer to those fatty acids and their pathways and products. 
 
Figure 28: Long-chain monounsaturated fatty acids (MUFAs) at time zero, palmitic acid (p=0.002), oleic acid (p=0.01) 
nervonic acid (p<0.001), vaccenic acid (p=0.069). Data is represented as means ± 1SE. 
 
Comparing the levels of monounsaturated long-chain fatty acids between the groups (Figure 
28), the baseline values of palmitic acid (p=0.002), oleic acid (p=0.01) and nervonic acid 
(p<0.001) differed significantly between the groups, whereas vaccenic acid did not show 
different values between the groups (p=0.069). Those types of fatty acids will be referred to in 
detail below. 
 
FA 16:1- c9 18:1ω9 18:1-c11 24:1ω9 
p 0.002 0.01 <0.001 0.069 
 
Comparing the PUFA levels of the three groups, only eicosadienoic acid (20:2 ω 9) and 
docosatetraenoic (22:4 ω 6) showed differences between the groups at baseline. The omega-3 
fatty acids did not show a basal difference between the groups. 
 
FA 18:2ω6 18:3ω6 18:3ω3 20:2ω9 20:4ω6 20:3ω3 
p 0.38 0.076 0.244 0.039 0.324 0.499 
FA 20:4ω 3 22:1ω9  20:5ω3 22:4ω 6 22:5ω3 22:6ω3 
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Figure 29: Polyunsaturated fatty acids (PUFAs) at time zero, the names were written out in full (trivial name or name of their 
salt) in order to avoid a complex systematic nomenclature. Data is represented as means ± 1SE. 
 
This study deals with the development of the pro- and anti-inflammatory fatty acids and their 
respective precursors, γ-linolenic, arachidonic acid, docosahexaeoic (DAH) and 
eicosapentaenoic (EPA), over time. Those fatty acid species will be referred to in detail 
below. When comparing the groups’ reaction to the OFTT, we found dissimilarities in the 
behavior of the following fatty acids which we studied in more detail: palmitoleic acid 
(16:1c9), eicosapentaenoic acid (EPA, 20:5 ω 3), arachidonic acid (20:4 ω 6), γ-linolenic 
(18:3 ω 6), eicosanoic acid (20:0), stearic acid (18:0), oleic acid (18:1ω 9) and lignoceric acid 
(24:0). 
 
Escape pathway in the metabolic syndrome group 
Initially, we took a closer look at palmitoleic acid, which has previously been associated with 
an undesirable adipokine profile [104]. In the case of palmitoleic acid (FA 16:1 (c-9)) 
(supplemetal, S 2), basal levels differed significantly between the groups (p=0.002). 
Metabolic syndrome subjects showed the highest values. The metabolic syndrome subjects 
and the risk group showed a significant reaction to the oral fat tolerance test (p<0.001, risk; 
n=20; p<0.001, metabolic syndrome; n=32). Control subjects did not show any significant 
reaction (Friedman test, p=0.07, control; n=12).  
0
1
2
3
4
5
6
m
m
o
l/
l 
PUFA control
risk
metabolic syndrome
  *   * 
 53  
 
Figure 30: Cell death or survival, based on the diagram by Thomas Kopf. 
 
There are two different synthesis pathways, starting either from fatty acids from the fatty acid 
palmitate from dietary origin or from de novo synthesis (Figure 30). The level of palmitic acid 
(C16:0), which was the main type of fatty acid in our oral fat tolerance test, and of products 
from this fatty acid produced by desaturases and elongases were significantly elevated in the 
metabolic syndrome group compared to the other groups. The metabolism of this fatty acid 
could either end in mortality and morbidity (“escape” pathway”) or in survival (“normal” 
pathway) (Figure 30). The product of the “escape” pathway is nervonic acid, which is 
described in detail below.   
In the normal pathway, stearic acid can be produced by palmitic acid. The levels of stearic 
acid (fatty acid 18:0, supplemental, S 3) showed a significant difference between the groups 
(Kruskal-Wallis test, p=0.048) at baseline. Over time, there was a significant response to the 
OFTT in all three groups (Friedman test, p=0.001, control, n=12; p<0.001 risk, n=20 and 
p<0.001 metabolic syndrome, n=32). We were also interested in arachidic acid, also called 
eicosanoic acid (FA C20:0). Our results are shown in figure S4 in the supplementary. The 
arachidic or eicosanoic acid (fatty acid 20:0) showed a significant difference between the 
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groups (Kruskal-Wallis, p=0.019) at baseline. The acute changes in the metabolic syndrome 
and risk groups were also significant (Friedman test, p=0.004, risk, n=20, risk; p<0.001 
metabolic syndrome, n=32), whereas in control subjects, there was no reaction to the oral fat 
tolerance test (p=0.113, control, n=12). Thus, after the increase in response to the drink, risk 
and metabolic syndrome subjects showed a decrease after 6 hours. In order to illustrate the 
escape pathway, oleic acid is depicted in supplemental, S 5. Oleic acid, which can be 
produced by stearic acid, was also elevated in the metabolic syndrome group compared to the 
other groups (Kruskal-Wallis, p=0.01). Over time, every group showed an increase, followed 
by a decrease. However, in the metabolic syndrome group, the increase was delayed 
(Friedman, p=0.01, control, n=12; P<0.001 risk, n=20, p<0.001 metabolic syndrome, n=32). 
Moreover, our results (S 6) showed that the level of the ω-9 fatty acid nervonic acid was 
elevated in the metabolic syndrome group compared to the control group (Mann-Whitney U, 
p<0.001). Over time, there was no significant change in any of the groups (Friedman, p=0.19, 
control, n=12; p=0.87, risk, n=20, p=0.17, n=32, metabolic syndrome). Alternatively, 
nervonic acid could also be produced from lignoceric acid (S 7), which was not significantly 
elevated in the metabolic syndrome group (Kruskal-Wallis, p=0.35). Over time, a significant 
response to the oral fat tolerance test only occurred in the metabolic syndrome group, which 
showed increased levels of lignoceric acid at 4 hours (Friedman, p=0.29, control, n=12; 
p=0.7, risk, n=20, p=0.01, n=32, metabolic syndrome). From this we can conclude that the 
elevated level of nervonic acid in metabolic syndrome subjects was produced on the basis of 
the “escape” pathway, from oleic acid. Nervonic acid is also part of certain types of cytotoxic 
ceramide species [105]. This ceramide species contributes to the apoptotic effect of 
lipotoxicity on ß-cells and moreover induces the expression of SCD-1 [105]. It has been 
published previously that level and activity of Stearoyl-CoA desaturase 1 (SCD-1) – that is 
the rate-limiting enzyme catalyzing the conversion of saturated to monounsaturated fatty acids 
– are increased in cardiovascular diseases, insulin resistance and obesity [106,107]. SCD-1 
catalyzes the biosynthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids 
which are either synthesized de novo or derived from the diet [107]. The endogenously 
MUFAs synthesized by SCD-1 most likely serve as the main substrates for the synthesis of 
hepatic TAG and cholesterol esters [107]. The preferred substrates are palmitoyl- and 
stearoyl-CoA, which are then converted into palmitoleoyl- and oleoyl-CoA respectively [107]. 
On the other hand, SCD-1 is necessary for the sufficient regulation of the clearance of 
circulating lipoproteins [107]. A higher ratio of SCD activity can be determined by the 
following ratios: (16:1n-7/16:0 and 18:1n-9/18:0). SCD activity was determined based on the 
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products of the desaturation and elongation of palmitoleic acid, the major fatty acid species in 
the oral fat tolerance test, in order to show that metabolic syndrome subjects are predestined 
to take the escape pathway, leading to an increased level in nervonic acid. Figure 31 depicts 
the ratio of the fatty acids 16:1/16:0. The ratio was significantly elevated in subjects with risk 
for metabolic syndrome and the metabolic syndrome (Kruskal-Wallis, p=0.006). There was 
no significant difference between the groups concerning the ratio of the fatty acids 18:1/18:0 
(Kruskal-Wallis, p=0.16). 
 
 
Figure 31: The fatty acid ratio (16:1/16:0), the.concentration differed significantly between the three groups, (Kruskal-Wallis, 
p=0.006), fatty acid 16:0 p=0.01., data is represented as means ± 1SE. 
 
 
ω-3/ ω-6 fatty acids 
We then looked at eicosapentaenoic acid (EPA) (Figure 32), a protective ω-3 fatty acid [64] 
and competitive substrate for the enzymes and products of arachidonic acid metabolism. ω-3- 
derived eicosanoids antagonize the pro-inflammatory effects of ω-6 fatty acids [64]. Both ω-3 
and ω-6 fatty acids are ligands/modulators for the nuclear receptors NFκB, PPAR and 
SREBP-1c, which control various genes responsible for inflammatory signaling and lipid 
metabolism. ω-3 fatty acids down-regulate inflammatory genes and lipid synthesis and 
stimulate fatty acid degradation. In addition, the ω-3/ ω-6 PUFA content of cell and organelle 
membranes, strongly influences cell death and survival [64]. 
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Figure 32: This graph shows the fatty acid 20:5-c5, c8, c11, c14, c17. Significant differences between the groups were 
calculated using Kruskal-Wallis n=14 control, n=20 (risk); n=33 (metabolic syndrome). Changes over time were evaluated 
using the Friedman test n=12 (control); n=20 (risk); n=32 (metabolic syndrome). Over time, there was a significant difference 
in the risk and in the metabolic syndrome group respectively. Data is represented as means ± 1SE. 
 
In terms of eicosapentaenoic acid, called EPA or FA 20:5 with double-bonds at C 5, C 8, C 
11, C 14, C 17 there were no significant differences between the groups at time zero (Kruskal-
Wallis, p=0.696). Our results showed that over time, there was a significant difference in the 
risk and in the metabolic syndrome group respectively (Friedman test, p=0.004, risk, n=20; 
p=0.001, metabolic syndrome; n=32). Both groups showed an increase in EPA serum 
concentration. The control group did not show any reaction to the oral fat tolerance test 
(p=0.069, control, n=12).  
 
Figure 33: Arachidonic acid (20:4ω6), Kruskal-Wallis test: p=0.324. Differences over time were calculated by Friedman test: 
p=0.25, control, n=12; p<0.001 risk and metabolic syndrome. Over time, there were differences in risk and metabolic 
syndrome subjects. Data is represented as means ± 1SE. 
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The predominant ω-6 fatty acid is arachidonic acid (20:4 ω 6), which is converted to 
prostaglandins, leukotrienes and other lipoxygenase or cyclooxygenase products [64]. The 
level of arachidonic acid (20:4 ω 6) showed no significant difference between the groups 
(Kruskal-Wallis test, p=0.324). Over time, there were differences in risk and metabolic 
syndrome subjects (Friedman, p<0.001 risk, n=20; p< 0.001, metabolic syndrome, n=32), 
whereas the control group did not show any reaction to the drink (Friedman, p=0.025, n=12). 
Another ω-6 fatty acid is γ-linolenic acid (18:3 ω 6). This essential fatty acid was examined in 
more detail (S 8) because it is the precursor of arachidonic acid (AA). While at the beginning 
there was no significant difference between the groups (Kruskal-Wallis test, p=0.076), there 
was a significant difference at two, four and six hours (Kruskal-Wallis test, p=0.03 at 2 hours; 
p=0.029 at 4 hours, p=0.031 at 6 hours). The difference between the groups disappeared again 
after eight hours (p=0.11). However, whereas the level of γ-linolenic acid was increased in 
metabolic syndrome subjects as a response to the fat load, there was no change in the control 
group and only a slight response in the risk group (Friedman, p=0.6, control, n=12; p=0.01, 
risk, n=20, p< 0.001, n=32, metabolic syndrome).  
3.3.4 Cell death, ceramide with antagonistic effects  
What was interesting for us was the ratio of ceramides with antagonistic effects: 24:0 and 24:1 
[108]. The former possesses antiapoptotic properties; the latter is responsible for cell death. 
 
Figure 34: This picture shows the ratio of ceramide 24:0/ceramide 24:1. Groups were compared using Kruskal-Wallis n=14 
(control); n=19 (risk); n=32 (metabolic syndrome). There was a significant difference between the groups. Changes over time 
were evaluated using the Friedman test, n=14, (control) n=18 (risk), n=31(metabolic syndrome). There were no significant 
differences over time. Data is represented as means ± 1SD. 
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A negative relationship was found between the ceramide 24:0–24:1-ratio (Figure 34) and the 
risk of metabolic syndrome (Kruskal-Wallis, p=0.003). The control group showed the highest 
level of ceramide 24:0 and the lowest level of 24:1 compared to the risk and the metabolic 
syndrome groups. Over time, there were no significant changes in any of the groups 
(Friedman, p=0.68, control, n=14; p=0.581, risk, n=18; p=0.626, metabolic syndrome, n=31). 
Thus, there were no reactions to the oral fat tolerance test in any group. 
 
 
3.3.5 Signal transduction, Sphingolipids 
Sphingomyelin (SPM), which belongs to the class of sphingolipids, is one of the major 
phospholipids in human cells and plays an important role in signal transduction, particularly 
with regard to growth and differentiation [109]. It is also a major component of lipid rafts in 
membranes (cholesterol-/sphingolipid-rich domains) [109]. Previous investigations stated 
increased sphingomyelin levels in human familial hyperlipidemia, especially in familial 
hypercholesterolemia and also in animal models of atherosclerosis [110]. Moreover, the SPM 
concentration in plasma correlates positively with the susceptibility of lipoprotein SPM to 
sphingomyelinase (SMase) [110].  
 
Schlitt et al. investigated the role of SPM in atherosclerosis by measuring plasma-SPM levels 
in 1.102 patients with angiographically proven coronary artery disease (CAD) and 444 
healthy controls. They found increased plasma levels in CAD subjects [110]. 
 
Elevated ceramide production from SPM and ceramide de novo production, both triggered by 
increased levels of palmitic acid and LPS due to gram-negative bacteria infection, are both 
involved in the development of chronic states of low-grade inflammation in patients with type 
2 diabetes and/or obesity [111]. Figure 35, Figure 36, Figure 37 show the distribution of 
sphingomyelin species in the three groups control, risk and metabolic syndrome. 
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Figure 35: Circulating SPM species concentration in plasma over time in the control group. Data is represented as means ± 
1SE. 
 
Figure 36: Circulating SPM species concentration in plasma over time in the risk group. Data is represented as means ± 1SE. 
 
Figure 37: Circulating SPM species concentration in plasma over time in the metabolic syndrome group. Data is represented 
as means ± 1SE. 
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Figure 35, Figure 36, Figure 37, show that the most abundant SPM species were SPM 16:0 
and 24:1 in all three groups. The sphingomyelin species (SPM 18: 0, SPM 18:1, SPM 22:4), 
which showed different baseline values between the three groups, are graphically represented 
in supplemental S 9, S 10, S 11. 
SPM species p-value 
SPM 12:0 0.328 
SPM 14:0 0.613 
SPM 15:0 0.622 
SPM 16:0 0.695 
SPM 18:0 0.035 * 
SPM 20:0 0.143 
SPM 22:0 0.679 
SPM 23:0 0.195 
SPM 24:0 0.377 
SPM 26:0 0.538 
SPM 16:1 0.266 
SPM 18:1 0.041 * 
SPM 22:1 0.238 
SPM 23:1 0.164 
SPM 26:1 0.594 
SPM 24:1 0.730 
SPM 18:2 0.756 
SPM 22:2 0.236 
SPM 24:2 0.803 
SPM 26:2 0.059 
SPM 28:2 0.071 
SPM 20:3 0.464 
SPM 22:3 0.681 
SPM 26:3 0.744 
SPM 27:3 0.745 
SPM 28:3 0.212 
SPM 26:4 0.450 
SPM 22:4 0.015 * 
SPM 28:4 0.760 
SPM 28:5 0.598 
Table 7: Comparison of the SPM species between the groups, p-value of Kruskal-Wallis test. 
Among the saturated SPMs, only SPM 18:0 showed significantly different baseline levels 
between the groups S 9. Over time, only the risk group showed a significant change. The peak 
in the metabolic syndrome group at 6 hours was also remarkable. However, the significant 
peak that can be seen in the risk group at 4 hours occurs in the metabolic syndrome group 
later (6h). Among the monounsaturated SPMs, only SPM 18:1 (S 10) showed significantly 
different baseline levels between the groups. However, the monounsaturated and the saturated 
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SPM species with 18 C atoms showed a significant difference between the groups. Among the 
polyunsaturated SPM species, only SPM 22:4 showed a significant difference between the 
baseline levels of the groups (S 11). This figure shows the peak in the control and the risk 
groups at 2 hours, whereas the response in the metabolic syndrome group was in delay and 
showed a peak at 6 hours. The changes over time were not significantly tested by the 
Friedman test. Next, a detailed description of the sphingomyelin profile over time as a 
response to the OFTT was carried out. Over time, the following sphingomyelin species 
showed significant responses to the OFTT. SPM 22:2 showed a significant difference in the 
control and the metabolic syndrome groups over time (p=0.04 control, p=0.39 risk, p=0.024 
metabolic syndrome); SPM 15:0 (p=0.49 control, p=0.013 risk, p=0.24 metabolic syndrome) 
and SPM 18:0 (p=0.27 control, p=0.004 risk, p=0.244 metabolic syndrome). The latter 
showed a significant difference in the risk group (S 9). SPM 14:0 (p=0.49 control, p=0.075 
risk, p=0.026 metabolic syndrome), SPM 23:1 (p=0.84 control, p=0.40 risk, p=0.016 
metabolic syndrome), SPM 24:0 (p=0.72 control, p=0.47 risk, p=0.003 metabolic syndrome), 
SPM 16:0 (p=0.9 control, p=0.15 risk, p=0.009 metabolic syndrome) only showed a response 
in the metabolic syndrome group. 
SPM  Control (p) Risk (p) Metabolic syndrome (p) 
SPM 12:0 0.37 0.28 0.21 
SPM 16:1 0.97  0.149 0.39 
SPM 18:2 0.96 0.65 0.48 
SPM 18:1 0.4 0.25 0.28 
SPM 20:3 0.9 0.35 0.08 
SPM 20:0 0.7 0.08 0.5 
SPM 22:3 0.08 0.82 0.9 
SPM 22:4 0.29 0.82 0.12 
SPM 22:1 0.62 0.89 0.19 
SPM 22:0 0.66 0.22 0.19 
SPM 23:0 0.21 0.92 0.86 
SPM 24:2 0.7 0.8 0.2 
SPM 24:1 0.76 0.09 0.34 
SPM 26:4 0.35 0.78 0.98 
SPM 26:3 0.45 0.43 0.6 
SPM 26:2 0.08 0.5 0.31 
SPM 26:1 0.6 0.5 0.4 
SPM 26:0 0.4 0.9 0.6 
SPM 27:3 0.9 0.9 0.72 
SPM 28:5 0.4 0.054 0.7 
SPM 28:4 0.9 0.57 0.8 
SPM 28:3 0.67 0.58 0.59 
SPM 28:2 0.51 0.09 0.12 
Table 8: p-values that were not significant. Comparison of the SPM species over time, p-value calculated by Friedman test  
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Those SPM species which could be relevant as biomarkers to identify metabolic syndrome 
subjects, due to their different responses to the OFTT compared to the other groups, are 
separately shown in graphics in the supplemental. Those were: SPM 14:0 (S 12), SPM 16:0 (S 
13), SPM 22:2 (S 14), SPM 23:1 (S 15) and SPM 24:0 (S 16). All of these species either 
showed a response only in the metabolic syndrome group but not in the other groups, or a 
different response in the three groups. The SPM species 16:0 showed no baseline differences 
between the groups (Kruskal-Wallis test p=0.69). The trend showed a progressively higher 
baseline level from the control to the risk to the metabolic syndrome groups. A significant 
increase at 6 hours could only be observed in the metabolic syndrome group. Also for SPM 
22:2, there was no significant difference between the groups when comparing the baseline 
levels. The metabolic syndrome showed a trend towards higher levels. A decrease as a 
response to the drink was observed in all three groups, but in the risk group the changes over 
time were not significant. In all cases, the metabolic syndrome showed a delayed decrease and 
thereafter delayed normalization. The SPM species 23:1 seemed to be elevated in the control 
group, even though not significantly. In the metabolic syndrome group, there was a significant 
increase 6 hours after the fat load. The other groups showed no response to the OFTT. 24:0 
belongs to the most protective SPM species and it showed decreased levels in the metabolic 
syndrome group. The metabolic syndrome group reacted to the OFTT by increasing its level. 
This increase could be interpreted as a protective response to an additional fat excess.  
 
3.3.6 Antioxidants: Plasmalogens  
Plasmalogens are phospholipids carrying fatty acid-ether bonds in sn-1 position, with C16:0, 
18:0 and 18:1 fatty acids and fatty acid esters in sn-2 position [62]. The fatty acid composition 
of plasma phospholipids reflects the ingested fatty acids, but is also influenced by various 
factors. The polyunsaturated fatty acids in sn-2 position are precursors for ω-3- or ω-6-based 
prostaglandins which are antagonists in inflammation and thrombosis [88]. The response of 
the plasmalogens to the OFTT in the three groups is shown in (Figure 38, Figure 39, Figure 
40). The plasmalogen species were separated into those which occur rarely, commonly and 
frequently and their dynamics in the respective groups were depicted over time in order to 
give an overview.  
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Figure 38: Minor abundance plasmalogens, data is represented as means ± 1SE. 
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Figure 39: Medium abundance plasmalogens, data is represented as means ± 1SE. 
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Figure 40: Major-abundance plasmalogens, ± 1 SE 
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The plasmalogens showed dynamic differences in the three groups. The examined 
plasmalogen species showed different basal levels in the three groups, and the application of 
the oral fat tolerance test helped to identify metabolic syndrome subjects. Functionally, the 
plasmalogens in the plasma serve as lipid supply for the brain, but it has also been proposed 
that they act as serum antioxidants preventing lipoprotein oxidation [112] and as regulators of 
membrane fluidity [62]. Predominant species are DHA and AA [112]. Our results also 
provided that the major species in the plasma compartment of all three groups were AA 
containing plasmalogens and PE (P-16:0/22:6), PE (P-18:0/22:6) followed by PE (P-
16:0/18:2) and PE (P-18:0/18:2). 
Species p-value 
PE (P-16:0/16:0) 0.081 
PE (P-16:0/18:0) 0.143 
PE (P-18:1/18:0) 0.011 
PE (P-16:0/16:1) 0.126 
PE (P-18:0/16:1) 0.232 
PE (P-18:1/16:1) 0.071 
PE (P-16:0/18:1) 0.159 
PE (P-18:1/18:1) 0.008 
PE (P-16:0/18:2) 0.07 
PE (P-18:0/18:2) 0.008 
PE (P-18:1/18:2) 0.037 
PE (P- 18:0/18:3) 0.190 
PE (P- 18:1/18:3) 0.26 
PE (P- 18:0/20:3) 0.428 
PE (P-18:0/22:3) 0.021 
PE (P- 18:1/22:3) 0.118 
PE (P-16:0/20:4) 0.604 
PE (P 18:0/20:4) 0.372 
PE (P-18:1/20:4) 0.248 
PE (P-16:0/22:4) 0.405 
PE (P-18:0/22:4) 0.670 
PE (P-18:1/22:4) 0.037 
PE (P-16:0/20:5) 0.185 
PE (P-18:0/20:5) 0.258 
PE (P- 18:1/20:5) 0.935 
PE (P- 16:0/22:5) 0.069 
PE (P- 18:0/22:5) 0.017 
PE (P 18:1/22:5) 0.205 
PE (P- 16:0/22:6) 0.607 
PE (P- 18:0/22:6) 0.823 
PE (P- 18:1/22:6) 0.384 
 
Table 9: Differences between the groups: Plasmalogen species and the p-value of the Kruskal-Wallis test. 
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Of the plasmalogen species with a saturated or monounsaturated acyl residue in sn-2 position, 
only the species PE (P-18:1/18:0) and PE (P-18:1/18:1) showed a basal difference between 
the groups. In the group of the polyunsaturated with 2 and 3 double bonds, the plasmalogens 
PE (P- 18:0/18:2) and PE (P-18:1/18:2) as well as PE (P-18:0/22:3) showed significant 
differences between the groups. From the plasmalogens with an acyl residue in sn -2 position 
with a desaturation degree of 4, only PE (P-18:1/22:4) showed a significant difference 
between the groups. Looking at the plasmalogens with 5 double bonds, the table shows that 
there was only a significant difference in the PE (P-18:0/22:5). In the comparison of the 
plasmalogens in the three groups at time zero, none of the plasmalogen species containing an 
acyl residue with 6 double bonds in sn2 position showed any difference in concentration. 
Plasmalogen control risk  metabolic syndrome 
PE(P-16:0/16:0) 0.8 0.35  0.008 ** 
PE(P-18:0/16:1) 0.88 0.2 0.07  
PE(P-18:1/16:1) 0.3 0.39 0.02 * 
PE(P-18:0/18:1) 0.7 0.008 ** 0.006 ** 
PE(P-18:1/18:1) 0.16 0.3 0.012 * 
PE(P-16:0/18:2) 0.3 0.38 0.009 ** 
PE(P-18:0/18:2) 0.6 0.07  0.003 ** 
PE(P-18:1/18:2) 0.2 0.2 0.3 
PE(P-18:1/20:3) 0.69 0.26 0.007 ** 
PE(P-18:0/20:4) 0.06 0.006 ** 0.001 ** 
PE(P-18:0/22:4) 0.02 * 0.043 * 0.005 ** 
PE(P-18:1/22:3) 0.32 0.1 0.03 ** 
PE(P-16:0/22:5) 0.127 0.042 ** 0.05 * 
PE(P-18:1/22:5) 0.6 0.4 0.02* 
PE(P-16:0/22:6) 0.2 0.3 0.02 * 
Table 10: Dynamic over time: Plasmalogens with p-value of Friedman test. 
Observation of the development over time revealed that most of the plasmalogen species 
showed a peak at 6 hours in the metabolic syndrome group. In the control group, most species 
did not show a response to the fat load, and those which did reached their peak levels earlier 
than metabolic syndrome subjects. PE (P-18:1/18:1) showed an increase in comparison to 
time zero in the metabolic syndrome group which did not occur in the control group 
(Friedman, p=0.16 control, p=0.3 risk; p=0.012, metabolic syndrome). Since there was no 
recognizable stringency when comparing the dynamics of the plasmalogens with the same 
fatty acid in sn-2 position, examining the most common plasmalogens individually, would 
provide more information. In biosynthetic pathways, plasmalogens serve as a reservoir for 
PUFAs, as they preferentially contain arachidonic acid, DPA and DHA in sn-2 position [62].  
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Reservoir for PUFA: DHA-containing plasmalogens 
With age, the peroxisome function decreases, which leads to a decrease in plasmalogen and 
DHA synthesis [62]. The half-life of plasmalogens is about 3 hours [62]. A look at the DHA-
containing plasmalogens (16:0/ 22:6), for example showed a significant reaction to the OFTT 
in the metabolic syndrome group. The peak is again 6 hours after ingestion.  
 
 
Figure 41: Plasmalogen (16:0/DHA). Kruskal-Wallis test: p=0.6; Friedman, p=0.2, control; p=0.304, risk; p=0.02 metabolic 
syndrome. The change over time was significantly different in the metabolic syndrome group. Data is represented as means 
±1 SE.  
Arachidonic acid, linolenic and stearic acid containing plasmalogens 
 
Figure 42: PE (P-18:0/20:4), Kruskal-Wallis test, p= 0.37; Friedman test, p= 0.06, control; p=0.006, risk ; p=0.01; metabolic 
syndrome. The changes over time were significantly different in the risk and the metabolic syndrome group. Data is 
represented as means ±1 SE. 
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
0h 2h 4h 6h 8h
m
m
o
l/
l 
PE(P-16:0/22:6) 
control
risk
metabolic syndrom
0
2
4
6
8
10
12
14
0h 2h 4h 6h 8h
m
m
o
l/
l 
PE(P-18:0/20:4) 
control
risk
metabolic syndrom
 69  
The basal differences in AA containing plasmalogens were not significant, but all species 
with 20:4 at sn-2 position showed the same trend. Over time, the metabolic syndrome and the 
risk groups showed a significant increase in their levels. Plasmalogens with linoleic acid were 
down-regulated in metabolic syndrome subjects (S 17) P (PE-18:0/18:2) and P (PE-18:1/18:2) 
initially showed significantly reduced levels in the metabolic syndrome subjects (Kruskal-
Wallis, p= 0.008 and p= 0.037). All of them showed a peak in the metabolic syndrome group 
6 hours after ingestion of the drink. The increase was significant in the plasmalogens with 
acyl residue 16:0 (Friedman, p=0.3, control; p=0.38, risk; p=0.009, metabolic syndrome) and 
18:0 (Friedman p=0.6, control; p=0.07, risk; p=0.003) in sn-1 position. The plasmalogen PE 
(P-16:0/18:0) was analyzed in more detail (supplemental, S 18), because stearic acid has been 
reported to be elevated in oxidative stress [113]. The plasmalogen 16:0/18:0 concentration 
showed a significant difference between the control and the risk group (Mann-Whitney-U p= 
0.048). Over time, a significant change was observed in the metabolic syndrome group 
(p=0.001, n=30), while the other groups’ levels did not change (p=0.97, control, n=12, control 
and p=0.93, risk, n=18). Thus, only the metabolic syndrome subjects showed an increase for 6 
hours and a decrease after 6 hours.  
Correlation of the plasmalogens with the fatty acids 
 
Figure 43: Correlation between plasmalogen species and free fatty acids in the control group. Positive correlation is shown in 
red, negative correlation in blue. Significance is assumed at correlation coefficients r>0.6. 
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When correlating the fatty acids with the plasmalogens in the control group (Figure 43) the 
baseline levels of the plasmalogens with a saturated acyl residue in sn-2 position showed a 
positive correlation between the short saturated fatty acids FA 10:0 and FA 12:0 and PE (P-
18:1/16:0) as well as with the plasmalogens PE (P-16:0/18:0) and PE (P-18:0/18:0). 
Moreover, a strong positive correlation was observed between the fatty acids 14:0, 16:0, 18:0, 
18:1 (n-6), 18:1 (n-7), 18:2 (n-6), 20:0, 22:4 (n-9), 24:0, 24:1 (n-9), 22:5 (n-3) and the 
plasmalogens PE (P-18:1/16:0) and PE (P-18:1/18:0). Fatty acid 20:2 (n-6) positively 
correlated with PE (P-18:0/16:0) and PE (P-16:0/18:0). Concerning the plasmalogens with 
monounsaturated fatty acids in sn-2 position in the control group, the fatty acids 10:0 and 12:0 
positively correlated with the plasmalogen species PE(P-16:0/16:1) and (18:1/16:1) in the 
control group. FA 18:3 (n-6) positively correlated with PE (P-18:1/16:1). FA 20:2 (n-6) 
positively correlated with PE (P-16:0/18:1). The control group showed a positive correlation 
between FA 10:0 and FA 12:0 and the plasmalogen species PE (P-16:0/18:3), PE (P-
18:1/18:3), PE (P-16:0/22:3), and PE (P-18:1/22:3). The fatty acid 10:0 also correlated 
positively with PE (P-18:1/20:3). The control group showed a positive correlation between 
FA 16:1 and PE (P-18:1/20:3). The fatty acid 20:2 (n-6) positively correlated with PE (P-
16:0/18:3). The fatty acids 22:0 and 20:4 (n-3) correlated positively with PE (P-16:0/22:3) 
and FA 20:4 (n-3) correlated positively with PE (P-18:1/22:3) and PE (16:0/22:3). Fatty acid 
20:5 (n-3) correlated positively with PE (P-18:1/20:3). The fatty acid 24:1 positively 
correlated with PE (P-16:0/22:3). The fatty acid 22:6 (n-3) correlated positively with PE (P-
18:1/22:3). Concerning the plasmalogens with four double-bonds, in the control group 
arachidonic acid (20:4 n-6) positively correlated with all the plasmalogens carrying 20:4 in 
sn-2 position and with PE (P-18:0/22:4) and PE (P-18:1/22:4). The plasmalogen PE (P-
18:1/20:4) positively correlated with almost all the fatty acids: FA 10:0, FA 14:0, FA 15:0, 
FA 16:0, FA 16:1, FA 17:0, FA 18:1 (n-6), FA 18:1 (n-7), FA 20:3 (n-6), FA 20:4 (n-3), FA 
20:5 (n-3), FA 22:6 (n-3), DHA (22:6 n-3) correlated positively with the plasmalogen PE (P-
18:0/20:4). The medium-chain fatty acids positively correlated with PE (P-18:1/22:4). In the 
control group, the plasmalogens carrying 5 and 6 double bonds showed that fatty acids 10:0 
and 15:0 correlated with plasmalogens carrying 22:6 in sn-2 position. Fatty acid 16:0 
positively correlated with the plasmalogen (18:1/22:5). Fatty acids with 17, 18, 22 and 24 C 
atoms as well as fatty acid 20:0 and 20:3 (n-6) positively correlated with PE (P-18:1/22:5). 
The fatty acids 20:5 (n-3), 22:5 (n-3), 22:6 (n-3) positively correlated with all of the 
plasmalogens carrying 22:6 as acyl residue in sn-2 position. 
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Figure 44: Correlation between plasmalogen species and free fatty acids in the risk group. Positive correlation is shown in 
red, negative correlation in blue. Significance is assumed at correlation coefficients r>0.6. 
In the risk group (Figure 44), the medium-chain fatty acids correlated positively with all 
plasmalogen species carrying 18:0 in sn-2 position and with PE (P-16:0/16:0). Fatty acid 20:4 
(n-3) correlated positively with certain plasmalogens carrying 18:0 and 16:0. Fatty acid 22:0 
also correlated positively correlated with PE (P-16:0/18:0). Fatty acid 20:4 (n-6) positively 
correlated with PE (P-18:0/18:1), but FA 20:4 (n-3) with PE (P-18:1/16:1) and PE (P-
18:1/18:1). The risk group showed a positive correlation between FA 10, FA 12 and PE (P-
18:0/22:3) and PE (P-18:1/22:3). FA 12:0 positively correlated with the plasmalogen PE (P-
18:1/18:3).The fatty acids 20:0 and 20:2 (n-6) positively correlated with plasmalogens PE (P-
18:0/22:3) and PE (P-18:1/22:3).The fatty acid 20:2 (n-6) correlated positively with PE (P-
18:0/22:3). The risk group showed a positive correlation between FA 20:4 (n-6) and PE (P-
16:0/20:3) as well as 20:4 (n-3) and PE (P-18:1/18:3), PE (P-18:0/22:3) and PE (P-18:0/22:3). 
FA 22:0 also correlated with the latter two plasmalogens. The fatty acid 24:0 and 24:1 
correlated with PE (P-18:1/22:3) and fatty acid 24:1 with PE (P-18:0/22:3) as well. The risk 
group showed a positive correlation between the plasmalogen PE (P-18:1/22:4) and almost all 
of the fatty acids. PE (P-18:1/22:4) positively correlated with the medium-chain fatty acids. 
PE (P-18:0/20:4) correlated positively with the medium-chain and saturated long-chain fatty 
acids, moreover with linolenic, linoleic 20:3 (n-6), 20:4 (n-3), and 20:4 (n-6). The fatty acid 
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20:4 (n-6) correlated with almost all of the plasmalogens and with all carrying 20:4 in sn-2 
position. In the risk group, 12:0 positively correlated with two plasmalogens carrying 22:6 in 
sn-2 position. Fatty acids 17:0, 18:0, 18:1 (n-7), 18:3 (n-3), 20:3 (n-6), 20:4 (n-6), 22:0, 20:4 
(n-3), 22:1 (n-9), 20:5 (n-3), 22:4 (n-3), 22:1 (n-9), 22:4 (n-9), 24:0 and 24:1 (n-9), as well as 
all the species with 22 C atoms, correlated positively with PE (P-16:0/22:5). The 
plasmalogens PE (P-18:0/22:6) and PE (P-18:1/22:6) correlated positively with almost all of 
the fatty acids with the exception of palmitoleic acid, palmitic acid, FA 17:0, the FA 18:1 
species,  γ-linolenic acid and 22:2 (n-6). In the metabolic syndrome group, we found the most 
correlations. Since nearly all of the plasmalogens and fatty acids correlated positively in this 
group, only the strongest correlations which are most relevant to the discussion will be 
described. The correlations are shown in Figure 45. In the metabolic syndrome group, 
saturated fatty acids and the plasmalogens containing a saturated fatty acid in sn-2 position 
showed significant correlation coefficients for the correlations of the fatty acids 10:0, 12:0, 
14:0 and all of the plasmalogen species. The fatty acid 20:3 (n-6) positively correlated with 
PE (P-18:0/16:0), FA 24:1 (n-9) positively correlated with PE (P-18:1/16:0). 
 
 
Figure 45: Correlation between plasmalogen species and free fatty acids in the metabolic syndrome group. Positive 
correlation is shown in red, negative correlation in blue. Significance is assumed at correlation coefficients r>0.6. 
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The fatty acids 10:0 correlated with all plasmalogen species, fatty acid 13:0 with all the 
plasmalogens carrying 16:1 as an acyl residue in sn-2 position and with the plasmalogen PE 
(P-18:1/18:0). The fatty acid 12:0 positively correlated with the PE (P-18:1/16:1), fatty acid 
24:1 (n-9) positively correlated with PE (P-18:0/18:1) and PE (P-18:1/18:1). Concerning the 
plasmalogens with three double bonds in the metabolic syndrome group, a positive correlation 
was found between the fatty acid 10:0 and the plasmalogens PE (P-16:0/18:3), PE (P-
18:1/18:3), PE (P-18:0/20:3), PE (P-18:1/20:3), PE( P-16:0/22:3), PE(P-18:0/22:3), PE (P-
18:1/22:3); fatty acid 12:0 and PE (P-18:0/22:3); fatty acid 18:0 and PE(P-18:1/20:3), FA 
18:1 (n-9) and PE (P-18:1/20:3). Fatty acid 20:4 (n-3) positively correlated with PE (P-
18:0/20:3). PE (18:1/20:3) positively correlated with most of the fatty acids. Fatty acid 13:0 
positively correlated with the plasmalogens PE (P-16:0/18:3), PE (P-18:1/18:3), PE(P-
18:1/20:3), PE (P-16:0/22:3), PE (P-18:0/22:3), PE (P-18:1/22:3), fatty acid 17:0 with the 
plasmalogen PE(P-18:1/20:3). All of the plasmalogens carrying 22:6 in sn-2 position 
correlated with the fatty acids 20:5 (n-3), 24:0, 24:1 (n-9), 22:6 (n-3), 22:0 20:0, 18:2 (n-6). 
PE (P-18:1/22:5) correlated positively with all of them as well, and in addition with FA 22:5 
(n-3). FA 20:5 (n-3) correlated positively with all plasmalogens carrying 20:5 in sn-2 position 
and all carrying 22:6. Linoleic 18:2 (n-6) and α-linolenic 18:3 (n-3) positively correlated with 
the plasmalogens carrying DHA in sn-2 position in the risk and metabolic syndrome groups, 
contrary to γ-linolenic acid which did not positively correlate with any of the plasmalogen 
species in these groups, but showed a discrete yet not significant negative correlation value in 
the metabolic syndrome group when correlated to the named plasmalogen species. 
Arachidonic acid 20:4 (n-6) correlated positively in the control and risk groups with the 
named plasmalogen species, e.g. species carrying 22:4 in sn-2 position, whereas in the 
metabolic syndrome group it only correlated positively with plasmalogens containing 20:4. 
Linoleic acid (18:2 n-6) positively correlated with PE (P-18:1/20:4) in the risk and metabolic 
syndrome groups.  
3.3.7 Lysophosphatidylcholine, lysophosphatidic acid 
Following these observations, lysophosphatidylcholine (LPC) and lysophosphatidic acid 
(LPA) were examined. LPC species play an important role as G-protein receptor ligands and 
are involved in regulating cellular proliferation and tumor cell invasion. They also have 
atherogenic and proinflammatory properties [65], [114]. Figure 46 provides an overview of the 
different LPC species and their dynamics over time in the different groups.  
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Figure 46: LPC species over time. A) Control group B) risk group C) metabolic syndrome group. Data is represented as 
means ± 1SD. 
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As obesity is associated with chronic low-grade inflammation, one might expect LPC levels 
to be elevated in obesity. Indeed, certain plasma LPC species have been reported to be raised 
in obesity and type 2 diabetes [65,114]. When comparing the groups, we found significant 
lower baseline levels of the LPC species 18:1, 18:2, 18:3 in the metabolic syndrome group 
than in the control and the risk groups (Figure 46). In addition, the levels of the LPC species 
20:3, 20:4, 20.5, 22:5 could be observed to be down-regulated in the metabolic syndrome 
group (Figure 46). P-values are depicted below (Table 11).  
 
LPC 15:0  16:0 16:1 18:1 18:2 18:3 18:0 19:0 20:0 20:3 20:4 20:5 22:4 22:5 22:6 
p 0.063 0.429 0.077 0.000 0.000 0.000 0.357 0.013 0.205 0.002 0.009 0.007 0.716 0.000 0.480 
Table 11: LPC species with p-value between the groups of the Kruskal-Wallis test. 
 
 
The differences in the behavior of the latter – and of other important species – will later be 
explicated in detail, and a relationship will be established between the PC and those fatty acid 
species necessary to form the respective phosphatidylcholine (PC) with the LPC species. 
First, an overview of the behavior of desaturated LPC and total LPA species is shown in 
Figure 47. 
Figure 47 A shows the differences in desaturated lysophosphatidylcholine species between the 
groups. The metabolic syndrome group showed significantly decreased values compared to 
the other groups (p<0.001). This was tested by Kruskal-Wallis. Over time, the results showed 
the following p values: p=0.92, control, n=12; p=0.13, risk, n=18; p<0.001 metabolic 
syndrome, n=31. Thus, only the metabolic syndrome group responded to the drink with 
increasing values.  
Figure 47 B shows the mean LPA values. There was a significant difference between the 
groups (Kruskal-Wallis test, p=0.016, n=23). The metabolic syndrome group had lower basal 
values than the control and the risk groups. The metabolic syndrome subjects also reacted to 
the drink (Friedman, p=0.78, control, n=; p=0.51, risk, n=9; p=0.026, metabolic syndrome, 
n=6). Thus, over time, the only significant increase was after four hours in the metabolic 
syndrome group. 
 
 76  
A 
 
Kruskal-Wallis test n=61, Friedman test n=12 control, n=18 risk, n=31, metabolic syndrome. 
B 
 
Kruskal Wallis: n=23, Friedman: n=7 control; n=9 risk; n=6 metabolic syndrome. 
 
Figure 47: Lysophopholipids. A) Comparison of LPC (unsaturated species) distribution between the groups and over time. 
There was a significant difference between the groups. Over time, the metabolic syndrome group responded to the drink with 
increasing values. B) Comparison of LPA distribution between the groups and over time. Distribution between the groups 
was compared using Kruskal-Wallis; changes over time were tested by Friedman. There was a significant difference between 
the groups. Over time, the metabolic syndrome group responded to the drink with increasing values. Data are represented as 
means ± 1SE. 
 
Unsaturated lysophosphatidylcholine and lysophosphatidic acid both showed decreased 
baseline values in the metabolic syndrome group. The oral fat tolerance test provided 
additional information to identify metabolic syndrome subjects.  
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LPC Control Risk Metabolic syndrome 
LPC 15:00 <0.001 0.11 <0.001 
LPC 16:00 0.26 0.057 0.7 
LPC 16:01 0.004 0.647 <0.001 
LPC 18:00 0.58 0.344 0.004 
LPC 18:01 <0.001 0.009 <0.001 
LPC 18:02 <0.001 0.247 0.001 
LPC 18:03 <0.001 0.002 0.001 
LPC 19:00 0.54 0.8 0.80 
LPC 20:00 0.8 0.54 0.59 
LPC 20:03 <0.001 0.13 <0.001 
LPC 20:04 <0.001 0.058 <0.001 
LPC 20:05 <0.001 0.571 0.001 
LPC 22:04 0.007 0.51 0.009 
LPC 22:05 <0.001 0.07 <0.001 
LPC 22:06 <0.001 0.11 <0.001 
 
Table 12: p-values calculated using the Friedman test for the LPC species of all three groups. 
 
Looking at LPC 18:0, a saturated LPC species, the change over time as a response to the 
OFTT only occurred in the metabolic syndrome group (Table 12). Therefore the OFTT could 
be applied to determine acute changes in metabolism which indicate that the respective 
subject has the properties of subjects belonging to the metabolic syndrome group. Thus, by 
reviewing the results, it may be possible to classify him or her into this group. LPC species 
18:0 has already been described in other examinations to be one of the rare LPC species that 
should be induced in rodents after a long-term high fat diet [115]. In these results, shown in 
supplemental, (S 19), no significant differences in the baseline level could be observed when 
comparing the groups (Kruskal-Wallis p=0.3), but over time the metabolic syndrome group 
showed an increase (p=0.004). In a next step, the desaturated LPC species with either 
chronically reduced or acutely changed levels over time in the metabolic syndrome group 
were depicted and described in detail (S 20, S 21, S 22, S 23, S 24, S 25, S 26). Reduced 
levels of LPC 18:1 in obese men have already been described [115]. According to those 
examinations, S 20 showed down-regulated baseline levels in the metabolic syndrome group, 
while LPC 18:1 levels over time were induced in all three groups as a response to the OFTT. 
S 21 also shows the decreased baseline level of LPC 18:3 in the metabolic syndrome group 
(p<0.001) and an increase over time in all three groups with the same peak at 6 hours 
(p<0.001 control, p=0.002 risk, p<0.001). This species will be referred to again below in the 
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context of changes over time in phosphatidylcholine (PC) concentration and the 
corresponding fatty acid that builds the PC species together with the LPC. LPC 22:4 (S 22) 
was increased after the OFTT in the control and the metabolic syndrome groups. This is in 
agreement with other examinations showing a long-term increase in LPC 22:4 levels in mice 
after a high-fat diet [115]. In the risk group, we did not find a significant increase, but as a 
trend was recognizable. Next, polyunsaturated LPC species with 20 C atoms were described 
(S 23, S 24, S 25). LPC 20:3, 20:4 and 20:5 all showed significantly decreased levels in the 
metabolic syndrome group, compared to the other groups. Over time, all of them showed a 
significant change in the control and also in the metabolic syndrome group. The LPC species 
LPC 22:5 also showed a significantly decreased level in the metabolic syndrome group and a 
significant change over time in all groups. Before we compared the LPC to the PC levels and 
to the appropriate fatty acid species that build the PC species with LPC, a closer look was 
taken at LPA. 
LPA has previously been described as correlating positively with diabetes [116]. LPC can be 
converted into LPA. Simultaneously to LPA secretion, adipocytes release an LPA-
synthesizing activator, which has been characterized as a lysophospholipase D activity and 
which catalyzes the transformation of lysophosphatidylcholine into LPA [117]. Figure 48 
provides an overview of the different LPA species and their dynamics over time in the 
different groups. 
Kruskal-Wallis, LPA 16:0 (palmitate), p=0.34; LPA 18:0 (stearate), p=0.265; LPA 18:1 
(oleate), p=0.009, LPA 18: 2 (linoleate), p=0.005, LPA 20:4 (arachidate), p=0.305.  
 
LPA species Control Risk  Metabolic syndrome 
LPA 16:0 0.63 0.31 0.5 
LPA 18:0 0.65 0.17 0.32 
LPA 18:1 0.63 0.23 0.029  
LPA 18:2 0.94 0.32 0.017  
LPA 20:4 0.9 0.31 0.7 
Table 13: p-values calculated using the Friedman test for LPA species of all three groups 
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Figure 48: LPA species over time. A) Control group B) risk group C) metabolic syndrome group. Data i s represented as 
means ± 1SD. 
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The LPA 20:4 species is a potent peroxisome proliferator-activated receptor gamma (PPARγ) 
ligand, which is a key regulator of atherogenesis [118]. However, our data record (Figure 48) 
showed that there is neither a significant difference in the LPA 20:4 concentrations between 
the groups (Kruskal-Wallis, p=0.3), nor over time (Friedman, p=0.9, control, p=0.7 metabolic 
syndrome). The LPA species carrying oleate and linoleate therefore showed a significant 
difference between the groups with down-regulated levels in the metabolic syndrome group. 
The total LPA concentration is better suited for classifying the groups than the different LPA 
species (Figure 47 B). The changes in LPC and LPA levels over time relative to baseline 
levels were depicted (Table 14) and compared in terms of direction of change (red: up, blue: 
down), since LPA can be produced out of the other lysophospholipids (e.g. LPC) via 
autotaxin (ATX) activity [119].  
 
A 
 
LPA 18:0 FA 18:0 LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
B LPA 18:0 FA 18:0 LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
C LPA 18:0 FA 18:0 LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
D LPA 18:0 FA 18:0 LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
 
Table 14: Control group, LPA (left), fatty acid (middle), LPC (right). Red indicates an increase, blue a decrease, black no 
change compared to the baseline level. A change compared to time zero is considered if it is ≥1.2, A) 2h, B) 4h, C) 6h, D) 8h.  
 
As a response to the OFTT, LPA 18:0 (Figure 48 and Table 14) and fatty acid 18:0 (S 3 and 
Table 14) levels both increased two hours after the application of the OFTT. Subsequently, 
LPA 18:0 decreased while fatty acid 18:0 increased further and the LPC level did not change. 
This could indicate a conversion of this LPA species either into another one or into 
 81  
phospholipid. Even though the change in the control group for the FA 18:0 was not described 
as significant above, in this section, an increase of the fatty acid 18:0 at 2 hours was found, 
since change was defined as 1.2 times the basal value. 
A 
 
LPA 18:0 FA 18:0 LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
B LPA 18:0 FA 18:0* LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
C LPA 18:0 FA 18:0* LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
D LPA 18:0 FA 18:0 LPC 18:0 
LPA 18:1   FA 18:1 LPC 18:1 
LPA 18:2 FA 18:2 LPC 18:2 
LPA 20:4 FA 20:4 LPC 20:4 
 
 
Table 15: LPA (left), fatty acid (middle), LPC (right). Red indicates an increase, blue a decrease, black no change compared 
to the baseline level. A change compared to time zero is defined as ≥ 1.2. Risk A) 2h, B) 4h, C) 6h, D) 8h.   
 
For the risk group, this protection mechanism – i.e. the conversion of LPA into other species 
or classes – seems to occur earlier. LPA 18:0 and 18:1 were already down-regulated at 2 
hours while the fatty acid 18:0 was up-regulated.  
In the metabolic syndrome group (Table 16) the increase in stearic acid, and probably also the 
consecutive increase in LPA species containing the desaturation products of this fatty acid 
(oleic and linoleic acid), seemed to be insufficient to extract stearic acid from the plasma; the 
respective LPC species also showed increased levels. This could indicate a conversion of the 
LPA species into the respective LPC species. The conversion of LPA 18:0 into other species 
did not result in a decrease of LPA 18:0 since the level of stearic acid in the metabolic 
syndrome group is so high that it could not be sufficiently eliminated. Stearic acid is increased 
and is included in LPA, LPA 18:0 is then converted into LPA species 18:1 and 18:2; the fatty 
acid concentration in the plasma remains increased, and neither does the LPA 18:0 
concentration in the plasma decrease, which can be interpreted as an insufficient elimination 
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of the fatty acid; eventually LPC concentrations increase, which are probably conversion 
products. 
 
A 
 
LPA 18:0 FA 18:0  LPC 18:0 
LPA 18:1*     18:1 LPC 18:1 
LPA 18:2 18:2 LPC 18:2 
LPA 20:4 20:4 LPC 20:4   
 
B LPA 18:0 18:0**   LPC 18:0 
LPA 18:1*     18:1 LPC 18:1*** 
LPA 18:2 18:2 LPC 18:2*** 
LPA 20:4 20:4 LPC 20:4**   
 
C LPA 18:0 18:0*  LPC 18:0 
LPA 18:1*  18:1 LPC 18:1*** 
LPA 18:2 18:2 LPC 18:2*** 
LPA 20:4 20:4 LPC 20:4**   
 
D LPA 18:0 18:0  LPC 18:0 
LPA 18:1 18:1 LPC 18:1*** 
LPA 18:2 18:2 LPC 18:2*** 
LPA 20:4 20:4 LPC 20:4* 
 
 
Table 16: Metabolic syndrome, LPA (left), fatty acid (middle), LPC (right). Red indicates an increase, blue a decrease, black 
no change compared to the baseline level. A change compared to time zero is considered if is ≥1.2. A) 2h, B) 4h, C) 6h, D) 
8h. 
 
Another way of LPA production is by conversion of phosphatidic acid (PA) [119]. The 
precursor phospholipids (PC, PS, or PE) can be converted into their corresponding 
lysophospholipids such as lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), or 
lysophosphatidylethanolamine (LPE) [120]. Next, correlation of PC to LPC and the 
corresponding FA were looked at.  
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Correlations of PC to LPC and fatty acids 
 
Figure 49: Phosphatidylcholines with <34 C atoms at baseline level 
 
Figure 50: Phosphatidylcholines with 36-38 C atoms at baseline level 
 
Figure 51: Phosphatidylcholines with >40 C atoms at baseline level 
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Table 17: Control (2h): PC, LPC and FA level at 2 hours were compared to baseline value by calculating the difference 
between the mean at two hours and at starting point. Increased levels compared to baseline are highlighted in bold (red), 
decreased levels compared to baseline are highlighted in light grey (blue), and those with no significant changes black. In the 
middle boxes, those fatty acid species are shown from which the respective PC species could potentially be built with the 
corresponding LPC species (at the top). PC species are shown on the left. A significant decrease is defined as >1.2. 
Additionally, the significance we calculated with is shown in stars: : *<0.05, **<0:01, ***<0.001, (scheme  based on 
description by Thomas Kopf).  
Table 17 showed a downregulation of the PC species 32:3, 42: 5, 38:1 and 44:1 as a response 
to the OFTT in the control group, whereas 42:4 and 42:0 were increased by the OFTT. 
Simultaneously, the fatty acid species FA 10, FA 12, FA 14, FA 15, FA 16, FA 17, FA 18, 
FA 20:3 and FA 14:1 increased after the fat load ( an increase is defined here as difference to 
the baseline level of >1.2, even if this may not be significant in a t-test or Friedman test). The 
decrease of PC 32:3 and increase of FA 14:0, 14:1 and FA 12:0 could be interrelated. The 
cleavage either resulted in increased LPC 20:3, 18:2 or 18:2. This could not be proved by the 
results. Whereas the oral fat response resulted in reduced PC 32:3 levels after the OFTT in the 
control group despite an increase in the medium-chain fatty acid concentration, no change in 
level could be observed in the risk group for this PC after 2 hours; after 4 hours, the level was 
even increased. This could be interpreted as a protective mechanism, a conversion of 32:3 into 
another lipid to fill up the PC reservoir with the medium-chain fatty acids again in the control 
group. In the metabolic syndrome group, PC 32:3 is instantly increased, which suggests a 
breakdown of the suggested protective mechanism. PC 32:2, a protective species associated 
with reduced mortality [121], was increased as a response to the OFTT in the control group 
after 4 hours, (supplement). The palmitoleic acid 16:1 (n-7) level was also increased. It is 
possible that palmitoleic acid is inserted in 32:2 and by this way withdrawn from plasma. The 
LPC 20:0 LPC 19:0 LPC 18:0 LPC 18:1 LPC 16:1 LPC 18:2 LPC 20:3 LPC 18:3 LPC 22:4 LPC 20:4 LPC 22:5 LPC 20:5 LPC 22:6
PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0**  16:0
PC 40:5 20:5 22:5 22:4 20:2 18:1 18:0 20:0
PC 42:5 22:5 22:1 20:0 22:0
PC 34:4 18:3 14:1 16:1 12:0*** 14:0**  
PC 36:4 18:3 20:3 18:2 16:1 18:1 14:0**  16:0
PC 38:4 20:4 20:3 20:2 18:1 16:0 18:0
PC 40:4 20:4 22:4 22:1 18:0 20:0
PC 42:4 22:4 22:1 24:1 20:0 22:0
PC 32:3 14:1 12:0*** 14:0**  
PC 34:3 18:2 16:1 14:0**  16:0
PC 36:3 18:3 18:2 20:2 18:1 16:0 18:0
PC 40:3 20:3 22:1 20:0 22:0
PC 32:2 14:1 16:1 14:0**  
PC 34:2 16:1 18:1 16:0
PC 38:2 18:2 20:2 22:1 20:0
PC 40:2 20:2 22:1 24:1 22:0
PC 30:1 12:0*** 14:0**  
PC 32:1 14:1 14:0**  16:0
PC 34:1 14:1 16:1 16:0 18:0
PC 36:1 16:1 18:1 18:0 20:0
PC 38:1 18:1 20:0 22:0
PC 40:1 22:1 22:0 24:0
PC 44:1 24:1
PC 26:0
PC 28:0 10:0***
PC 30:0 10:0*** 12:0***
PC 32:0 12:0*** 13:0 14:0**  
PC 34:0 14:0**  15:0*    16:0
PC 36:0 16:0 17:0 18:0
PC 40:0 20:0 22:0
PC 42:0 22:0 24:0
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development over time is graphically represented in the supplement. After 6 hours (S 28), 
32:1 – another PC associated with a reduced mortality compared to PC 32:0 [121] – was 
increased. In the risk and metabolic syndrome groups, PC 32:2 also showed increased levels 
as a response to the OFTT, but without an increase of PC 32:1 in the metabolic syndrome 
group. After four hours (S 27), PC 40:2 increased significantly in the control group whereas 
the fatty acid 20:2 decreased. This could be interpreted as an integration of this fatty acid into 
PC 40:2. LPC 20:0 showed a tendency towards decreased levels, which is not significant but 
visible. In the metabolic syndrome group, PC 40:2 was not up regulated (S 33, S 34, S 35), 
which might be due to the initially much higher baseline level (Figure 51). After 6 hours, the 
fatty acid species 22:1, 20:0, 22:0 were increased, LPC 20:0 was induced while PC 42:5 was 
still decreased. PC 32:1 also showed increased levels as a response to the increase of the fatty 
acids 14:1, 14:0 and 16:0. After 8 hours (S 29), LPC 18:3 increased, while PC 32:3 decreased 
and the fatty acid 14:0 increased. This supports the hypothesis that PC is cleaved into the fatty 
acid and the LPC species eight hours after the OFTT. The fact that the level of PC 42:5 was 
reduced 8 hours after the fat load indicates that docosapentaenoic acid (22:5) containing PCs 
released the protective fatty acid. 
 
Table 18: Risk (2h), increased levels compared to baseline are highlighted in bold (red), decreased levels compared to 
baseline are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, those fatty acid 
species are shown from which the respective PC species could potentially be built with the corresponding LPC species (at the 
top). PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the significance we calculated 
with is shown in stars: *<0.05, **<0:01, ***<0.001, (scheme based on description by Thomas Kopf).  
LPC 20:0 LPC 19:0 LPC 18:0 LPC 18:1 LPC 16:1 LPC 18:2 LPC 20:3 LPC 18:3 LPC 22:4 LPC 20:4 LPC 22:5 LPC 20:5 LPC 22:6
PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0**  16:0
PC 40:5 20:5 22:5 22:4 20:2 18:1 18:0 20:0
PC 42:5 22:5 22:1 20:0 22:0
PC 34:4 18:3 14:1 16:1 12:0*** 14:0**  
PC 36:4 18:3 20:3 18:2 16:1 18:1 14:0**  16:0
PC 38:4 20:4 20:3 20:2 18:1 16:0 18:0
PC 40:4 20:4 22:4 22:1 18:0 20:0
PC 42:4 22:4 22:1 24:1 20:0 22:0
PC 32:3 14:1 12:0*** 14:0**  
PC 34:3 18:2 16:1 14:0**  16:0
PC 36:3 18:3 18:2 20:2 18:1 16:0 18:0
PC 40:3 20:3 22:1 20:0 22:0
PC 32:2 14:1 16:1 14:0**  
PC 34:2 16:1 18:1 16:0
PC 38:2 18:2 20:2 22:1 20:0
PC 40:2 20:2 22:1 24:1 22:0
PC 30:1 12:0*** 14:0**  
PC 32:1 14:1 14:0**  16:0
PC 34:1 14:1 16:1 16:0 18:0
PC 36:1 16:1 18:1 18:0 20:0
PC 38:1 18:1 20:0 22:0
PC 40:1 22:1 22:0 24:0
PC 44:1 24:1
PC 26:0
PC 28:0 10:0***
PC 30:0 10:0*** 12:0***
PC 32:0 12:0*** 13:0 14:0**  
PC 34:0 14:0**  15:0*    16:0
PC 36:0 16:0 17:0*    18:0
PC 40:0 20:0 22:0
PC 42:0**  22:0 24:0
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After four hours, PC 38:2 (S 30) was reduced in the risk group while the fatty acid 20:2, from 
which PC 38:2 could be built, was elevated. PC 36:5, which can contain 20:4 and is supposed 
to be protective against CVD [121] increased at 6 hours as a response to the OFTT, whereas 
FA 20:3 was also increased but concentration in the plasma of 20:4 did not change, indicating 
a withdrawal of FA 20:4 by the formation of PC 36:5.  
 
Table 19: Metabolic syndrome (2h), increased levels compared to baseline are highlighted in bold (red), decreased levels 
compared to baseline are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, 
those fatty acid species are shown from which the respective PC species could potentially be built with the corresponding 
LPC species (at the top). PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the 
significance we calculated with is shown in stars:  *<0.05, **<0:01, ***<0.001, (scheme  based on description by Thomas 
Kopf).  
 
In the metabolic syndrome group, the increase of fatty acids does not co-occur with a decrease 
in PC species. PC 26:0, which has already been described to be increased in obesity, increased 
after two hours. In the metabolic syndrome group, PC 32:2 increased like in the risk group, 
LPC 18:3 increased and fatty acid 14:0 also increased. Four hours after the OFTT (S 33), the 
LPC species 18:1, 18:2, 18:3, 20:4 and 22:6 showed increased levels. PC 32:0 level, having 
the strongest association with mortality [121], did not show any remarkable change over time 
in any of the groups, even though the fatty acid species that this PC species contains were 
upregulated in all the groups after the OFTT. 
LPC 20:0 LPC 19:0 LPC 18:0 LPC 18:1 LPC 16:1 LPC 18:2 LPC 20:3 LPC 18:3 LPC 22:4 LPC 20:4 LPC 22:5 LPC 20:5 LPC 22:6
PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0**  16:0
PC 40:5 20:5 22:5 22:4 20:2 18:1 18:0 20:0
PC 42:5 22:5 22:1 20:0 22:0
PC 34:4 18:3 14:1 16:1 12:0*** 14:0**  
PC 36:4 18:3 20:3 18:2 16:1 18:1 14:0**  16:0
PC 38:4 20:4 20:3 20:2 18:1 16:0 18:0
PC 40:4 20:4 22:4 22:1 18:0 20:0
PC 42:4 22:4 22:1 24:1 20:0 22:0
PC 32:3 14:1 12:0*** 14:0**  
PC 34:3 18:2 16:1 14:0**  16:0
PC 36:3 18:3 18:2 20:2 18:1 16:0 18:0
PC 40:3 20:3 22:1 20:0 22:0
PC 32:2 14:1 16:1 14:0**  
PC 34:2 16:1 18:1 16:0
PC 38:2 18:2 20:2 22:1 20:0
PC 40:2 20:2 22:1 24:1 22:0
PC 30:1 12:0*** 14:0**  
PC 32:1 14:1 14:0**  16:0
PC 34:1 14:1 16:1 16:0 18:0
PC 36:1 16:1 18:1 18:0 20:0
PC 38:1 18:1 20:0 22:0
PC 40:1 22:1 22:0 24:0
PC 44:1 24:1
PC 26:0
PC 28:0 10:0***
PC 30:0 10:0*** 12:0***
PC 32:0 12:0*** 13:0 14:0**  
PC 34:0 14:0**  15:0*    16:0
PC 36:0 16:0 17:0 18:0
PC 40:0 20:0 22:0
PC 42:0 22:0 24:0
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3.4 Inflammatory markers in the blood compartment 
Inflammation markers were elevated in metabolic syndrome subjects. Although all the 
concentrations of inflammation markers changed during the application of the oral fat 
tolerance test, we found CRP to be the best inflammation marker for identifying the metabolic 
syndrome subjects. Metabolic syndrome subjects are in a state of chronic inflammation [122]. 
Therefore, we searched for differences in the time levels of well-established inflammation 
parameters using the oral fat tolerance test (OFTT). The inflammation parameters under 
investigation were CRP, the leukocyte counts and soluble urokinase-type plasminogen 
activator receptor (suPAR).  
The urokinase-type plasminogen activator receptor (uPAR), which can be segregated into 
soluble uPAR (suPAR), is involved in immune activation and present in several cell types 
[123]. It plays a role in plasmin activation, modulation of cell adhesion, migration and 
proliferation, tissue remodeling and systemic inflammation. suPAR is generated in 
inflammatory response and is elevated in type II diabetes [123]: 
“The urokinase plasminogen activator receptor (uPAR), which is present in several cell types , 
plays a role in numerous physiological pathways mainly involving immune activation, e.g. the 
plasminogen activating pathway, the modulation of cell adhesion, migration and proliferation, 
and tissue remodeling and systemic inflammation.”[123]. uPAR is cleaved and released from 
cells in response to inflammatory stimulation, this leads to generation of suPAR [123]. SuPar 
can be regarded as a pro-inflammatory marker, thus providing a risk marker for type 2 
diabetes [123]. A few studies have shown that, after adjustment for conventional risk factors, 
increased levels of suPAR in the general population are associated with an increased risk of 
death from all causes, as well as increased risk of several chronic diseases, including cancer, 
cardiovascular disease and type 2 diabetes” [123]. 
SuPar is known to be a predictor for CVD [124], and the results showed that basal suPar 
levels were significantly higher in the metabolic syndrome subjects than in the other groups 
(Figure 52 A). After the oral fat tolerance test, the values decreased in all three groups (Figure 
52 B): Friedman test, p<0.001. 
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A 
 
n=14(control); n=19 (risk); n=29 (metabolic syndrome), p<0.05= *; p <0.01=**; p<0.001=*** 
B 
 
n=14 (control); n=19 (rik); n=29 (metabolic syndrome), p<0.05=*; p<0.01=**; p<0.001=*** 
Figure 52 A) Comparison of the SuPar distribution in the groups at the start of the experiment and at 4 hours (p<0.05 = *; 
p<0.01 = **; p<0.001 = *** ). Data is represented as means ± 1SE B) Comparison of the SuPar concentrations over time 
(p<0.05= *; <0.01=**;<0.001=***. Data is represented as means ± 1SD.  
  
Furthermore, the leukocyte count was significantly lower in the control group compared to the 
metabolic syndrome group. To compare the leukocyte number between the groups, the 
Kruskal-Wallis test was used (p=0.03). The leukocyte concentration was corrected by the 
dilution factor as explained in the “Material and Method” section. In order to compare the 
leukocyte concentration over time, Friedman was used (p<0.001 control, n=11; p<0.001, risk, 
n=19; p=0.02, metabolic syndrome; n=22).  Levels changed significantly over time for all 
three inflammation markers.  
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Figure 53: Representation of the leukocyte concentrations, corrected by dilution factor. The data was represented in means ± 
1SE. Distribution between the groups was compared using Kruskal-Wallis, n=67, and Mann-Whitney U. Changes over time 
were tested by Friedman. 
 
 
Figure 54: Representation of CRP n=13 (control); n= 20 (risk), n=33 (metabolic syndrome). 
There was a significant difference in CRP concentration between the groups. The changes over time were significantly 
different in the metabolic syndrome group. The data was presented in  means ± 1SE.  Distribution between the groups was 
compared using  Kruskal-Wallis and Mann-Whitney U. Changes over time were tested by Friedman. 
 
CRP exhibited different kinetics over time in the different groups (Figure 54). Interestingly, 
the metabolic syndrome group showed decreases in CRP (Friedman test, p=0.027), while the 
levels of the other groups remained constant (p=0.291, control and p=0.658 risk). There also 
was a significant difference in CRP concentration between the groups (Kruskal-Wallis test, 
p=0.003). Summing up, levels of SuPar (Figure 52), CRP (Figure 54) and leukocyte counts 
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(Figure 53) were significantly lower in the control group compared to metabolic syndrome 
subjects and showed an acute response to the OFTT. The CRP concentration differed between 
the groups, reflecting chronic alteration of metabolism. CRP also reflects an acute alteration 
of the metabolism in metabolic syndrome subjects, manifested in a different reaction of the 
metabolic syndrome group to the drink compared to the other groups. 
 
Figure 55: Dynamic over time of CRP and plasmalogen species 18:1/22:6 in the risk group 
 
We found a negative correlation between CRP levels of the risk group (Figure 55) and the 
plasmalogen species 18:1/22:6 (correlation coefficient r = -0.63, risk). In the other groups 
there was no significant correlation (r = -0.05, control; r = 0.31 metabolic syndrome). The 
fatty acid docosahexaenoic acid (DHA) in sn-2 position has been reported to have an anti-
inflammatory function. A decreased level of this fatty acid results in a decrease of all 
plasmalogens species [125]. The fact that only the risk group showed a significant negative 
correlation between this DHA-containing plasmalogen and CRP might be due to the small 
size of the groups.  
3.5 Adipose tissue hormones 
The measurement of the adipokine levels of ghrelin and leptin after the OFTT enables the 
discrimination between subjects with risk for metabolic syndrome. Des-acyl-ghrelin [126], 
adiponectin[127] and omentin [128] are involved in the adipose tissue metabolism. In this 
study, omentin, adiponectin and ghrelin were analyzed as potential marker cytokines for the 
regulation of adipose tissue metabolism. We found that baseline levels of these adipokines 
were significantly lower in metabolic syndrome subjects compared to controls, indicating 
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chronic long-term adaptations of the adipose tissue in metabolic syndrome. As a reaction to 
the oral fat challenge, we found delayed and – in some cases – diminished reactions of the 
metabolic syndrome group compared to the others, which indicates an acute change in 
metabolic reaction to fat load.  
3.5.1 Omentin   
A 
 
 n=14 (control); n=18 (risk) ;n=28 (metabolic syndrome) 
B 
 
n=14(control); n=18 (risk) ; n=28 (metabolic syndrome) 
Figure 56 A) Comparison of omentin distribution in the groups at the start of the experiment and at 8 hours (p<0.05 = *; p 
<0.01=**; p<0.001=*** ) B) Comparison of omentin concentrations over time (p<0.05= *; p <0.01=**; p<0.001=*** The 
data are represented as means±1SE. Distribution between the groups were compared using  Kruskal-Wallis and Mann-
Whitney U. Changes over time were tested by Friedman. 
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Omentin is a cytokine which modulates inflammation [129]. Omentin levels were found to be 
decreased in metabolic syndrome subjects compared to control subjects [129]. This study 
(Figure 56) confirmed the decreased basic omentin values of the metabolic syndrome subjects 
[130] (Mann-Whitney U, p=0.013). Moreover, the results showed a significant response to the 
oral fat tolerance test in control (Friedman, p=0.002) and metabolic syndrome subjects 
(Friedman, p=0.016). The risk subjects also showed the same trend, but this result was not 
statistically significant (p=0.059). Since reactions to the oral fat tolerance test in the groups 
were the same, the oral fat tolerance test did not exhibit discriminatory potential for 
identifying subjects from the respective groups (Figure 56).  
3.5.2 Leptin 
“Leptin is involved in various physiological processes. It derives mostly from adipocytes, but 
it is also produced by immune cells.” [131] Under physiological conditions, the amount of 
leptin produced by the adipose tissue (AT) is related to its mass [131]. “Shortly after food 
intake, leptin levels rise, interacting with its receptors in the hypothalamus, being followed by 
a decreased food intake and increased energy expenditure. Leptin also seems to be a critical 
mediator in the host defense during infections, stimulating innate responses as well.” [131] 
 
 
 
Figure 57: Leptin concentrations. Comparison between the groups was calculated by Kruskal-Wallis and Mann-Whitney U, 
p***, n=10 (control); n=19 (risk); n=31 (metabolic syndrome). Over time, the changes were calculated using the Friedman 
test n=3, (control); n=10 (risk); n=19 (metabolic syndrome). The changes over time were significantly different in the 
metabolic syndrome and the risk group. The data is represented as means±1SE. 
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Basal leptin values were significantly higher in risk and metabolic syndrome subjects (Figure 
57) compared to control subjects (Mann-Whitney U test, p<0.001). Each group, as compared 
to the others, showed a significant difference. Over time, the values of the control subjects 
remained constant (Friedman, p=0.066, control, n=3), while the risk and metabolic syndrome 
subjects showed a significant change (Friedman, p=0.001, risk; n=10; p<0.001, metabolic 
syndrome, n=19). After the oral fat tolerance test, metabolic syndrome subjects had their 
nadirs at 4 hours, whereas the other groups did not show this significant decrease. Since 
serum half-life of leptin is 90 minutes, its elimination was obviously delayed in metabolic 
syndrome subjects, or its production was increased. The risk group showed a nadir at 120 
minutes, which was not significant. The oral fat tolerance test provided additional information 
on an acute adapted metabolism in the metabolic syndrome subjects. When comparing those 
adipokines with the lipids, we observed that leptin correlates positively with the palmitoleic 
acid 16:1 in the risk group. 
3.5.3 Adiponectin  
As a next step, we measured the adiponectin concentration using ELISA. Adiponectin is an 
insulin-sensitizing adipokine as well as an anti-inflammatory and antiatherogenic hormone 
[132]. 
 
Figure 58 : The mean value of adiponectin concentrations between the groups was calculated by Mann-Whitney U. All points 
in time included n= 75(control), n=98(risk) n=159(metabolic syndrome.). Over time, there was a response to the OFTT in the 
control and risk groups. Data is represented as means ± 1SE.  
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When we compared the control group to the metabolic syndrome group (Figure 58) using the 
Mann-Whitney U test by considering all points in time simultaneously, we found a basal 
difference between the control group and the metabolic syndrome group (p<0.001) as well as 
between the control and the risk groups (p=0.006). There was no significant difference 
between the risk and the metabolic syndrome groups (p= 0.114). However, mean adiponectin 
levels were higher in the control group than in the risk group and mean adiponectin levels in 
the risk group were higher than in the metabolic syndrome group. As a reaction to the drink, 
there was a response over time in the control group (p<0.01) and the risk group (p<0.01), 
whereas there was no significant change over time in the metabolic syndrome group 
(p=0.056). The behavior of the groups over time was similar: at two and six hours all groups 
reached their nadirs. At 4 hours there was a peak in each group, but these peak levels still 
remained statistically lower than the basal levels of the groups. 
3.5.4 Leptin-adiponectin ratio 
Earlier in this thesis, the leptin-adiponectin ratio has been described to be a more sensitive 
predictor for CVD than adiponectin and leptin alone [133]. Metabolic syndrome subjects, as 
shown in Figure 59, had a higher leptin-adiponectin ratio than the other groups as an 
indication of an elevated risk of CVD. 
 
 
Figure 59: The comparison of the adiponectin-leptin ratio between the groups was tested by Mann-Whitney U (control-
metabolic syndrome);(control-risk); (risk-metabolic syndrome). The adiponectin-leptin ratio showed a significant difference 
at time = 0 hours between the groups. Over time, there was a significant difference in the risk and the metabolic syndrome 
groups. Significance of the changes over time tested using Friedman test n=3 (control); n=10 (risk); n=20 (metabolic 
syndrome). Data is represented as means ± 1SE.  
 
0
0,5
1
1,5
2
2,5
3
3,5
0h 2h 4h 6h 8h
ra
ti
o
 
Leptin-adiponectin-ratio 
control
risk
metabolic syndrome
 95  
The adiponectin-leptin ratio showed a significant difference at time = 0 hours between the 
groups (Mann-Whitney U, p<0.001 control-metabolic syndrome; p=0.016 control-risk; p= 
0.047 risk-metabolic syndrome). Over time, there was a significant difference in the risk and 
the metabolic syndrome groups (Friedman test, p=0.316, control, n=3; p<0.001, risk, n=10; 
p<0.001, metabolic syndrome, n=20). The results show that the metabolic syndrome and the 
risk groups showed a significant reaction to the drink, whereas the control group did not react. 
The ratio may reflect not only the chronic, but also the acute adaptation of the metabolism in 
metabolic syndrome subjects and also in the risk group. The adiponectin-leptin ratio could be 
used as a marker to identify metabolic syndrome subjects in prevention screenings. 
3.6 Gastrointestinal tract: Ghrelin 
Ghrelin is a cytokine that is secreted mainly by the gastrointestinal tract but also by the fatty 
tissue [134] and that is involved in inflammation [135].  
A 
 
 
B 
   
 control n=13 
0
100
200
300
400
500
600
700
800
control risk metabolic syndrome
p
g/
m
l 
Des-acyl-ghrelin 
0h
4h
   * 
* 
0
200
400
600
800
1000
0h 4h
G
h
re
lin
 p
g/
m
l 
time 
Ghrelin control group 
 96  
The mean ghrelin concentration (Figure 60 A) showed significant differences between the 
control and the metabolic syndrome groups (Mann-Whitney U, p=0.048). The significance 
was calculated using the Mann-Whitney U test. The comparison of the other groups showed 
no significant differences (p=0.1, control–risk; p=0.3 risk-metabolic syndrome). At different 
points in time, there was a significant difference within the risk and the metabolic syndrome 
groups (Friedman test, p=0.414, control, n=7; p=0.034, risk, n=8; p=0.035, metabolic 
syndrome, n=11). In order to increase the number of cases, graphs B, C and D in Figure 60 
were created, which also include the cases with values below detection limit. For the purpose 
of those diagrams, as described in the “Material and Method” section, the values below 
C 
  
Risk, n=16 
D 
 
Metabolic syndrome, n=31 
Figure 60, A-D: Ghrelin. A) Comparison of the ghrelin distribution over time (t=0 and t=4hours) (p<0.05= *; 
<0.01=**;<0.001=*** ); Control; n=7,  risk; n=8, metabolic syndrome n=11.  B) Changes over time of the ghrelin levels in 
the control group, including values below detection limit; C) Changes over time of the ghrelin levels in the risk group, 
including values below detection limit;  D) Changes over time of the ghrelin levels in the metabolic syndrome group, 
including values below detection limit. The data is represented as means ± 1SD, distribution between the groups was 
compared using Kruskal-Wallis and Mann-Whitney U. Changes over time were tested by Friedman test. The mean is 
represented as a yellow line in B,C and D. 
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detection limit were set at 0.2. The result of the significance test was similar to previous 
results. Thus, the control group (Figure 60 B) showed no changes over time (p=0.096), the 
risk (Figure 60 C) and the metabolic syndrome (Figure 60 D) groups showed significant 
changes as a reaction to the drink (p=0.02 and p=0.008). In the final analysis, basal levels of 
ghrelin were significantly lower in subjects with metabolic syndrome (Figure 60 D) than in 
control subjects (Figure 60 B) and showed a significant decrease four hours after the fat 
tolerance test in the metabolic syndrome (Figure 60 D)  and the risk subjects (Figure 60 C). In 
the control group (Figure 60 B), there was no significant response to the drink. 
3.7 Renal system 
3.7.1 Creatinine  
 
Figure 61: The comparison of creatinine concentrations was calculated by Kruskal-Wallis n=13 (control); n=20 (risk) , n=33 
(metabolic syndrome). There was a significant difference between the groups at baseline. Changes over time were calculated 
using the Friedman test: (control; n=3); (risk; n=7); (metabolic syndrome; n=17). Data is represented as means ± 1SE 
 
The creatinine concentration (Figure 61) did not change significantly over time in any of the 
groups (Friedman test, p=0.087, control, n=3; p=0.439, risk, n=7; p=0.596, metabolic 
syndrome, n=17). However, basal values of the metabolic syndrome subjects were chronically 
elevated, considering all points in time at once (Kruskal-Wallis, p= 0.002). In order to show 
that the kidney function was also impaired in those metabolic syndrome subjects without 
diabetes, we correlated kidney function with diabetes (Figure 62). A reduced kidney function 
was defined by elevated creatinine levels (>1.1 mg/dl) at any point in time. 
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Figure 62: Diabetes and kidney function. 
 
3.7.2 FGF-23 
FGF-23 is a fibroblast growth factor which acts as a hormone and is produced by 
osteoblasts/osteocytes in the bone. It acts on the kidney by regulating the phosphate and 
vitamin D metabolism through activation of the FGF receptor/α-Klotho co-receptor 
complexes [136]. It is possible that elevated FGF-23 may exert its negative impact through 
distinct mechanisms of action independent of its role as a regulator of phosphorus 
homeostasis [136]. Elevated circulating FGF-23 concentrations have been associated with left 
ventricular hypertrophy (LVH), and it has been suggested that FGF-23 exerts a direct effect 
on the myocardium [136]. While it is possible that ‘off-target’ effects of FGF-23 present in 
very high concentrations could induce LVH, this possibility is controversial, since α-klotho is 
not expressed in the myocardium. Another possibility is that FGF-23's effect on the heart is 
mediated indirectly, via ‘on-target’ activation of other humoral pathways [136]. 
We found significant chronically (p<0.001) and acutely elevated FGF-23 levels in patients 
with metabolic syndrome compared to the other groups (Figure 63). The acute reaction to the 
oral fat challenge in the metabolic syndrome subjects (p<0.001) and constant FGF-23 levels 
in healthy subjects renders FGF-23 a suitable biomarker for the metabolic syndrome. The 
acute elevation after the drink could be due to a reduced clearance capacity in metabolic 
syndrome subjects. This reduced clearance capacity could again be interpreted as a sign of 
resistant metabolism in the metabolic syndrome subjects.  
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Figure 63: FGF-23 concentrations. Comparison of the FGF distribution between the groups at the start of the experiment and 
at 4 hours, tested by Kruskal-Wallis. FGF-23 concentrations over time showed a significant difference in the metabolic 
syndrome group, tested by Friedman test: p<0.001 (The data are presented as means ± 1SD, distribution between the groups 
were compared using  Kruskal-Wallis and Mann-Whitney U.Changes over time were tested by Friedman test, p<0.05= *; p 
<0.01=**; p<0.001=***). 
 
To clarify whether the elevated FGF-23 level in the metabolic syndrome subjects is only an 
accompanying parameter of the reduced kidney function or whether it is independent of 
kidney function and a consequence of the metabolic syndrome, the FGF-23 levels of non-
diabetic subjects with normal kidney function were selected and shown in Figure 64. In order 
to find out whether FGF-23 could be a biomarker for the metabolic syndrome subjects in 
general and independently of kidney function, the FGF-23 levels of the three groups were 
compared by only referring to selected subjects with normal kidney function and without 
diabetes. Since the number of non-diabetic subjects with intact kidney function was low at 
time zero, the standard error was too large. Therefore, all time-points were accumulated and 
the FGF-23 levels were then compared. 
The chronic elevation of FGF-23 in healthy-kidney and non-diabetic metabolic syndrome 
subjects was significant at all points in time together (Kruskal-Wallis test, p<0.001, control, 
n=63, risk n=92, metabolic syndrome, n=82). The response to the drink was different when 
comparing the groups. Whereas the control and risk group did not show any significant 
changes over time, the metabolic syndrome group showed an increase of the FGF-23 levels as 
reaction to the oral fat tolerance challenge (Friedman, p=0.147, control, n=11; p=0.205, risk, 
n=18; p=0.031, metabolic syndrome, n=16). The values increased until 6 hours, afterwards 
they decreased again. Measuring FGF-23 was a method to prove an acutely altered 
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metabolism in metabolic syndrome subjects, so FGF-23 could be a new biomarker measured 
in non-fasting condition for metabolic syndrome. Further analysis with a larger group size 
could be useful for evaluating the benefit of fasting values.  
 
Figure 64: The FGF-23 concentration in the subjects with normal kidney function (creatinine <1,1 in at least one point in 
time) and without diabetes. Comparison between the groups was tested using Kruskal-Wallis including all points in time. 
n=13 (control) n=18 (risk) n=16 (metabolic syndrome). Changes over time were calculated using the Friedman test: n=11 
(control); n=18(risk); n=16(metabolic syndrome). Over time, there was a response to the OFTT in the metabolic syndrome 
group. Data is represented as means ± 1SE.  
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4 Discussion 
4.1 Accuracy of choice of stratification criteria  
To find several biomarkers which in combination could help to classify subjects in a risk 
group for the metabolic syndrome early and provide early treatment, at first the 67 volunteers 
were classified in three groups according to IDF criteria as described above. The distribution 
of the individuals in the three groups control, risk and metabolic syndrome results in different 
group sizes. The metabolic syndrome group contains 33 subjects, whereas the control group 
contains only 14 subjects (Figure 5). We measured different parameters before and during the 
oral fat tolerance test (OFTT). The comparison of the mean concentrations showed 
differences between the groups. At first, the triglyceride and cholesterol concentrations, as 
well as the concentrations of their vehicles, were analyzed. Since the criteria for the metabolic 
syndrome [77] include TAG and HDL levels as stratification parameters, the groups showed 
significantly different HDL and TAG levels. Interestingly, we only found diabetes in the 
metabolic subjects group, although we did not – as suggested by the WHO [77] – include 
insulin resistance as a necessary criterion for the metabolic syndrome. Fasting glucose was 
significantly higher in the subjects with risk factors than in the control subjects, which was 
expected since normal glucose concentration was an inclusion criterion for control subjects. 
Hypertension occurred significantly more frequently in the metabolic syndrome group than in 
the risk group. In the control group, we did not have any subject with hypertension.  
OFTT 
The oral fat load consisted of 66% fat with mostly saturated fatty acids. A drink containing a 
bigger proportion of fat and less carbohydrate would be better suited for relating the effects to 
the fat challenge more easily. The contained glucose can distort the reaction to FA in insulin 
sensible subjects [137]. This could cause different reactions in the groups. On the other hand, 
we did not only add the sugar for the taste, but also because a pure fat load would fail to elicit 
the metabolic responses that depend on the increase in plasma-insulin concentrations. That is 
because insulin is a key agent for changes in adipose tissue, caused by fatty acid circulation, 
during the transition from fasting to fed state [138]. 
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4.1.1 Lipid vehicles and other Cholesterol fractions 
There was no significant difference in total cholesterol concentrations, non-HDL cholesterol 
concentration and LDL concentration between the groups. We had expected a higher LDL 
concentration in the metabolic syndrome group than in the control group. The results proved 
that with a probability of 90% there is no difference between the concentrations in the groups. 
This might be due to the small group sizes. But since no trend was recognizable, it can be 
assumed that the LDL values were in fact the same in all groups. But the treatment needs 
differ between the groups. The control group had none of the risk factors linked with 
atherosclerosis (impaired glucose tolerance, low HDL concentration, elevated TAG 
concentration, elevated body weight or blood pressure) and for primary prevention, it is not 
reasonable to treat subjects without risk factors and cholesterol values beneath 160 mg/dl 
[139]. Even the risk subjects with a mean LDL of 129 mg/dl are “near optimal” and do not 
exceed the threshold value for treatment of 130 mg/dl [139]. It should be considered to treat 
the metabolic syndrome subjects, since the target value for secondary prevention is 100 mg/dl 
[139]. Over time, there was no significant change of LDL concentration in any of the groups, 
but we observed a trend towards a decrease in LDL concentration in the control group without 
statistical significance. This is in line with previously published literature [140]. Another work 
group recently tested the responses of normo- and hypertriglyceridemic subjects to a high-fat 
meal. Their study revealed a decrease in LDL concentration between 0 and 6 hours following 
a high-fat meal in normotriglyceridemic men. In hypertriglyceridemic subjects, they found no 
change of LDL concentration over time [140]. Their study included a larger number of 
subjects and their shake consisted of a higher fat concentration, which adds validity to their 
study. In general, LDL is not a good predicting parameter for metabolic syndrome and CVD, 
which is why it is not included in the definition of the symptom complex of the metabolic 
syndrome [141,142]. A greater positive correlation between CVD and the apo B/apoA-I ratio 
has been proved previously [142]. 
“The ratio of apoB-100 to apoA-I reflects the balance of cholesterol transport in a simple way. 
The higher the value of the apoB-100/apoA-I ratio, the more cholesterol is likely to be 
deposited in the arterial wall, thereby provoking atherogenesis and hence also increasing CVD 
risk” [98]. 
We calculated the ratio, which was significantly higher in the metabolic syndrome subjects 
than in the control subjects. This result was in line with previous reports, which stated that the 
ratio is higher and associated with an elevated risk for CVD [143]. In summary, the metabolic 
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syndrome group showed a higher apoB-100/apoA-I ratio compared to the other groups, 
although there was no significant difference in basal LDL levels. The higher apoB-100/apoA-
I ratio indicates a chronic metabolic adaptation of the metabolic syndrome group to the 
constantly high calorie load.  
The constant HDL concentration over time diverged from previously published observations 
of a decrease in HDL concentration in a diabetic group with visceral obesity at 3 and 5 hours 
[144]. A study by Wojczynski et al. found a decrease of HDL in a control and a hyper-
triglyceridemic collective of men 3 and 5 hours after an oral fat challenge [140]. The latter’s 
fat drink contained 83% fat, as opposed to 66% in ours. Another work group observed a 
decrease of the HDL and LDL concentrations in a metabolic syndrome group in the 
LIPGENE study. Their study population consisted of 60 men and 120 women. Their 
parameters were tested after several fat load tests of different concentrations [145].  
Atherogenic properties of HDL and LDL species 
Other chronic metabolic adaptations were revealed by the sizes of the cholesterol transporter 
particles in relation to their atherogenity. Less atherogenic species showed higher 
concentrations in the control group, shown by the LDL/apoB-100 ratio and apo A-I/HDL-
ratio we used to differentiate between size and number of LDL and HDL particles. The 
LDL/apoB-100 ratio was higher in healthy subjects than in risk and metabolic syndrome 
subjects. This corresponds to a previous publication which shows that a higher ratio of apoB-
100/LDL is associated with the metabolic syndrome [146]. A higher ratio of LDL/apoB-100 is 
a sign of larger LDL particles, which means that they are less atherogenic [147]. To conclude, 
the control subjects had fewer and larger LDL particles, but the total amount of LDL was the 
same in all three groups. The apo A-I/HDL-ratio was lower in the control subjects than in the 
risk and the metabolic syndrome subjects. HDL levels were higher in the control subjects than 
in risk subjects and the apo A-I concentration did not show a significant difference between 
the groups. Large HDL particles have four copies of apo A-I, small HDL particles have two 
copies of apo A-I [100]. The lower ratio in the control group leads to the conclusion that the 
control group has smaller HDL particles than the metabolic syndrome group. This result does 
not correspond to previous publications [148]. But it is known that in healthy subjects, small 
HDL particles are the ones which possess protective mechanisms against atherosclerosis, 
whereas in the metabolic syndrome group this capacity is lost [149]. This supports our results. 
Moreover, the results indicated an increase in apo A-I containing HDL fractions and a failure 
to generate mature, cholesterol-rich HDL in the metabolic syndrome group. This can be 
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deduced from the fact that the premature discoid HDL contains primarily apo A-I [99]. Thus, 
the ratio may indicate a chronic metabolic adaptation in the metabolic syndrome subjects and 
could therefore serve as a biomarker for the risk of metabolic syndrome in fasting and 
postprandial conditions.  
Lipid transport from the intestine and to the liver reflected by apoB-48/apo A-I 
No data on the apoB-48/apo A-I ratio, which reflects the relation of the chylomicrons to apo 
A-I, has been published previously. Our results did not show a difference of this ratio between 
the groups. But in both the risk and the metabolic syndrome groups, an acutely altered 
metabolism was reflected by an acute response to the drink. Thus, in postprandial state, the 
apoB-48/apo A-I ratio can serve as biomarker for the overproduction and disturbed metabolic 
clearance of chylomicron remnant particles in the metabolic syndrome subjects.  
 
4.2 Adaptation to metabolic syndrome by acute and chronic changes 
of the physiology in metabolic syndrome subjects  
4.2.1 CVD association with postprandial state marked by acutely elevated-
chylomicron concentration 
Postprandial or fasting lipid profiling for risk evaluation of the metabolic 
syndrome 
Diabetes can be a reason for hyper- and dyslipoproteinemia. Hyper- and dyslipoproteinemia 
are associated with an elevated risk for CVD. “Dyslipidemia and impaired glucose intolerance 
are associated with atherosclerosis and coronary heart disease” [150]. Under fasting 
conditions and non-fasting conditions, cardiovascular disease correlates with low HDL and 
high LDL levels. Several researchers have examined whether the postprandial lipid profile 
could be a more sensible indicator for the risk of cardiovascular disease than the fasting lipid 
profile and whether this could be applied to diabetic persons [151]. Their results support using 
non-fasting blood samples to assess dyslipidemia and CVD risk in diabetic and non-diabetic 
subjects [151]. Kolovou et al. recommend a single plasma TAG measurement four hours after 
an oral fat load [152]. In our study, we tried to achieve a valid statement about the connection 
between plasma lipid profile, metabolic syndrome and CVD risk, assuming that metabolic 
syndrome subjects have an elevated risk for CVD. We found out that the most sensitive 
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method of evaluating the CVD risk is by comparing the fasting lipid profile with the 
postprandial lipid profile. The importance of looking at the postprandial lipid profile has 
already been stated by Pang et al. His work group suggested that especially postprandial 
dyslipoproteinemia exacerbates inflammation and oxidative stress. This affects the walls of 
arteries, which is a risk factor for atherosclerosis and cardiovascular disease [153]. The 
metabolic syndrome subjects, whom we consider to always be in a postprandial state, have an 
elevated risk for CVD and an elevated TAG concentration. Metabolic syndrome subjects have 
a higher fasting VLDL than the control group but the same fasting apoB-48 concentration as 
healthy subjects. The apoB-48 concentration shows an acute increase in both the metabolic 
syndrome and the control groups after the oral fat tolerance test, but over time we observed a 
slower decrease in apoB-48 concentration in the metabolic syndrome subjects. The 
application of an OFTT resulted in a diminished increase in the serum apoB-48 concentration 
in the metabolic syndrome group compared to the increase in the control group. This indicates 
that metabolic syndrome patients are not able to reach a proper fasting state anymore but 
remain in a constant postprandial response. It also shows an “absorption resistance” 
(malabsorption syndrome) in metabolic syndrome subjects. ApoB-48 is already known as an 
exclusive marker of the number of circulating particles of chylomicrons and their remnants 
[154] and is hence the most specific postprandial marker whose turnover can also be 
determined with a stable isotopically labeled isotopomer [153]. In the metabolic syndrome 
subjects, insulin resistance might be a cause for the dyslipoproteinemia. Reyes-Soffer et al. 
state in their article: “measures of postprandial lipoproteins are not associated with CAD in 
patients with diabetes 2” and only apoB-48 would be a useful marker for CAD (coronary 
artery disease) risk in persons with diabetes [155]. We assume that it would be more suitable 
for determining the risk for CVD no matter whether individuals are diabetic or not. Thus, we 
aimed to find a difference in lipid profiles of healthy subjects and subjects with the risk of 
CVD, assuming that diabetes belongs to the risk factors for CVD and that the full risk 
spectrum is reached by the metabolic syndrome subjects.  
Reasons for increased apoB-48 plasma levels in risk subjects  
Chylomicrons (CM) are lipoproteins that serve as a vehicle for the fatty acid transport from 
the intestine to the target tissue. In healthy subjects, an acute fatty acid supply raises the 
concentration of chylomicrons and the risk for CVD [156]. The insulin resistance is jointly 
responsible for increased enterocyte production of chylomicrons, and the latter play a role in 
the induction of dyslipoproteinemia, like in a circulus vitiosus [153]. A bigger offer of 
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chylomicrons indicates a bigger amount of intestinal absorption of TAGs. In their article 
“Postprandial dyslipidemia and diabetes: mechanistic and therapeutic aspects”, Pang et al. 
question whether the postprandial chylomicrons concentration can be a useful marker for 
CVD risk. Referring to this question, this study reveals different postprandial dynamics of 
chylomicron concentration over time comparing the plasma of individuals with an increased 
risk for CVD and control subjects. As an indicator for the chylomicron concentration, apoB-
48, which is secreted by the intestine, was measured in plasma. An elevated apoB-48 plasma 
concentration indicates an increased chylomicron production in humans. The liver only 
secretes apoB-100 whereas the small intestine only secretes apoB-48 [157]. ApoB-48 is an 
essential constituent of chylomicrons, which transport TAGs through the plasma and could be 
measured and used as markers of exogenous TAG absorption via the intestine. Chylomicron 
secretion and size correlates with the present TAG concentration [153]. Type 2 diabetes is 
associated with an increased secretion rate of apoB-48, but also with an impaired clearance 
capacity. This leads to an elevated concentration of apoB-48 in plasma. This is firstly because 
the secretion is not stopped by insulin and secondly because the free FAs resulting from a 
diminished tissue uptake of FAs trigger apoB-48 secretion, while the clearance capacity of the 
lipolysis pathway is disturbed. Insulin suppresses lipolysis since it is anabolic and lipolysis is 
therefore elevated in diabetic subjects. The fatty acid spillover in the plasma which is due to 
diminished uptake and increased lipolysis in diabetics is responsible for higher apoB-48-
levels [156]. ApoB-48 clearance competes with VLDL clearance and thus apoB-48 not only 
positively correlates with chylomicron levels but also with the VLDL concentration. The 
adiponectin concentration, which is reduced in the metabolic syndrome group, correlates with 
VLDL clearance since the LPL activity in the adipose tissue is lower in persons with low 
adiponectin [153,158]. However, the VLDL concentration is elevated in the metabolic 
syndrome subjects with a lower adiponectin concentration. The endogenous TAG secretion is 
also elevated in insulin resistance because of the diminished FA uptake, resulting in an FA 
spillover. This experiment shows via apoB-48 that after a high fat load, chylomicron secretion 
is elevated in all of the groups but extremely so in the metabolic syndrome group. Combining 
this result with the observation that those fatty acids which are resorbed via chylomicrons are 
those which show different reactions to the OFTT due to the group they belong to, whereas 
those which are independent of chylomicrons show no different reactions in the three groups, 
we assumed that the disturbance of the chylomicron metabolism is associated with the longer 
half-life of the lipotoxic fatty acids in the plasma compartment.  
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Comparison of the behavior of the long-chain fatty acids and their transporters 
(chylomicrons) 
The examined medium-chain FAs (FA 10:0 and FA 12:0), which are absorbed without 
chylomicrons, show exactly the same behavior in all of the groups. For the long-chain fatty 
acids, which we will discuss in detail later – such as the polyunsaturated γ-linolenic acid – the 
metabolic syndrome subjects showed a different dynamic compared to the control group. In 
this work, not all the differences of fatty acid dynamics are presented, but a focus is put on 
those which could serve as potential biomarkers.  
Need of elevated fasting apoB-48 in risk subjects deduced by their chronic 
postprandial state 
Referring again to apoB-48, the basal apoB-48-level should also be elevated if these 
individuals are in a chronically fed state and apoB-48 serves, as stated in recent articles by 
Pang et el., as a maker for the fed state. I suggest two reasons why our plasma levels of apo-
B-48 were basally not significantly different between the groups. We could see a difference, 
but it was not significant. This might have been due 1.to the small size of groups and due to 2. 
the low basal values of apoB-48, which lay in the 4µl range. At such low values and with a 
standard deviation of 2 µl, a significant basal difference might not be seen, even if it exists. In 
other sources, a basal difference of apoB-48 is described [156]. Whereas free fatty acids are 
released from circulating TAGs by LPL in fasting state [159], postprandially the lipolysis is 
suppressed by insulin in adipose tissue and the exogenous fatty acids are transported into the 
plasma by chylomicrons.  
4.2.2 Liver: Chronically elevated VLDL secretion due to elevated TAG 
production 
An adipose tissue which does not efficiently absorb fatty acids can be the cause for an 
oversecretion of TAGs by the liver. Under such conditions, VLDL, which brings the TAGs 
from the liver to its target tissue, is also overproduced. The overspill of VLDL is associated 
with elevated chylomicron levels as chylomicrons compete with VLDL for clearance 
pathways, regulated by LPL [160]. CMs are formed postprandially, whereas VLDLs are 
formed in the fasting state [157]. In order to compare the fasting values, VLDL is therefore 
more suitable than chylomicron levels [156]. This was confirmed in our study. Next, the 
VLDL concentration over time was examined. Recent studies have shown that the four-hour 
values are sufficient to see the maximum postprandial VLDL production, which does not 
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change four hours after an oral fat load neither in healthy nor in metabolic syndrome subjects 
[161]. The VLDL concentration has previously been examined after application of an oral fat 
meal over time in other studies. These were not able to show a reaction to the oral fat 
tolerance test either in healthy or in metabolic syndrome subjects [155]. Similarly, our results 
did not show a significant change in the VLDL concentrations in any group over time. 
Summing up, we can say that apoB-48 is a marker for acute change, whereas VLDL is a 
marker for a chronically fed state. This is due to the fact that the secretion of VLDL is a 
longer process since the FAs first have to reach the liver to be taken up by VLDL. The 
metabolic syndrome subjects are constantly in a postprandial state; this is again demonstrated 
by the high VLDL levels in metabolic syndrome subjects, which are a sign of a constantly 
elevated fatty acid transfer to the liver and of a constantly elevated apoB-100 secretion. But 
the elevated VLDL-level is also a sign of reduced degradation due to the insulin resistance. 
VLDL could be used either in a fasting or in a postprandial state as a marker for chronic 
changes; the apoB-48 concentration should be measured postprandially to evaluate acute 
changes in the metabolism. ApoB-100 and VLDL are related to familial combined HLP [162], 
the most frequent form of hyperlipidemia [163] in type 2 diabetes [162]. 
4.2.3 Fatty acids: Comparison of the baseline levels, dynamic over time and 
transformation catalyzing enzymes of the cytotoxic and protecting 
fatty acids  
Fatty acids as established marker of postprandial state 
As mentioned above, the medium-chain fatty acids that are not chylomicron-dependent show 
no significant differences between the groups. The subsequent analysis of the chylomicron-
dependent fatty acids demonstrates differences between the basal levels of the three groups 
and in response to the OFTT. FA 17:0 cannot be built by carbohydrate, even when saturated. 
It is known as a marker for oral fat load [164]. This fatty acid showed an elevated 
concentration under fasting conditions in the metabolic syndrome group. This result indicates 
that those subjects do not reach a fasting state. In the risk group, the fasting value is also 
higher than in the control group.  
Dynamic over time of the pro- and anti-inflammatory fatty acids 
The thesis of an acute change of the metabolism was supported once again by the pro- and 
anti-inflammatory fatty acids. The main precursors of the pro- and anti-inflammatory fatty 
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acids γ-linolenic, arachidonic acid (AA), docosahexaenoic (DHA) and eicosapentaenoic 
(EPA) showed differences in risk and metabolic syndrome subjects over time, whereas the 
control group did not show any reaction to the OFTT. This makes them a new potential 
biomarker for the risk of metabolic syndrome. For eicosapentaenoic acid (20:5-c5, c8, c11, 
c14, c17), one of the protective omega-3 fatty acids, plasma levels in humans have not been 
examined after acute fat administration over time yet, apart from EPA administration itself. 
The reason for the increase over time in the metabolic syndrome group is not clear. Since in 
all groups the content of the drink is the same, this difference after the drink can be due to 
different absorption by the intestine, different intake by the tissues, decomposition and 
conversion by desaturases. Desaturases and elongases are involved in maintaining 
homeostasis in obesity. The increased activity of desaturases might be the best explanation. 
The predominant ω-6 fatty acid is arachidonic acid (20:4 ω 6), which is converted to 
prostaglandins, leukotrienes and other lipoxygenase or cyclooxygenase products [64] that are 
regulators of inflammation, atherogenic and prothrombotic effects [64]. The increased levels 
of AA in the metabolic syndrome group and the further increase over time could be explained 
with an excessive activity of Δ6 and Δ5 desaturase in subjects with elevated insulin levels 
leading to an increased production of 20:4 ω -6 from 18:2 ω -6. As insulin activates both 
enzymes, this situation may occur in subjects with chronic hyperinsulinemia periods [165]. 
Another ω-6 fatty acid is the essential γ-linolenic acid (18:3 ω 6). This fatty acid is the 
precursor of arachidonic acid (AA). Basally there were no differences in concentration 
between the groups, whereas the level of γ-linolenic acid increased over time in the metabolic 
syndrome subjects as a reaction to the OFTT. In the control group there was no reaction.  
Palmitic acid and its transformation products produced by normal or escape 
pathway 
The thesis of chronic and acute changes of the metabolism in metabolic syndrome subjects 
was supported by the differences between the groups concerning the metabolic pathways of 
the most common nutritive fatty acid 16:0. One pathway results in lignoceric acid, and the 
“escape” pathway leads to nervonic acid, which we expected to be elevated in the metabolic 
syndrome subjects, since the phospholipids containing this fatty acid are associated with an 
increased mortality [105]. The first step of the escape pathway is the conversion of palmitic 
acid into palmitoleic acid via Stearoyl-CoA desaturase 1 (SCD-1). Previous publications 
showed that SCD-1 is increased in cardiovascular diseases, insulin resistance and obesity 
[106,107]. The 16:1/16:0 ratio which we took as an indicator for the SCD-1 activity was 
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indeed elevated in the metabolic syndrome group compared to the other groups. Our 
observation of an elevated basal concentration of palmitoleic acid (16:1 n-7) in plasma of 
metabolic syndrome subjects is consistent with previous publications [166]. Metabolic 
syndrome subjects show the highest values, which is a sign of their chronically postprandial 
state. We also observed an acute reaction to the OFTT in the metabolic syndrome and the risk 
subjects and no reaction in the control subjects. Zong et al. showed the connection between an 
undesirable adipokine profile, elevated inflammation markers and elevated erythrocyte 
palmitoleic acid concentration. The concentration of fatty acids in erythrocytes reflects the 
concentration of fatty acids in plasma [104]. This is in line with our observations. However, 
palmitoleic acid (16:1 c-9) not only has unfavorable effects but is also protective against 
apoptosis of pancreatic cells [167]. As far as FA 18:0 (stearic acid) is concerned, which is 
known to enhance the development of diabetes [164], our results support recent findings 
because we observed progressively higher fasting values in the control group, risk group and 
the metabolic syndrome group. We cannot tell which is the cause and which is effect, but the 
initial values differ when the groups are compared and moreover, there is a difference in the 
reaction to the OFTT in all three groups. The control group has its peak after 4 hours and 
already shows decreased values after 6 hours. The risk group and the metabolic syndrome 
group have their peaks at 6 hours and decrease thereafter. This again points out the inertia of 
the metabolism in the metabolic syndrome group. The reason for the stronger increase in the 
metabolic syndrome group can be found by combining this observation with the observation 
that the chylomicron level is more elevated after an oral fat tolerance test in the metabolic 
syndrome group than in healthy subjects. Therefore, the most probable explanation is a higher 
intake of fat by the intestine in the metabolic syndrome group. Another potential reason is a 
faster transport from the liver to the plasma due to the observed elevated VLDL levels in the 
metabolic syndrome subjects. The difference in the fasting values underlines our thesis that 
the metabolic syndrome subjects are never in an actual fasting state. Looking at the following 
product in the “normal” pathway, arachidic acid, also called eicosanoic acid (FA 20:0), the 
metabolic syndrome group again showed elevated levels. This again supports the hypothesis 
of a chronic adaptation of the metabolism and a chronically postprandial state. The acute 
changes in metabolic syndrome and risk groups were significant, whereas in control subjects, 
there was no response to the OFTT. Thus, the risk and the metabolic syndrome groups show, 
after an initial increase in response to the OFTT, a decrease 6 hours later. The increase can be 
seen as an overload with a limited capacity to process the fatty acids in other fatty acids or 
lipid species. Therefore, the FA 20:0 could be a new biomarker for the risk of metabolic 
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syndrome. Looking at the “escape” pathway, oleic acid and nervonic acid both showed 
elevated levels in the metabolic syndrome group, whereas lignoceric acid did not show a basal 
difference between the groups. This result supports the hypothesis that metabolic syndrome 
subjects use the escape pathway more often than the control subjects. In conclusion, the 
serum’s fatty acid composition as analyzed by GC-MS shows distinct differences between the 
metabolic syndrome, the risk and the control subjects. Saturated and unsaturated fatty acid 
profiles differ basally and over time between the groups. The palmitoleic acid shows basal 
differences and different responses to the oral fat tolerance test in the three groups. 
Eicosapentaenoic acid showed different responses over time and the fatty acid 20:0 showed an 
increase as a reaction to the OFTT in the metabolic syndrome and the risk patients which is 
not present in control subjects. Concerning oleic and nervonic acid, the oral fat tolerance test 
provided no further information, but the hypothesis of an altered metabolism with use of the 
“escape” pathway is supported by the results.  
4.2.4 Fasting and postprandial sphingomyelin profile as risk indicator  
SPM species associated with unfavorable lipid profile and elevated apoptosis 
The distribution of the SPM species in plasma with SPM 16:0 and 24:1, representing the 
major SPM species, is in agreement with previous studies [168]. Generally, high levels of total 
SPM are associated with atherosclerosis and CVD [169]. Elevated levels of SPM in 
individuals with CVD must be partly caused by higher levels of the main species 16:0 and 
24:1, since positive mortality associations were described for SPM 16:0 and 24:1 [121]. Even 
though our results did not show a chronically elevated level in the metabolic syndrome group, 
they showed a trend towards a higher concentration of SPM 16:0 in the metabolic syndrome 
group, which was insignificant, most likely due to the small number of cases. Over time, the 
SPM species 16:0 increased as a response to the OFTT in the metabolic syndrome group, 
whereas the concentration did not change in the other groups. The fact that the change only 
occurred in the metabolic syndrome group makes the SPM species carrying palmitic acid a 
potential prognostic biomarker for the metabolic syndrome. This is in accordance with the 
result described below, which is that palmitate and stearate belong to the undesirable lipid 
profile. They have previously been shown to induce apoptosis in cultured cells, and part of 
cardiomyocyte loss in the genesis or progression of heart failure in humans is mediated by 
apoptosis [121]. The result shows a significantly higher SPM 18:0 level in the metabolic 
syndrome group and an elevated level of SPM 18:1. Higher levels of SPM 18:0 and 18:1 have 
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already been described in mice after high-fat diets and in obese mice [115]. The SPM 22:4 
concentration showed decreased levels in the metabolic syndrome group. Since ELOVL2 
catalyzes the rate-limiting PUFA elongation steps of ω-6 arachidonyl-CoA (20:4) to 
docosatetraenoyl-CoA (22:4), and on to tetracosatetraenoyl-CoA (24:4) [121], decreased 
levels in the metabolic syndrome group support the thesis of an undesirable fatty acid profile 
with a decreased transformation rate of AA into 22:4 in the plasma. Arachidonic acid itself 
has not been described in literature as being a part of sphingomyelin species in humans, which 
is why we did not measure AA-containing SPM species. On the contrary, it has been 
described that sphingomyelin inhibits the release of AA from membrane phospholipids 
[170,170].  
Sphingomyelin 23:1, the anti-depression species 
The SPM 23:1/SPM 16:0 ratio has been described to correlate inversely with depressive 
symptom scores [171]. Our results showed elevated levels of SPM 23:1 in the control group 
compared to the other groups. This could support the thesis that SPM 23:1 belongs to the 
“good” SPM species. The decrease as a response to the OFTT and the ensuing normalization 
towards the baseline level was only observed in the metabolic syndrome group. This result 
makes SPM 23:1 a potential biomarker, and the further decrease in the metabolic syndrome 
group after the OFTT makes it more likely that an undesirable lipid profile is connected with 
a decrease in SPM 23:1. 
Sphingomylin 24:0 as a protective species 
In order to confirm this thesis and our results, further tests and examinations will be needed. 
SPM 24:0 is one of the most protective SPM species [121] and its level was decreased in the 
metabolic syndrome group. The metabolic syndrome group reacted to the OFTT with an 
increase in level. This increase could be interpreted as a protective response to an additional 
fat excess.  
4.2.5 Antioxidants: plasmalogen down-regulation in metabolic syndrome 
subjects 
The predominance of plasmalogens carrying DHA and AA in sn-2 position was consistent 
with the previous literature [112]. Most of the plasmalogen species were initially down-
regulated in the metabolic syndrome group compared to the control group, which makes them 
potential biomarkers. This is in line with findings that plasmalogens, especially as part of 
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LDL particles, have an antioxidant effect [62]. The results are also consistent with previous 
studies, as the examination of Colas showed that PE plasmalogens were down-regulated in 
subjects with T2D [165], whereas in contrast to this Goto`s group showed that plasmalogens 
were increased in T2D subjects without microangiopathy [172]. The Obesity Society 
published results showing that uniform increases were observed in plasmalogens and their 
precursors after short-term overnutrition. They speculated that this was due to plasmalogens 
as powerful antioxidants and that the increase might be an appropriate response to increased 
oxidative stress generated by 28-day overnutrition[173].  
Protective up-regulation in the metabolic syndrome group due to acute oxidative 
stress 
Their hypothesis could be an explanation for the acute response to the OFTT observed in the 
metabolic syndrome group since, interestingly, most of the plasmalogen species showed a 
peak at 6 hours as a reaction to the drink in the metabolic syndrome group, whereas in the 
control group most species did not respond to the OFTT and those which did had their peak 
earlier than the metabolic syndrome subjects. Another possible explanation is that this 
increase in plasmalogen concentration in the metabolic syndrome group is caused by an 
excess of those fatty acids in the respective plasmalogen which are incorporated into the 
plasmalogens and are therefore responsible for an increase in the plasmalogen concentration. 
In terms of AA containing plasmalogens, fasting values did not differ between the groups, 
while after ingestion of the OFTT, the metabolic syndrome and the risk groups showed a 
significant increase in their levels and after 6 hours, the metabolic syndrome subjects showed 
even higher levels than the control group. These results diverge from previous publications 
where especially the PE-plasmalogens with sn-20:4 were described as significantly lower in 
the metabolic syndrome group compared to the control group [174]. 
Plasmalogens with linoleic acid are down-regulated in metabolic syndrome subjects. Here too, 
the peak in the metabolic syndrome group occurred 6 hours after ingestion of the drink. In this 
case, the peak stayed below the levels of the control group. In contrast to previous literature 
[62] PE (P-16:0/18:0) with stearic acid in sn-2 position, which has been reported to be 
elevated in oxidative stress [113], is up-regulated in the metabolic syndrome group. Marked 
differences in fatty acid composition in adipose tissue have previously been published, 
comparing obese and lean twins. The results included reduced levels of stearic (C18:0) and 
reduced levels of linoleic (C18:2 ω-6) acid. This work group proposed that the observed lipid 
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changes were consistent with the proportion of ether lipid [174]. In our results, stearic acid 
showed increased plasma levels and the PE (P-16:0/18:0) also showed increased plasma 
levels in the metabolic syndrome group. Changes concerning linoleic acid as acyl residues in 
sn-2 position reflect in plasma the results this work group found for the fatty acid in adipose 
tissue. Next, the fatty acid profile was compared to the plasmalogen profile. 
4.2.6 Differences in dynamic and baseline plasmalogen levels  
This part of the thesis dealing with correlations is exclusively descriptive. No definite 
conclusion can be drawn from it. A positive correlation between a fatty acid species and a 
plasmalogen might be a sign of an increased integration of the respective fatty acid into the 
plasmalogen, the high fatty acid level leading to an increased plasmalogen concentration. A 
negative correlation, on the other hand, could be a sign of an increased release of the fatty 
acid from the plasmalogen, the increasing fatty acid causing a decrease of the respective 
plasmalogen. In view of the results described in the sections above, this is the most probable 
explanation for the correlation coefficients, which will also be worked with in the following 
section. In this section we do not care too much about the odd-chain fatty acids, since these 
odd-numbered fatty acids are only biomarkers for the intake of dairy products [175]. The fatty 
acid 13:0 was used as an internal standard, but slight variations of the levels among the 
individuals existed because this fatty acid also exists in traces in human serum.  
The fact that the medium-chain fatty acids positively correlated only with the plasmalogens 
carrying 18:0 in sn-2 position in the control and the risk groups but with all of the 
plasmalogens species carrying a saturated acyl residue in sn-2 position in the metabolic 
syndrome group subjects might indicate that the medium-chain fatty acids are primarily 
elongated and integrated in the 18:0 species, and after a certain level could be achieved in the 
risk and metabolic syndrome groups, the other plasmalogens species carrying an saturated 
acyl residue were filled up. In biosynthetic pathways, plasmalogens serve as a reservoir for 
PUFAs, since they preferentially contain arachidonic (20:4), docosapentaenoic (22:5 n-6) and 
docosahexanoeic (DHA, 22:6) acid in the sn-2 position [176]. Eicosanoid biosynthesis begins 
with the hydrolysis of fatty acids from the sn-2 position of neutral membrane 
glycerophospholipids to produce free fatty acids and lysophospholipids upon receptor-
mediated events [177]. Arachidonic acid is actively incorporated into the membrane 
phospholipids and selectively targeted to ethanolamine plasmalogens [174]. Low levels of 
PUFAs correlate with decreased plasmalogen levels [178]. Low levels of polyunsaturated 
fatty acids are a sign of low levels of PUFAs containing plasmalogens which cannot be built, 
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and the degradation of those plasmalogens carrying PUFAs is elevated. An elevated 
degradation of PUFAs containing plasmalogens is a sign of oxidative stress [178]. In 
literature, especially the interrelations described above, between plasmalogens containing 
arachidonic (20:4), docosapentaenoic (22:5 ω-6) and docosahexanoeic (DHA, 22:6) acid and 
PUFA serum levels, are described. EPA, which showed increased levels in the plasma over 
time in the metabolic syndrome group, could indicate a release by the plasmalogens. The fact 
that arachidonic acid (20:4 ω-6) correlated negatively with the plasmalogens carrying 
linolenic acid (18:2 ω-6), the precursor of arachidonic acid (AA) [179], in the control group 
but not in the metabolic syndrome group could be an indication that the proinflammatory 
arachidonic acid is produced additively by another way in the metabolic syndrome group than 
in healthy subjects. Since sn-2 (R2) is esterified predominantly with ω-6- or ω-3-derived 
polyunsaturated fatty acids [180,181], it was not surprising that the highest prevalence of 
significant correlations with PUFAs occurred between the plasmalogens carrying arachidonic 
acid in sn-2 position. If one PUFA is up-regulated in serum, it can serve plasmalogen 
synthesis and AA in plasma can derive from the appropriate plasmalogen species. It is 
noticeable that the arachidonic acid 20:4 (n-6) correlated with the named plasmalogen species 
in the control and risk groups, e.g. species carrying 22:4 in sn-2 position, whereas in the 
metabolic syndrome group it only correlated positively with plasmalogens containing 20:4. 
This might indicate that in the metabolic syndrome group, arachidonic is most often 
integrated as arachidonic acid itself, but in the other groups its less harmful desaturation 
product docosatetraenoic acid 22:4 is integrated. The deduced fact that it can also be 
converted into 22:4 and stored in plasmalogens in the control and in the risk groups matches 
the results of the comparison of plasmalogen species between the three groups described 
above, in which PE (P-18:1/22:4) showed a significant difference in baseline levels between 
the groups . Linoleic acid (18:2 n-6) positively correlated with PE (P-18:1/20:4) in the risk 
and metabolic syndrome groups, but not in the control group. Thus, the level of linoleic acid 
may have been elevated in the metabolic syndrome and risk groups, but the concentration in 
plasma was not significantly different between the groups, because its elongation and 
desaturation product arachidonic acid is generated and integrated in the plasmalogen. The 
case of all plasmalogens containing 20:4 in sn-2 position correlating with FA 24:1 (n-9) only 
occurred in the metabolic syndrome group. This supports the fact that the metabolic syndrome 
subjects have an undesirable fatty acid profile with elevated nervonic acid which leads to 
death and that an up-regulation of plasmalogens containing arachidonic acid takes place. α-
linolenic 18:3 (ω-3) positively correlated with the plasmalogens carrying DHA in sn-2 
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position in the risk and metabolic syndrome groups, contrary to γ-linolenic acid which did not 
correlate with any of the plasmalogen species in these groups and showed a discrete but not 
significant negative correlation value in the metabolic syndrome group when correlated to the 
named plasmalogen species. This is not astonishing, since linoleic 18:2 (ω-3) and α-linolenic 
18:3 (ω-3) are precursors of DHA, and γ-linolenic 18:3 (ω-6) is a precursor of the 
proinflammatory arachidonic acid 20:4 (ω-6). But the described correlation phenomena were 
not observed in the control group. This might be due to the fact that in the control group, the 
DHA reservoir in plasmalogens is full, it is not necessary to adapt plasmalogen levels 
containing DHA acyl residues to the concentration of its precursors, for example by 
increasing DHA synthesis and the incorporation of DHA into plasmalogens. The results 
described above showed that the PE (P-18:0/22:5) baseline level was reduced in the metabolic 
syndrome group; this would support the thesis, that the DHA containing plasmalogen levels 
could be sustained by the processing of their precursors. The reduced level of DPA as a 
precursor of DHA could not be compensated anymore, whereas DHA production could be 
maintained due to an increased production from the precursors.  
4.2.7 Proapoptotic and protective ceramides and risk for metabolic 
syndrome 
Another potential biomarker in fasting and postprandial state for the risk of metabolic 
syndrome could be the ceramide ratio 24:0/24:1. The ceramide 24:0 is known to have 
antiapoptotic properties [182], but ceramide 24:1 is responsible for cell death [183]. We 
calculated the ratio of Cer 24:0/24:1 and found a higher ratio of Cer 24:0/24:1 in the control 
subjects. This result shows a higher rate of the “survival” or protective ceramide 24:0 and a 
lower rate of the “death” ceramide 24.1 in healthy subjects. Majumadar et al. found no 
association between metabolic syndrome and elevation of the ceramide 24:0 in their study 
with children, but they found an elevation of this ceramide species in association with insulin 
resistance and inflammation [184]. Another study in which total ceramide levels showed a 
tendency toward increased levels in sepsis patients described an inverse behavior of the two 
main species, Cer 24:1- and Cer 24:0 [108].  
4.2.8 Low LPC species, increased mortality and sepsis 
It has been published previously that LPC levels increase while the plasmalogen levels 
decrease in metabolic syndrome subjects. High LPC and low ether phospholipids result in 
oxidative stress. LPC produced by the impact of the proinflammatory phospholipase A2 on 
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phosphatidylcholine (PC) promotes inflammatory effects, including an increased endothelial 
expression of adhesion molecules and an activation of the growth factors monocyte 
chemotaxis and macrophages [108]. In contrast, this study observed lower LPA and LPC 
concentrations in the metabolic syndrome group compared to the other groups. A lower level 
of LPC correlating with unfavorable metabolic aspects resulting in an increased mortality risk 
is supported by a study which showed that the total LPC level was markedly decreased in 
sepsis patients [108]. In addition, a study finding a decreased LPC concentration in obese 
subjects has been published previously [65]. Another fact which supports our results is that 
lecithin-cholesterol acyltransferase (LCAT) activity, a major source of LPC in circulation, has 
been shown to be decreased in obesity. This  potentially leads to a decrease in circulating LPC 
[169]. Another work group found higher concentrations of LPC 14:0 and LPC 18:0 in 
overweight/obese men, while LPC 18:1 was found reduced [115]. LPC 18:2 and 
sphingomyelin 16:1 in serum were found inversely related to type 2 diabetes risk [115]. Our 
results also showed that the reduced levels of LPC 18:1, 18:2, 18:3, 20:3, 20:4, 20:5 and 22:5 
were responsible for the reduced LPC levels in the metabolic syndrome group compared to 
the other groups. A study using mice which were fed a high fat diet for 12 weeks and again 
for 14 weeks showed induced levels of LPC 17:0, 18:0 and 18:3, while most of the other 
species decreased in the fat-fed mice [115].  
Acute increase of LPC species reflects chronic increase 
This is applicable to our results, which showed significantly induced LPC 18:0 in the 
metabolic syndrome group as early as 4 hours after the OFTT; LPC 18:3 increased in all three 
groups. Even though we did not observe an elevation of the baseline level in the metabolic 
syndrome group, we found induced levels of the LPC species 18:0 and 18:3 as a response to 
the OFTT in metabolic syndrome subjects. It can thus be assumed that an additional fat-load 
leads to a short-term/acute elevation of LPC 18:0 in subjects which already have an 
undesirable metabolic profile. These results, which show an increase of LPC 18:0 as a 
response to the OFTT 4 hours after a high fat load in subjects with an already chronically 
elevated fatty acid profile, support the study with mice mentioned above. In that investigation 
LPC 18:0 increased after a certain period of a high-fat diet resulting in an undesirable 
metabolic profile.  
The reduced levels of LPC 18:1 in obese subjects that have already been described [115] were 
also reflected in our study. According to those examinations, S 20 showed down-regulated 
baseline levels in the metabolic syndrome group, while the LPC 18:1 level was induced in all 
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three groups as a response to the OFTT over time. This makes LPC 18:1 an appropriate 
indicator for long-term changes in lipid profile, applicable to the metabolic syndrome. 
LPC has also been identified as being a ligand for the immunoregulatory receptor G2A, which 
is predominantly expressed in immature T-and B-cells [108], where G2A is coupled to inhibit 
Gi proteins, while G2A in PMN-innate immunity cells is coupled to activate Gα and Gq. 
Based on previous data, LPC may force a shift of the immunomodulatory pathways resulting 
in an activation of the unspecific immune system (PMN) and the suppression of the specific 
system (T- and B-cells). Other authors proposed that the decreased LPC concentration might 
reflect its enhanced conversion to lysophosphatidic acid (LPA) by the activity of a plasmatic 
lysophospholipase D [108].  
4.2.9 Lower immunomodulatory lysophosphatidic acid in metabolic 
syndrome subjects 
LPA binds itself to different G-protein receptors from the edg-receptor family (edg-2, edg-4, 
edg-7) and is known to induce a multitude of cellular responses, including LPA-driven effects 
on immune cells such as the promotion of T-cell and macrophage survival, and increased 
endothelial adhesion molecule expression [108]. Moreover, LPA-mediated activation of edg-2 
on T-cells was shown to stimulate interleukin-2 production and inhibit cell migration, whereas 
binding itself to edg-4 had the opposite effect [108]. In the case of our results, where LPA also 
showed decreased levels in the metabolic syndrome group, the shift provides no sufficient 
explanation. The inverse behavior of the LPA levels between the different groups is in 
contrast to another publication, which states that high LPA concentrations positively correlate 
with obesity [67]. 
The result suggests an integration of a fatty acid and its desaturation products in LPA species 
after an increase of the fatty acid concentration as a response to the OFTT. Those LPA species 
are probably converted into other phospho- or lysophospholipids. It may be speculated that 
the protective effect is based on withdrawing pro-inflammatory fatty acids by integration and 
LPA species by conversion from their signaling pathways and the resulting formation of LPC 
species which appeared to be associated with a protective effect. In the metabolic syndrome 
group, the conversion of LPA into LPC species LPC 18:2 and 20:4, associated with positive 
effects, might not be sufficient. In those cases, the oral fat tolerance test was able to provide 
further information about the metabolic state. Additional tests will be needed to explore the 
usefulness of this postprandial dynamic as a biomarker.  
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4.2.10 Correlations between PC and LPC species 
Baseline differences between groups due to chain-length of PC species 
Regarding the PC species it is remarkable that when comparing the baseline levels of the 
control and metabolic syndrome groups, those with short-chain acyl residue showed higher 
baseline levels in the control group while those containing more C atoms showed higher 
values in the metabolic syndrome group. It has been published previously that four LPCAT 
subtypes responsible for LPC to PC conversion have been identified and each LPCAT has 
different substrate specificities [185]. This thesis concentrated on the behavior of the PC 
species in the groups over time, which was especially analyzed by considering the formation 
of Lyso PCs. It is known that enzymatic hydrolysis of one fatty acid (FA) mainly by 
phospholipase A2 activity leads to Lyso PC (LPC) species formation, which act as highly 
abundant signaling molecules through specific G-protein coupled receptors [9]. A recent 
study revealed associations between phospholipase A2, LPC, lysophosphatidic acid and 
proinflammatory cytokine levels [121]. In the control group, certain PC species were 
downregulated while the fatty acid species and LPC species were upregulated. This relation is 
less present in the metabolic syndrome group.  
Refilling of protective PC species 
The thesis of a conversion of PC species into the corresponding fatty acid and LPC species,  
and especially differences in the conversion behavior in the metabolic syndrome subjects (as 
adaption mechanism to chronic fat overload), is supported by the increase of PC 32:2 in the 
metabolic syndrome and in the risk group and a simultaneous increase of the fatty acid 14:0 
and LPC 18:2 and by the increase of LPC 18:3, while PC 32:3 decreased and the fatty acid 
14:0 increased as a response to the OFTT after 8 hours in the control group. In the metabolic 
syndrome group, the increase of fatty acids does not co-occur with a decrease in PC species at 
all. The fact that PC 32:2 is still increased after the conversion indicates that PC 32:2 may be 
refilled by another mechanism such as the desaturation of PC 32:0. The delta-9-desaturase 
(D9D) stearoyl-CoA desaturase (SCD/FADS5/D9D) shows a specific affinity to the two main 
dietary saturated FAs palmitate and stearate, converting them into the corresponding 
monounsaturated FAs palmitoleate (16:1n-7) and oleate (18:1n-9). This indicates a protective 
role of SCD in PC 32:1 and PC 32:2, which contain SCD desaturation products. Compared to 
PC 32:0, the presence of the two PC species indicates a lower mortality risk, with PC 32:2 
being slightly but significantly protective [121]. Another interesting observation in the risk 
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group was that PC 36:5, which can contain 20:4 and so far is supposed to be protective 
against CVD [121], increased at 6 hours as a response to the OFTT, while FA 20:3 was also 
increased but the plasma concentration of 20:4 did not change, indicating a withdrawal of FA 
20:4 by the formation of PC 36:5. The saturated and monounsaturated PC species identified 
are positively associated with mortality, with PC 32:0 revealing the strongest positive 
association. PC 32:0 is most likely composed of two palmitates (16:0) at sn-1 and sn-2 
position; alternatively myristate (14:0) and stearate (18:0) could also form PC 32:0 [121]. 
Loss of SCD’s protective function in the metabolic syndrome group 
PC 32:2 is a protective species associated with reduced mortality [121]. It was induced as 
response to the OFTT in the control group. Palmitoleic acid 16:1 (n-7) was also increased. 
This indicates an activity of SCD, which catalyzes the conversion of palmitic acid (16:0) into 
palmitoleic acid, in this case a protective procedure. After 6 hours, 32:1 – another PC 
associated with a reduced mortality compared to PC 32:0 [121] – was induced. In the risk and 
metabolic syndrome groups, PC 32:2 also showed induced levels as a response to the OFTT, 
but without an increase in PC 32:1 in the metabolic syndrome group. This indicates a loss of 
the protective function in the metabolic syndrome group and needs further research. 
PC 32:0 strongly associated with morality 
The PC 32:0 level, having the strongest association with mortality [121], did not change 
remarkably in any of the groups over time, even though the fatty acid species that this PC 
species contains were upregulated in all the groups after the OFTT. But it is one of the short-
chain PC species that shows the rare phenomenon of a reduced baseline level in the control 
group compared to the metabolic syndrome subjects. 
Postprandial release of DPA in the control group 
The fact that the level of PC 42:5 was reduced 8 hours after the fat load in the control group 
indicates that the docosapentaenoic acid (22:5) containing PCs releases the protective fatty 
acid. 
Elevated baseline levels, reduced possibility for further elevation  
The PC species 40:2, 26:0 and 40:5 have been described earlier to be induced in obesity [115]. 
For those PC species, we only found elevated baseline levels in the metabolic syndrome 
group. The control group, showed an elevation of 40:2 over time, which could not be 
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observed in the metabolic syndrome group. In the risk group even a reduction was seen after 
the OFTT application. This could be interpreted as being due to basally elevated levels in the 
metabolic syndrome and risk groups, which leaves less room for an elevation as a reaction to 
the OFTT.  
Loss of FADS1/D5D-activity  
Another factor to consider were the enzymatic pathways. FADS1 catalyses delta-5 
desaturation (D5D), converting eicosatrienoyl-CoA (20:3) to arachidonyl-CoA (20:4). These 
FAs can for example be found in the PC species 36:3 and PC 36:4, and the ratio between PC 
36:3 and 36:4 is regarded as a good predictor of FADS1/D5D activity [121]. The ratio of PC 
36:3 and 36:4 as good predictor of FADS1/D5D-activity, which reflects the conversion of 
eisosatrienoyl-CoA (20:3) into arachidonic acid (20:4) [121], unfortunately showed no 
remarkable differences over time. But on a basal level, the metabolic syndrome subjects 
showed a lower ratio, indicating less activity of the enzyme. Delta-6 desaturase 
(D6D)/FADS2 may be involved, generating octadecadienate (18:2n-9) from oleate. This 
effect is less pronounced for PC 36:2 and PC 38:2, although a similar tendency is visible in 10 
PC species containing long-chain PUFAs, which were associated with a protective effect in 
previous analysis [121]. In the risk and the metabolic syndrome groups, PC 38:2 showed 
reduced values over time, which could indicate a reduced activity of this enzyme.  
Oppositional effects in the modulation of the inflammation systems  
PC species containing long-chain saturated and monounsaturated n-9 FAs positively associate 
with mortality, whereas long-chain PUFAs appeared to be associated with a protective effect 
[121]. It may be speculated that the protective effect is based either on the withdrawal of pro-
inflammatory eicosanoids of the n-6 series from their signaling pathways or on the provision 
of anti-inflammatory eicosanoids of the n-3 series.  
4.2.11 Inflammatory markers and chronic inflammation in the 
metabolic syndrome 
With this work we not only succeeded in confirming chronic long-term inflammation in 
metabolic syndrome subjects or the tests conducted e.g. by Lemieux et al., which showed that 
fasting C-reactive protein (CRP) correlates with visceral adipose tissue mass [186], but we 
also showed that in terms of the inflammation state, there is a change in the postprandial 
behavior in response to a high fat load in metabolic syndrome subjects. It is known that CRP 
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is not associated with fasting dyslipidemia but with the metabolic syndrome and CHD risk 
[186]. In addition, we found a significant decrease in CRP in the metabolic syndrome group 
two hours after the oral fat load. Such an examination has not been made until now. This 
supports our thesis of chronic and acute changes in the body composition of metabolic 
syndrome subjects. CRP could therefore serve as a new biomarker for metabolic syndrome by 
applying the oral fat tolerance test. Another work group looked for CRP concentrations after 
an oral fat challenge in a healthy collective [187]. They found an increase in CRP 
concentration 6 hours after the fat load. This slight increase was also observed in our study, 
although it did not reach statistical significance (p=0.291). Since their OFTT did not differ 
much from ours, with the fat content being only 2% higher, but included a much larger study 
population (>100 participants), we can assume that the observed change in our subjects might 
have been significant if our groups had been larger. Another inflammation parameter, suPAR, 
is known to be a predictor for CVD [124], but the suPAR levels in the different groups have 
not been compared yet. The reaction to an oral fat load has not been tested yet either. Since 
basal suPAR levels are significantly higher in the metabolic syndrome subjects, the suPAR 
level under fasting conditions could serve as a biomarker for the metabolic syndrome. 
4.2.12 Functional changes of the adipose tissue  
Omentin 
Subsequently, we dedicated our attention to the adipose tissue. Omentin – a cytokine which is 
specifically expressed by the visceral fat tissue – was analyzed. It has an important influence 
on paracrine and autocrine ways of fat distribution and obesity-associated diseases. It also has 
endocrine effects on insulin enhancement. Omentin attenuates the CRP concentration and 
inflammation pathways [129]. It is already known that the omentin concentration is decreased 
in metabolic syndrome subjects [129]. We were able to confirm chronically decreased levels 
of omentin concentration in metabolic syndrome subjects compared to control subjects. Since 
the response to the OFTT was the same in each group, the OFTT unfortunately provided no 
further information.  
Leptin 
However, we did find a prognostic advantage of administering the oral fat load for another 
cytokine, leptin, which is also mainly expressed by adipocytes [55]. Our results confirm 
previous publications, as the basal leptin concentration was significantly higher in the risk and 
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the metabolic syndrome subjects compared to the control subjects. Moreover, our results 
showed that there were acute leptin responses during the 8 hours following an oral fat 
tolerance test in the metabolic syndrome and the risk subjects. This is a deviation from the 
results of the group of Guerci et al. [188], who observed the reaction of control and obese 
subjects to an oral fat load and then compared the two groups’ reactions. Their results indicate 
that there is no acute response, neither in obese nor in slim subjects. A possible explanation 
for the differing results is that our stratification criteria for the groups differed from theirs. 
Moreover, we did not only compare subjects with different body fat compositions, but also 
subjects with metabolic syndrome, a risk and a control group. It is known that leptin is 
regulated by the adipose tissue mass and by food intake [188]. But Guerci et al. suggested in 
their review that there is a lack of postprandial regulation by fat intake [188]. Our results 
prove otherwise. The fact that our OFTT consisted of 66% fat and their drink consisted of 
85% fat may be a disadvantage of our study. But since over 30% of our drink were 
carbohydrate and only 3% proteins, the protein concentration can be ignored. Our study 
population was larger than that of Guerci et al., who only tested 32 persons and included men 
and women. The reason for the striking decrease in leptin concentrations 4 hours after the fat 
load in the metabolic syndrome group is not clear. But since the decrease took place at 12 
o’clock and not at 10 o’clock, it cannot be explained with a previously published paper, which 
reports a nadir of the leptin concentration at 10 o’clock due to the circadian rhythm [188]. Our 
results for the chronically different basal concentrations of leptin in the three groups are in 
good agreement with previous reports [188]. Thus, in summary our results provide evidence 
that fat intake is only linked to an acute change in postprandial leptin in the metabolic 
syndrome and the risk subjects, whereas in the control group the leptin concentration is not 
acutely influenced by the oral fat tolerance test.  
Adiponectin 
Already in 1996, Spiegelman et al. demonstrated that low adiponectin levels in plasma 
correlate negatively with obesity in rodents [189]. We also found decreased levels in the 
metabolic syndrome group compared to the other groups. In 2005, Kadowaki’s group stated 
the role of adiponectin in insulin resistance and as an antiatherosclerotic hormone [54]. 
Adiponectin has protective effects on the kidney, heart and pancreas due to its antiapoptotic 
effects [54]. Fruebis et al. found out that adiponectin negatively correlates with postprandial 
fatty acid levels in the blood [190]. A further global effect of adiponectin is a stimulation of 
the lipid catabolism. It is well-known today that adiponectin increases ß-oxidation [191]. The 
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adiponectin dynamic after an oral fat challenge has not yet been evaluated. Annuzi et al. 
already compared the reaction of 10 diabetics with the reaction of non-diabetics to a normal 
meal. Adiponectin in diabetics decreased 6 hours after the meal, but there were no significant 
changes in the other group [192]. We looked at the human serum adiponectin levels in vivo 
before and during OFTT and compared the control, risk and metabolic syndrome subjects’ 
response. The dynamics of adiponectin have not yet been measured this way. Our results 
showed that the control group had the highest, the risk group had lower and the metabolic 
syndrome group had the lowest adiponectin levels. This is in agreement with many recent 
publications. This obvious trend in the three groups, was not significant at time zero. With a 
p-value of 0.150, the observation of the basal differences in the three groups could not be 
confirmed by the first statistic calculation. But since the groups were very small [n=14 
(control, 0h) and n=31 (metabolic syndrome, 0h)], it was more representative to include all 
points in time to show that the mean adiponectin concentration was significantly different in 
the three groups. As expected, there was a significant difference between the adiponectin 
levels in the groups. The adiponectin level of the control group was significantly higher than 
in the other groups. We observed a significant difference in a reaction to the OFTT. There 
was a change in the metabolism of the metabolic syndrome subjects, which again suggests the 
thesis of a retarded and reduced reaction to the OFTT. In the control and the risk groups, the 
decrease of the adiponectin concentration as a response to OFTT was striking and significant. 
Summarizing, there was a chronic change in metabolism, as well as a change in the acute 
response to OFTT. The lower basal levels in the metabolic syndrome groups and the absence 
of a reaction again confirms the hypothesis that metabolic syndrome subjects are in a 
chronically fed state, which was reflected by their basal levels, and that there was no acute 
response to the OFTT because the metabolism function shifts towards metabolic resistance. In 
Figure 58, a minimal reaction on the OFTT is visible, but the change in time is not significant. 
With a 95% probability, there is no reaction to the oral fat tolerance test in the metabolic 
syndrome group. The visible and similar trend in all groups, with a peak at 4 hours after the 
oral fat load, is particularly interesting. The same development was previously shown with 
women fed a carbohydrate-dominated meal [193]. Since the half-time of adiponectin is 
between 65 minutes in lean and 75 minutes in obese subjects [194], it is either possible that 
after this time, adiponectin secretion increases again but does not reach the basal secretion 
rate and adiponectin is cleared again rapidly, or that secretion is cut back again. Our results 
showed that postprandial adiponectin levels are more informative with regard to the metabolic 
state than fasting adiponectin levels.  
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Leptin-adiopnectin ratio 
We also looked at the leptin-adiponectin ratio which is a better predicting factor for CVD than 
leptin or adiponectin alone [133]. The metabolic syndrome and the risk groups showed a 
significant response to the OFTT, with an elevated leptin-adiponectin ratio. This could be 
interpreted as a shift toward the non-favorable cytokine composition as a response to the 
OFTT. The control subjects did not show any significant change in the leptin-adiponectin 
ratio. Here, the OFTT could be used to predict the risk of the metabolic syndrome. 
Ghrelin 
For another adipokine, ghrelin, we also found interesting results which will require further 
exploration, since our number of valid cases was too small. “Ghrelin is a growth hormone-
releasing peptide that has been shown to improve cachexia in heart failure and cancer and to 
ameliorate the hemodynamic and metabolic disturbances in septic shock.” [195] The fact that 
cytokine-induced inflammation is critical in these pathological states, and that the growth 
hormone secretagogue receptor has been identified in blood vessels, led to a study by Li 
which confirms the thesis that ghrelin inhibits proinflammatory responses in human 
endothelial cells [195]. Ghrelin is not only secreted by the adipose tissue but is mainly 
synthesized and secreted in the stomach and the intestine [196]. It reaches its maximum 
plasma levels before meals in order to stimulate food intake [196]. We examined des-acyl 
ghrelin, which accounts for 90% of the circulating ghrelin [197] and which plays a role as an 
antiapoptotic, antilipolytic hormone improving medium-chain FA uptake. In this way, it acts 
against lipotoxicity and inflammatory responses [198]. Its role in hunger has been described 
differently by different authors, though acylated ghrelin has an orexigenic effect [197]. 
Morever, des-acyl ghrelin improves glucose tolerance. Roux et al. have already shown that 
fasting ghrelin is lower in obese subjects than in control subjects, which confirms our thesis 
that obese or metabolic syndrome subjects are in a postprandial state. Ghrelin increases 
hunger [199]. Its secretion is suppressed depending on the caloric intake, and also depends on 
the food composition [199]. In the decrease after a normal meal, the nadir generally lies 
between 2-4 hours after the meal [200]. We observed fasting ghrelin levels and how ghrelin 
levels developed during OFTT after four hours. Erdmann observed a decrease of ghrelin 
levels after an OFTT, but an increase after protein load [201]. At four hours, we found no 
significant change in ghrelin levels in control subjects compared to the concentration at time 
zero. In metabolic subjects, the ghrelin levels were lower four hours after the drink, which 
shows that ghrelin levels were still suppressed. The first interpretation of Figure 60 A would 
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be that the nadir of ghrelin in control subjects lies before four hours and basal ghrelin levels 
are reached again four hours after the OFTT, whereas in metabolic syndrome subjects the 
thesis of the inert metabolism can be supported since the basal levels were not reached yet at 
that point. Since the number of cases in which both points in time were measured were very 
few, and since the standard error is very large due to the fact that many values lie beyond the 
detection value, graphs B-D depict each single case, including the cases lying beyond the 
detection limit. For this purpose the values beyond detection limit were set on the detection 
limit: 0.2 pg/ml. The graphs show decreased ghrelin levels at four hours compared to the basal 
value in most of the cases in each group. The decrease is not as large as in the metabolic 
syndrome subjects, where most of the values were below detection value. This might be either 
due to the fact that the ghrelin concentration does not decrease as much in the control subjects 
as it does in the metabolic syndrome subjects, or the fact that – as mentioned above – the 
ghrelin values were not on the way to return to their basal values yet in the metabolic 
syndrome group, whereas the control group shows a return to the values. Further tests on the 
ghrelin concentration at two hours should be conducted in order to clarify this. This could 
reveal whether the hypothesis of the inertia of the metabolism in metabolic syndrome subjects 
can be confirmed by their ghrelin concentration. To evaluate whether the OFTT can be useful 
in the case of ghrelin, further studies should feature a larger population and a longer time 
span.  
4.2.13 Changes in the renal system and FGF-23 in the metabolic 
syndrome  
Next, we took a look at the kidney. In order to examine kidney values, two parameters were 
explored: creatinine and FGF23. Both parameters showed significantly higher levels in the 
metabolic syndrome subjects than in control subjects. Our results were consistent with the 
recently published results by Mirza et al. [202]. This work group found an association 
between elevated FGF23 levels and lowered HDL, increased TAG and higher BMI [150]. But 
in contrast to them, who stated “we did not find any significant evidence for the relationship 
between FGF23 levels and the number of metabolic syndrome criteria met”, we did find 
higher levels in the metabolic syndrome group than in the risk group – which fulfilled only 
one or two criteria of the metabolic syndrome criteria – and higher levels in the risk than in 
the control group. Recent publications showed that lower adiponectin and elevated leptin 
levels are associated with elevated FGF23 levels [202]. Leptin directly stimulates FGF23 
expression in the bone [202]. All those findings were not surprising, as the other fibroblast 
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growth factors – which have structural features in common with FGF23 – also play a role in 
the lipid and glucose metabolism [202]. Mirza et al. found a link between FGF23 and CVD 
[202]. FGF23 levels significantly increased in the metabolic syndrome subjects, but they did 
not change in the control subjects. Since the FGF23 level is associated with kidney function 
[203] and diabetes [204], it is useful to look at the FGF23 levels in subjects without kidney 
failure and without diabetes. Normal kidney function is defined by a creatinine level lower 
than or equal to 1.1. The presence of chronically elevated FGF23 levels in the metabolic 
syndrome subjects was independent of kidney function. This renders FGF23 useful as a new 
biomarker for the metabolic syndrome. Regarding the behavior of FGF23 values of non-
diabetic subjects with normal kidney function over time, we found that the different behavior 
of the groups supported the thesis of the inertia of the physiological functions in metabolic 
syndrome subjects. Further analyses will need to be conducted using larger populations. 
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5 Summary 
In this study, we examined the influence of an oral fat tolerance test (OFTT) on the plasma 
levels of lipids, inflammatory biomarkers in human serum and biomarkers of the kidney, the 
bone, adipose tissue and blood compartment in order to test whether metabolic syndrome 
patients exhibited acute or chronic alterations in their metabolism. To this end, 67 volunteers 
were stratified into three groups according to the IDF criteria metabolic syndrome, diabesity 
risk and control. Blood samples were taken following a strict 12-hour fasting period at time 
points 0, 2, 4, 6 and 8 hours after consuming a high-calorie shake. The shake consisted of 250 
ml cream, 100 ml fruit juice and 60 g sugar, resulting in 3% protein, 66% fat and 32% 
carbohydrate, with a total energy content of 1016 kcal. Samples were then analyzed for their 
lipidomic profile, inflammatory markers as well as cellular parameters and cytokines. In fact, 
metabolic syndrome subjects showed an inert metabolism, but also a loss of protective 
functions, such as the decrease of DPA levels containing PC 42:5 due to the release of 
protective docosapentaenoic acid 22:5 as a response to high fat load, which could be observed 
in the control group. On the other hand, other protection mechanism seemed to be recruited. 
This study supports the thesis, also stated in a previous publication involving sepsis patients 
with reduced LPC levels [108], that reduced LPC levels are part of an unfavorable lipid 
profile, as LPC levels (mostly LPC 18:1 and 18:2) were reduced in the metabolic syndrome 
subjects in our tests. This may also have been a protective mechanism. Another one may be 
the withdrawal of pro-inflammatory fatty acids by the conversion of certain LPA into LPC 
species, which our results indicate. They also suggest that this protective mechanism is not 
sufficient to reach a more favorable lipid profile. The unfavorable lipid profile of the 
metabolic syndrome subjects included lower levels of anti-oxidative plasmalogens, protective 
SPM species 24:0 [121] and the LDL/apoB-100 ratio as a sign of smaller and more 
atherogenic LDL particles. It also showed a decreased transformation rate of AA into 22:4, 
which was reflected by a decreased level of SPMs carrying the elongation product of 22:4 and 
24, an increase in basally elevated FA 18:0, FA 20:0 and SPM species containing acyl 
residues 18:0 and 18:1. Obesity-related PC 26:0, 40:2 and 40:5 [115] and mortality-associated 
[121] PC 32:0, PCs 38:4 and 40:6, which have been described as being raised in fat-fed mice 
and as positively correlating with fasting glucose [115], were basally increased in the 
metabolic syndrome group. In terms of ceramides, the results showed a higher rate of 
“survival” or protective ceramide 24:0 and a lower rate of “death” ceramide 24:1 in healthy 
subjects compared to the others. The SPM containing 16:0, which also belongs to an 
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unfavorable lipid profile [121], increased over time in the metabolic syndrome group as a 
response to the OFTT. The thesis that metabolic syndrome patients are not able to reach a 
proper fasting state anymore, but stay in a constant postprandial condition which is resistant to 
fat load, was supported by markers showing basally increased levels in the metabolic 
syndrome group, but only a minor reaction or increase in serum in the control group, such as 
apoB-48 and PC 40:2. The simultaneous increase in PC 32:2 and 16:1 (n-7) as a response to 
the OFTT in the control group supported this thesis and, moreover, indicated a difference in 
SCD enzyme activity between the groups. Another conversion mechanism by which LPC is 
converted into the corresponding PC species by different LPCAT subtypes [185] indicates 
different degrees of predominance and efficacy in the different groups. The results indicate 
different concentrations of the various LPCAT subtypes responsible for LPC-to-PC 
conversion [185] in the different groups. As an example, LPC 18:3 and fatty acid 14:0 
increased, while PC 32:3 decreased only in the control group as a response to the OFTT. 
Moreover, the results support the thesis that metabolic syndrome subjects are in a chronic 
state of inflammation, reflected by elevated leukocyte, SuPar and CRP levels, accompanied 
by an elevated level of proinflammatory w6 fatty acids in plasma. A significant decrease of 
the CRP level could only be observed in the metabolic syndrome group as a response to the 
drink. Correspondingly, the correlation of plasmalogens with the fatty acids indicates that the 
elevated fatty-acid concentration in metabolic syndrome patients causes an increased 
integration or transformation of the fatty acid into the plasmalogens. Omentin, adiponectin 
and ghrelin were analyzed as marker cytokines for the regulation of adipose tissue 
metabolism. Basal levels of these adipokines were significantly lower in the metabolic 
syndrome group than in the control group, indicating chronic long-term adaptations of the 
adipose tissue in metabolic syndrome subjects. We found delayed and – in some cases – 
diminished responses of the groups to the OFTT, which indicates an acute change in the 
metabolic response. Serum levels of creatinine and FGF23 were significantly higher in 
metabolic syndrome than in control subjects and further increased over time. Kidney function-
associated FGF23 was separately analyzed in subjects without impaired kidney function or 
diabetes. Remarkably, chronically elevated FGF23 levels in metabolic syndrome subjects as 
well as their different acute reactions were independent of kidney function. In conclusion, the 
results of our study shows that an OFTT represents an appropriate means of exerting 
metabolic stress on subjects in order to increase the sensitivity in laboratory measurements 
related to pathologies of the lipid metabolism.  
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6 Zusammenfassung 
Der orale Fetttoleranztest zur Bestimmung der Nüchtern- und Postprandialwerte im Serum 
(2,4,6,8 Stunden nach Aufnahme eines oralen Fettshakes; 1016 kcal und 66% Fettanteil) 
hinsichtlich spezifischer ausgewählter Lipidspezies, Signalpeptide und Hormone, eignet sich 
besser als herkömmliche Methoden zur frühzeitigen Risikostratifizierung der Entwicklung 
eines metabolischen Syndroms. Dies geht aus unserer Studie mit 67 Probanden, die in eine 
Kontroll-, Risiko- und Metabolische Syndrom Gruppe (nach IDF Kriterien für Metabolisches 
Syndrome) eingeteilt wurden. Die sich gut zur Risikostratifzierung eignenden Unterschiede 
zwischen metabolischen Syndrom-, Risiko- und Kontrollgruppe, basieren auf einer 
Anpassung des Stoffwechsels des metabolischen Syndroms an die chronische Fettbelastung. 
Patienten, die von einem metabolischen Syndrom betroffen sind, weisen einen trägeren 
Stoffwechsel auf im Vergleich zur Kontrollgruppe, mit zum Teil verlangsamtem Abbau der 
Metaboliten sowie einen trägeren Anstieg von Marker Peptiden und Lipiden bei chronisch 
erhöhten Nüchtern-Werten. Bei Patienten mit metabolischem Syndrom fehlen zum Teil 
protektive Mechanismen, die bei Gesunden als Reaktion auf erhöhte Fettbelastung einsetzen, 
wie z.B. die Abnahme der DPA enthaltenden Spezies PC 42:5, als Reaktion auf den OFTT, 
welche bei der Kontrollgruppe beobachtet wurde und zur Freisetzung der protektiven 
Docosapentaensäure (22:5) führt. Dagegen setzen wiederum neue Protektionsmechanismen 
ein. Auffallend waren chronisch erniedrigte Gesamt-LPC-Werte, vor allem bedingt durch die 
verringerte Konzentration der Hauptspezies LPC 18:1 und 18:2 bei Patienten mit 
metabolischem Syndrom. Dieses Ergebnis passt zu einer Studie [106], in der diese bei 
Sepsispatienten erniedrigt und somit als Teil eines unvorteilhaften Lipidprofil zu werten sind. 
Die Reduktion könnte auch protektiv bei Risiko Patienten gewertet werden  unter der 
Annahme, dass LPC positive Effekte haben. Ein weiterer protektiver Mechanismus ist die 
Entfernung proinflammatorischer Fettsäuren aus dem Plasma aller Probanden über eine 
Konversion von LPA und einer spezifischen Fettsäure zu LPC, für die unsere Ergebnisse 
Hinweise liefern. Die Konversion scheint bei Patienten mit metabolischem Syndrom nicht 
auszureichen, um ein günstigeres Lipidprofil zu schaffen. Zum ungünstigen Lipidprofil der 
Patienten mit metabolischem Syndrom gehören ein geringes LDL/apoB-100-Verhältnis als 
Zeichen kleinerer, atherogener LDL-Teilchen, erhöhte Werte der SPM 18:0, 18:1, PC 26:0 
und wie vorbeschrieben der langkettigen PC Spezies insbesondere des PC 40:2 und PC 40:5 
als Marker für Adipositas [113] sowie des PC 32:2, des mortaliätsassozierten PC 32:0 sowie 
der PCs 38:4 und 40:6, die in Mäusen positiv mit dem nüchtern Glucose Wert korrelieren 
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[113], eine niedrigere Rate an “survival” Ceramid 24:0 und eine geringere Konzentration von 
“death” Ceramid 24:1 und der Fettsäuren FA 18:0 und FA 20:0, die sich gut als Biomarker 
eigenen, wobei letztere ausschließlich in der Gruppe der Patienten mit metabolischem 
Syndrom mit einem signifikanten Anstieg auf den OFTT reagiert. Ähnlich verhält es sich mit 
dem sich auf den Organismus ungünstig auswirkenden SPM mit dem Acyl-Rest 16 [119], die 
mit einem Anstieg in der Gruppe mit metabolischem Syndrom auf den OFTT reagiert. Wie 
die antioxidativen Plasmalogene sind auch die protektiven SPM 24:0 [119] im metabolischen 
Syndrom basal herabreguliert und gleichzeitig zeigen sich erniedrigte Werte von SPM 22:4 
und seinem Elongationsprodukt 24:4, die auf eine verminderte Transformation von der 
proinflammatorischen AA in diese hinweisen. Als Marker für einen chronisch postprandialen 
Zustand kommen vor allem diese Metaboliten in Frage, die in der Gruppe mit metabolischen 
Syndrom basal erhöht und keine oder eine nur abgeschwächte Reaktion auf den OFTT zeigen 
wie ApoB-48, PC 40:2. Der Anstieg in der Kontrollgruppe von protektiven PC 32:1 und FA 
16:1 (n-7) unterstützen unsere These vom chronisch gesättigtem Status eines Patienten mit 
metabolischem Syndrom und von veränderter Enzymaktivität mit verringerter SCD-1 
Aktivität. Weiter wiesen unsere Probanden im Vergleich zu der Kontrollgruppe 
laborchemisch eine chronische Entzündung auf, gekennzeichnet durch basal erhöhte 
Leukozytenzahl, erhöhten SuPar-Wert und CRP-Wert sowie erhöhte Werte von 
proinflammatorischen ω-6-Fettsäuren im Serum. Trotz des auch erhöhten Basalwertes von 
CRP, verzeichnete sich postprandial in der metabolischen Syndrome Gruppe eine nicht zu 
erklärende Senkung der CRP-Werte, die bei Gesunden nicht beobachtet werden konnte. Auch 
die Konversion von PC-Spezies in LPC-Spezies bei der verschiedene LPCA Subtypen mit 
Substratspezifität [183] verantwortlich sind, weisen unterschiedliche Ausprägung bzw. 
Effizienz in den verschieden Gruppen auf. Z.B. nimmt die Konzentration von LPC 18:3 und 
der Fettsäure 14:0 zu, während PC 32:3 in der Kontrollgruppe abnimmt, in den anderen 
Gruppen aber nicht. Die Ergebnisse weisen auf unterschiedliche Konzentrationen der LPCA 
in den unterschiedlichen Gruppen hin. Weitere Enzyme, die in den Gruppen unterschiedlich 
hoch vorliegen, sind SCD, wie sich an der höheren Konzentration der protektiven PC Spezies 
32:1 und PC 32:2 zeigt, die Desaturationsprodukte von SCD enthalten [119] und erhöhte 
Werte in der Gruppe mit metabolischen Syndrome aufweisen und in dieser reaktiv auf den 
OFTT ansteigen. Adiponektin, Ghrelin und Leptin wurden als Marker Zytokine für die 
Regulation im Fettgewebe bestimmt und wiesen als Zeichen einer chronischen Adaption des 
Fettgewebes an den chronischen postprandialen Status mit konsekutiver Veränderung der 
Regulation veränderte Werte im Vergleich zur Kontrollgruppe auf. Serum Kreatinin und 
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FGF23 waren in der metabolischen Gruppe signifikant höher, auch wenn man FGF23 bei 
nierengesunden Nichtdiabetikern bestimmte. 
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7 Appendix 
7.1 Abbreviations 
Abbreviation Description 
AA  Arachidonic Acid 
ACC Acetyl Coenzyme A carboxylase 
ACE Angiotensin Converting Enzyme 
AChE Acetyl Cholinesterase  
ACOX Acyl-CoA oxidas 
AHA American Heart Association  
AMPK AMP-activated protein kinase 
Apo Apolipoprotein 
AT Adipose Tissue 
ATP Adenosine triphosphate 
ATP III  Adult Treatment Panel III 
ATX Autotaxin 
BMI Body Mass Index 
C Celsius 
C atom Carbohydrate Atom 
CAD Cardiac Artery Disease 
cAMP Cyclic Adenonsin-Monophosphat 
CarboH Carbohydrate  
CE Cholesterylester 
Cer Ceramide 
CHD Coronary Heart Disease  
CM Chylomicron 
Co Control Group 
co A Coenzyme A 
CPT-1 Carnitine palmitoyl transferase 1  
CRP C-reactive Protein 
CVD Cardiovascular Disease 
D9D Delta-9-Desaturase  
DAG Deutsche Adipositas Gesellschaft 
DGAT Diacylglycerol Acyltransferase 
DHA   Docosahexaeoic Acid 
DPA Docosapentaenoic Acid 
EDTA Ethylendiamintetraacetat 
EIA Enzyme Immunoassay 
ELISA Enzyme Linked Immunosorbent Assay 
ELVOL Elongation Of Very Long Chain Fatty Acids Protein  
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EPA Eicosapentaenoic Acid 
ER Endoplasmic Reticulum 
ESI Electrospray Ionization 
eV Electron Volt 
FA Fatty Acid 
FABP Fatty-acid-binding proteins 
FAD Fatty Acid Desaturase 
FAME Fatty Acid Methyl Esters 
FAS Fatty acid synthase 
FATP Fatty-acid transport protein 
FCH Familial combined hyperlipidemia 
fFA Free Fatty Acids 
FGF-23 Fibroblast Growth-Factor 2 
G Gramm 
GC-MS Gas chromatography 
GISIS Glucose-Stimulated Insulin Secretion  
GLUT Glucose transporter  
GPAT Glycerol-3-phosphate acyltransferase 
GPI Glycosylphosphatidylinositol 
H Hour 
HB Hemoglobin 
HDL High Density Lipoprotein 
HLP Hyperlipidemia 
HMW High molecular weight 
HPTLC High Performance Thin Layer Chromatography 
HRP Horseradish 
HTS High Throughoutput Screening 
ICAM Intercellular Adhesion Molecule 
IDF International Diabetes Federation 
IDL Intermediate Density Lipoprotein 
IKKβ  Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta 
IL Interleukin 
Kcal Kilo Calorie 
Km Michaelis Konstante 
L Liter 
LC Liquid Chromatography 
LCAS Long chain acyl-CoA synthetase  
LCAT Acyltransferase 
LDL  Low Density Lipoprotoein 
Li.Hep Lithium Heparin 
LPA  Lysophosphatidic Acid 
LPC Lysophosphatidylcholine 
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LPCAT Lyso-PA Acyltransferase 
LPL Lipoprotein Lipase 
LPS Lipopolysaccharide  
LPS Lysophosphatidylserine  
LVH Left ventricular Hypertrophy  
M Meter 
M Mol/L 
m/z Mass-To-Charge Ratio 
Max Maximal 
MetSyn Metabolic Syndrome 
MGAT Monoacylglycerol Acyltransferase 
Min Minute 
mmHg Mm Quecksilbersäule 
MS  Mass Spectrometry 
MSH Melanocyte-Stimulating Hormones 
MUFA Monounsaturated Fatty Acids 
N Normal = Molar 
N Number 
NCEP National Cholesterol Education Program 
NEFA Not Esterified Fatty Acids,  
NF-kB Nuclear Factor (NF)- kB Transcription 
Ng Nanogramm 
NHLBI National Heart, Lung and Blood Institute  
OFTT Oral Fat Tolerance Test 
OGTT Oral Glucose Tolerance Test 
P Probability 
PAI Plasminogen-Activator-Inhibitor, 
PE Phosphatidylethanolamine 
PE(P- Plasmalogen 
PepT Peptide transporter 
PHMB Polyhexamid 
PMN Polymorphonuclear Leukocytes 
PPAR Peroxisome Proliferator-Activated Receptors 
PROCAM Prospective Cardiovascular Münster 
PS Phosphatidylserin 
PTFE Polytetrafluoroethylene 
PTV Programmed Temperature Vaporizer  
PUFA Polyunsaturated Acids 
R Risk Group 
ROS Reactive oxygen species 
RR Blood pressure 
RXR Retinoid X Receptor 
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SCD Stearoyl-CoA desaturase 
SD Standard Deviation 
SE Standard Error 
SGLT Sodium-glucose linked transporter 
SHP Small Heterodimer Partner 
SIM Selected Ion Monitoring 
SPM Sphingomyelin 
SREBP2  Sterol Regulatory Element-Binding Protein 
SRM Selected Reaction Monitoring  
SUFA  Saturated Fatty Acids 
SuPar Soluble  
SuPar Soluble Urokinase-Type Plasminogen Activator Receptor  
t  Time 
T2D Type 2 diabetes 
TAG  Triglyceride 
TLC Thin layer chromatography 
TMB Tetramethylbenzidin 
TNFα Tumor Necrosis Factor 
UCP Uncoupling Protein 
UKR Universitätsklinikum Regensburg 
UPAR Urokinase-Type Plasminogen Activator Receptor  
V Velocity 
V Volt 
V/V Volume/Volume 
VLDL Very Low Density Protein 
VSMC  Vascular Smooth Muscle Cell 
W/H Waist-To-Hip-Ratio 
WHO World Health Organisation 
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7.2  Questionnaire       
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7.3  CURRICULUM VITAE       
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Name:  Kaviany, Afssun         
Address: Prinzenweg 27, 93047 Regensburg    
Mobile: 0176 70 140773 
E-mail: Sonnenblumekaviany@googlemail.com   
Nationality: German 
Date of birth: 12.12.1982   
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09/2005 - 09/2006   Medical student at Luxembourg University 
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Summer 2008    Clinical elective at Giessen Hospital 
02/2009 - 04/2009   Clinical elective in Cameroon 
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7.7 Supplement 
7.7.1 Apo A-I 
 
S 1: Apo A-I showed no significant difference over time in any of the groups p (control)=0.057; p (risk)=0.071; p(metabolic 
syndrome)=0.4, data is represented as means ± 1SE. 
 
7.7.2 Fatty acids 
.  
S 2: The comparison of the fatty acid 16:1(c-9) concentration of the groups at time zero was calculated using the  Kruskal-
Wallis test  n=13 (control); n=20 (risk); n=33 (metabolic syndrome). Changes over time were evaluated using the Friedman 
test: n=12 (control) p=0.07; n=20 (risk) p<0.001; n=32 (metabolic syndrome), p<0.001. Data is represented as means ± 1SE. 
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S 3: This graph shows fatty acid 18:0. The significance of the differences between the groups at time zero was calculated 
using Kruskal-Wallis: p=0.048, n=14 (control); n=20 (risk) n=33 (metabolic syndrome).   
Changes over time were tested by Friedman, p<0,001, n=12 (control); n=20 (risk); n=32; (metabolic syndrome). Data is 
represented in means ± 1SE. 
 
 
S4: Significantly different levels of arachidic acid between the groups (Kruskal-Wallis p=0.019).  
Changes over time were tested by Friedman n=12 (control), p=0.113; n=20 (risk) p=0.004; n= 32; (metabolic syndrome) 
p<0.001. Data is represented as means ± 1SD. 
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S 5: Oleic acid, significant differences between the groups, Kruskal-Wallis, p=0.01, and dynamics over time (Friedman-test, 
p=0.01, control, n=12; p<0.001 risk, n=20, p<0.001 metabolic syndrome, n=32). Data is represented as means ± 1SD.  
 
 
 
 
S 6: Nervonic acid (Mann-Whitney U, p<0.001). Over time, there was no significant change in any of the groups (Friedman, 
p=0.19, control, n=12; p=0.87, risk, n=20, p=0.17, n=32, metabolic syndrome). Data is represented as means ± 1SE. 
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S 7: Lignoceric acid, Kruskal-Wallis, p=0.35, Friedman, p=0.29, control, n=12; p=0.7, risk, n=20, p=0.01, n=32, metabolic 
syndrome. Data is represented as means ± 1SE. 
 
 
 
 
S 8: Friedman, p=0.6, control, n=12; p=0.01, risk, n=20, p< 0.001, n=32, metabolic syndrome. Data is represented as means ± 
1 SE.   
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7.7.3 SPM 
 
S 9: SPM 18:0, Kruskal-Wallis test: p=0.035, Friedman test p=0.27 control, p=0.004 risk, p=0.24 metabolic syndrome. Data 
is represented as means ± 1SE. 
 
 
S 10: SPM 18:1, Kruskal-Wallis test: p=0.041, Friedman test p=0.488 control, p=0.251risk, p=0.28 metabolic syndrome. 
Data is represented as means ± 1SE. 
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S 11: SPM 22:4, Kruskal-Wallis test p=0.015, Friedman test p=0.29 control, p=0.82 risk, p=0.12 metabolic syndrome. Data is 
represented as means ± 1SE. 
 
 
S 12: SPM 14:0, Kruskal-Wallis test: p=0.63, Friedman test p=0.49 control, p=0.075 risk, p=0.026 metabolic syndrome. Data 
is represented as means ± 1SE. 
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S 13: SPM 16:0, Kruskal-Wallis test 0.69; Friedman test: p=0.9 control p=0.15 risk, p=0.009 metabolic syndrome. Data is 
represented as means ± 1SE. 
 
 
S 14: SPM 22:2 Kruskal-Wallis test p=0.23, Friedman test p=0.04 control, p=0.39 risk, p=0.024 metabolic syndrome. Data is 
represented as means ± 1SE. 
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S 15: SPM 23:1 Kruskal-Wallis test p=0.164, Friedman test p=0.84 control, p=0.40 risk, p=0.016 metabolic syndrome Data is 
represented as means ± 1SE. 
 
 
 
S 16: SPM 24:0; Kruskal-Wallis test p=0.37, Friedman test p=0.72 control, p=0.47 risk, p=0.003 metabolic syndrome. Data is 
represented as means ± 1SE. 
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7.7.4 Plasmalogens 
 
S 17: Sn-2: Linoleic acid: P(PE-16:0/18:2) Kruskal Wallis, p=0.07; Friedman, p=0.3, control; p=0.38, risk; p= 0.009, 
metabolic syndrome, P(PE-18:0/18:2) Kruskal Wallis, p=0.008 Friedman, p=0.6, control; p=0.07, risk; p=0.003, metabolic 
syndrome, P(PE-18:1/18:2) Kruskal-Wallis, p=0.037 Friedman, p=0.2, control; p=0.2 risk; p=0.3, metabolic syndrome. Data 
is represented as means ± 1 SE. 
0
0,5
1
1,5
2
2,5
3
3,5
0h 2h 4h 6h 8h
m
m
o
l/
l 
PE(P-16:0/18:2) 
control
risk
metabolic syndrome
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
5
0h 2h 4h 6h 8h
m
m
o
l/
l 
PE(P-18:0/18:2) 
control
risk
metabolic syndrome
0
0,5
1
1,5
2
2,5
0h 2h 4h 6h 8h
m
m
o
l/
l 
PE(P-18:1/18:2) 
control
risk
metabolic syndrome
 152  
 
 
S 18: This picture depicts the plasmalogen 16:0/18:0. The differences between the groups were evaluated using the Mann-
Whitney-U test n=13 control, n=31 metabolic syndrome.For changes over time, the Friedman test was used: n=12(control); 
n=18 (risk); n=30 (metabolic syndrome) There was only a change in the metabolic syndrome group (p=0.001). Data is 
represented as means ± 1SE 
 
 
 
7.7.5 LPC 
 
 
S 19: LPC 18:0: Kruskal-Wallis test: p=0.3, Friedman test p=0.58 control, p=0.3 risk, p=0.004 metabolic syndrome. Data is 
represented as means ± 1SE. 
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S 20: LPC 18:1, Kruskal-Wallis test: p<0.001, Friedman test p<0.001 control, p<0.009 risk, p<0.001 metabolic syndrome, 
data is represented as means ± 1SE. 
 
 
S 21: LPC 18:3, Kruskal-Wallis test: p<0.001, Friedman test p<0.001 control, p=0.002 risk, p<0.001 metabolic syndrome, 
data is represented as means ± 1SE. 
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S 22: LPC 22:4, Kruskal-Wallis test: p=0.7, Friedman test p=0.007 control, p=0.51 risk, p=0.009 metabolic syndrome, data is 
represented as means ± 1SE. 
 
 
S 23: LPC 20:3, Kruskal-Wallis test: p=0.002 Friedman test p<0.001 control, p=0.13 risk, p<0.001 metabolic syndrome, data 
is represented as means ± 1SE. 
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S 24: LPC 20:4, Kruskal-Wallis test: p=0.009, Friedman test p<0.001 control, p=0.058 risk, p<0.001 metabolic syndrome, 
data is represented as means ± 1SE. 
 
S 25: LPC 20:5, Kruskal-Wallis test: p=0.007, Friedman test p=0.007 control, p=0.51, p=0.009 metabolic syndrome, data is 
represented as means ± 1SE. 
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S 26: LPC 22:5, Kruskal-Wallis test: p<0.001, Friedman test, p<0.001 control, p=0.07 risk, p=0.001 metabolic syndrome, 
data is represented as means ± 1SE. 
7.7.6 PC and LPC 
 
S 27: Control (4h), PC, LPC and FA level at 4 hours were compared to baseline value by calculating the difference between 
the mean at four hours and at starting point. Increased levels compared to baseline are highlighted in bold (red), decreased 
levels compared to baseline are highlighted in light grey (blue), and those with no significant changes black. In the middle 
boxes, those fatty acid species are shown from which the respective PC species could potentially be built with the 
corresponding LPC species (at the top). PC species are shown on the left. A significant decrease is defined as ≥ 1.2. 
Additionally, the significance we calculated with is shown in stars:: *<0.05, **<0:01, ***<0.001, (scheme based on 
description by Thomas Kopf).  
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S 28: Control (6h), increased levels compared to baseline are highlighted in bold (red), decreased levels compared to baseline 
are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, those fatty acid species 
are shown from which the respective PC species could potentially be built with the corresponding LPC species (at the top). 
PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the significance we calculated with 
is shown in stars: *<0.05, **<0:01, ***<0.001, (scheme based on description by Thomas Kopf).  
 
 
S 29: Control (8h), increased levels compared to baseline are highlighted in bold (red), decreased levels compared to baseline 
are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, those fatty acid species 
are shown from which the respective PC species could potentially be built with the corresponding LPC species (at the top). 
PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the significance we calculated with 
is shown in stars:  *<0.05, **<0:01, ***<0.001, (scheme based on description by Thomas Kopf).  
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PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0**  16:0
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PC 32:2 14:1 16:1 14:0*    
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S 30: Risk (4h), increased levels compared to baseline are highlighted in bold (red), decreased levels compared to baseline 
are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, those fatty acid species 
are shown from which the respective PC species could potentially be built with the corresponding LPC species (at the top). 
PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the significance we calculated with 
is shown in stars: : *<0.05, **<0:01, ***<0.001, (scheme  based on description by Thomas Kopf).  
 
 
S 31: Risk (6h), increased levels compared to baseline are highlighted in bold (red), decreased levels compared to baseline 
are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, those fatty acid species 
are shown from which the respective PC species could potentially be built with the corresponding LPC species (at the top). 
PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the significance we calculated with 
is shown in stars: : *<0.05, **<0:01, ***<0.001, (scheme  based on description by Thomas Kopf).  
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PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
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S 32: Risk (8h), increased levels compared to baseline are highlighted in bold (red), decreased levels compared to baseline 
are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, those fatty acid species 
are shown from which the respective PC species could potentially be built with the corresponding LPC species (at the top). 
PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the significance we calculated with 
is shown in stars: *<0.05, **<0:01, ***<0.001, (scheme based on description by Thomas Kopf).  
 
 
S 33: Metabolic syndrome (4h), increased levels compared to baseline are highlighted in bold (red), decreased levels 
compared to baseline are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, 
those fatty acid species are shown from which the respective PC species could potentially be built with the corresponding 
LPC species (at the top). PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the 
significance we calculated with is shown in stars:: *<0.05, **<0:01, ***<0.001, (scheme based on description by Thomas 
Kopf).  
LPC 20:0 LPC 19:0LPC 18:0 LPC 18:1 LPC 16:1 LPC 18:2 LPC 20:3 LPC 18:3 LPC 22:4 LPC 20:4 LPC 22:5 LPC 20:5 LPC 22:6
PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0 16:0
PC 40:5 20:5 22:5 22:4 20:2 18:1 18:0 20:0
PC 42:5 22:5 22:1 20:0 22:0
PC 34:4*    18:3 14:1 16:1 12:0 14:0
PC 36:4*    18:3 20:3 18:2 16:1 18:1 14:0 16:0
PC 38:4*    20:4 20:3 20:2 18:1 16:0 18:0
PC 40:4 20:4 22:4 22:1 18:0 20:0
PC 42:4 22:4 22:1 24:1 20:0 22:0
PC 32:3*    14:1 12:0 14:0
PC 34:3 18:2 16:1 14:0 16:0
PC 36:3 18:3 18:2 20:2 18:1 16:0 18:0
PC 40:3 20:3 22:1 20:0 22:0
PC 32:2 14:1 16:1 14:0
PC 34:2 16:1 18:1 16:0
PC 38:2 18:2 20:2 22:1 20:0
PC 40:2 20:2 22:1 24:1 22:0
PC 30:1 12:0 14:0
PC 32:1*    14:1 14:0 16:0
PC 34:1*    14:1 16:1 16:0 18:0
PC 36:1*    16:1 18:1 18:0 20:0
PC 38:1 18:1 20:0 22:0
PC 40:1 22:1 22:0 24:0
PC 44:1 24:1
PC 26:0
PC 28:0 10:0**  
PC 30:0*** 10:0**  12:0
PC 32:0 12:0 13:0 14:0
PC 34:0 14:0 15:0 16:0
PC 36:0 16:0 17:0 18:0
PC 40:0 20:0 22:0
PC 42:0 22:0 24:0
LPC 20:0 LPC 19:0LPC 18:0 LPC 18:1***LPC 16:1*    LPC 18:2***LPC 20:3***LPC 18:3***LPC 22:4 LPC 20:4**  LPC 22:5**  LPC 20:5*    LPC 22:6***
PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0**  
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0*** 16:0
PC 40:5 20:5 22:5 22:4 20:2 18:1 18:0**  20:0
PC 42:5 22:5 22:1 20:0 22:0
PC 34:4 18:3 14:1 16:1 12:0*** 14:0***
PC 36:4 18:3 20:3 18:2 16:1 18:1 14:0*** 16:0
PC 38:4 20:4 20:3 20:2 18:1 16:0 18:0**  
PC 40:4 20:4 22:4 22:1 18:0**  20:0
PC 42:4 22:4 22:1 24:1 20:0 22:0
PC 32:3 14:1 12:0*** 14:0***
PC 34:3*    18:2 16:1 14:0*** 16:0
PC 36:3 18:3 18:2 20:2 18:1 16:0 18:0**  
PC 40:3 20:3 22:1 20:0 22:0
PC 32:2 14:1 16:1 14:0***
PC 34:2 16:1 18:1 16:0
PC 38:2*    18:2 20:2 22:1 20:0
PC 40:2 20:2 22:1 24:1 22:0
PC 30:1 12:0*** 14:0***
PC 32:1 14:1 14:0*** 16:0
PC 34:1 14:1 16:1 16:0 18:0**  
PC 36:1 16:1 18:1 18:0**  20:0
PC 38:1 18:1 20:0 22:0
PC 40:1 22:1 22:0 24:0
PC 44:1 24:1
PC 26:0
PC 28:0 10:0***
PC 30:0**  10:0*** 12:0***
PC 32:0*    12:0*** 13:0 14:0***
PC 34:0 14:0*** 15:0***16:0
PC 36:0 16:0 17:0**  18:0**  
PC 40:0 20:0 22:0
PC 42:0 22:0 24:0
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S 34: Metabolic syndrome (6h), increased levels compared to baseline are highlighted in bold (red), decreased levels 
compared to baseline are highlighted in light grey (blue), and those with no significant changes black. In the middle boxes, 
those fatty acid species are shown from which the respective PC species could potentially be built with the corresponding 
LPC species (at the top). PC species are shown on the left. A significant decrease is defined as ≥ 1.2. Additionally, the 
significance we calculated with is shown in stars: *<0.05, **<0:01, ***<0.001, (scheme based on description by Thomas 
Kopf).  
 
S 35: Figure 65: Metabolic syndrome (8h), increased levels compared to baseline are highlighted in bold (red), decreased 
levels compared to baseline are highlighted in light grey (blue), and those with no significant changes black. In the middle 
boxes, those fatty acid species are shown from which the respective PC species could potentially be built with the 
corresponding LPC species (at the top). PC species are shown on the left. A significant decrease is defined as ≥ 1.2. 
Additionally, the significance we calculated with is shown in stars: *<0.05, **<0:01, ***<0.001, (scheme based on 
description by Thomas Kopf).   
LPC 20:0 LPC 19:0LPC 18:0 LPC 18:1***LPC 16:1 LPC 18:2***LPC 20:3***LPC 18:3***LPC 22:4 LPC 20:4**  LPC 22:5**  LPC 20:5*    LPC 22:6**  
PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0*    
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0*** 16:0
PC 40:5 20:5 22:5 22:4 20:2 18:1 18:0*    20:0
PC 42:5 22:5 22:1 20:0 22:0
PC 34:4 18:3 14:1 16:1 12:0*** 14:0***
PC 36:4 18:3 20:3 18:2 16:1 18:1 14:0*** 16:0
PC 38:4 20:4 20:3 20:2 18:1 16:0 18:0*    
PC 40:4 20:4 22:4 22:1 18:0*    20:0
PC 42:4 22:4 22:1 24:1 20:0 22:0
PC 32:3 14:1 12:0*** 14:0***
PC 34:3 18:2 16:1 14:0*** 16:0
PC 36:3 18:3 18:2 20:2 18:1 16:0 18:0*    
PC 40:3 20:3 22:1 20:0 22:0
PC 32:2*    14:1 16:1 14:0***
PC 34:2 16:1 18:1 16:0
PC 38:2 18:2 20:2 22:1 20:0
PC 40:2 20:2 22:1 24:1 22:0
PC 30:1 12:0*** 14:0***
PC 32:1 14:1 14:0*** 16:0
PC 34:1 14:1 16:1 16:0 18:0*    
PC 36:1 16:1 18:1 18:0*    20:0
PC 38:1 18:1 20:0 22:0
PC 40:1 22:1 22:0 24:0
PC 44:1 24:1
PC 26:0*    
PC 28:0 10:0***
PC 30:0*** 10:0*** 12:0***
PC 32:0*    12:0*** 13:0 14:0***
PC 34:0 14:0*** 15:0***16:0
PC 36:0 16:0 17:0**  18:0*    
PC 40:0 20:0 22:0
PC 42:0 22:0 24:0
LPC 20:0 LPC 19:0LPC 18:0 LPC 18:1***LPC 16:1*    LPC 18:2***LPC 20:3**  LPC 18:3***LPC 22:4 LPC 20:4*    LPC 22:5**  LPC 20:5*    LPC 22:6**  
PC 40:7 22:6 22:5 20:4 22:4 18:3 20:3 18:2 20:2 18:1
PC 38:6 20:5 22:5 20:4 18:3 20:3 18:2 16:1 18:1 16:0
PC 40:6 22:6 22:5 22:4 20:3 18:2 20:2 18:1 18:0
PC 36:5 20:4 18:3 18:2 14:1 16:1 14:0**  16:0
PC 40:5 20:5 22:5 22:4 20:2 18:1 18:0 20:0
PC 42:5 22:5 22:1 20:0 22:0
PC 34:4 18:3 14:1 16:1 12:0*** 14:0**  
PC 36:4 18:3 20:3 18:2 16:1 18:1 14:0**  16:0
PC 38:4 20:4 20:3 20:2 18:1 16:0 18:0
PC 40:4 20:4 22:4 22:1 18:0 20:0
PC 42:4 22:4 22:1 24:1 20:0 22:0
PC 32:3 14:1 12:0*** 14:0**  
PC 34:3 18:2 16:1 14:0**  16:0
PC 36:3 18:3 18:2 20:2 18:1 16:0 18:0
PC 40:3*    20:3 22:1 20:0 22:0
PC 32:2*    14:1 16:1 14:0**  
PC 34:2 16:1 18:1 16:0
PC 38:2 18:2 20:2 22:1 20:0
PC 40:2 20:2 22:1 24:1 22:0
PC 30:1*    12:0*** 14:0**  
PC 32:1 14:1 14:0**  16:0
PC 34:1 14:1 16:1 16:0 18:0
PC 36:1 16:1 18:1 18:0 20:0
PC 38:1 18:1 20:0 22:0
PC 40:1 22:1 22:0 24:0
PC 44:1 24:1
PC 26:0
PC 28:0 10:0***
PC 30:0*** 10:0*** 12:0***
PC 32:0 12:0*** 13:0 14:0**  
PC 34:0 14:0**  15:0**  16:0
PC 36:0 16:0 17:0 18:0
PC 40:0 20:0 22:0
PC 42:0 22:0 24:0
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